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SUMMARY
The origin of the defects leading to pathogenicity in systemic lupus erythematosus 
(SLE), an autoimmune disorder characterised by multi-system involvement, female 
preference, B-cell hyperactivity, autoantibody production and immune complex 
deposition, is still controversial. The therapeutic strategies today for treatment of lupus 
disease are mainly based on a general suppression of the immune system with 
uncertainty about their long term effects being beneficial or rather harmful to the 
patients. These treatments that may achieve a temporary symptomatic relief do not cure 
the disease and are often followed by problematic side effects including infections. The 
underlying mechanism for the development of the disease is yet to be clarified. There 
is, however, some evidence that defects in the ability of lymphocytes to produce or 
respond to cytokines may disturb the finely balanced immune system resulting in 
abnormal B-cell regulation. In contrast to the B-cell hyperactivity, deficient T-cell 
functional activity is another prominent feature of the disease. Many cytokine disorders 
have been reported in both SLE patients and the animal models but findings are often 
difficult to reconcile, especially differences between data from the in vitro and in vivo 
studies. In order to understand the mechanism of immune regulation in SLE, 
experiments were designed, in the present study, to give a detailed analysis of the 
nature and pathological relevance of those immunological abnormalities, the T-helper 
cell functional defects in particular.
Much of the work focused on and described in this thesis was based mainly on 
two well established murine models of SLE including an early-life (MRL/lpr) model 
and a later-life (NZB/W) disease model. Both the NZB/W and the MRL/lpr strains are 
mutant mice which spontaneously develop a disease similar to human SLE. Female 
mice of different ages were used in the study and the normal control strains were sex 
and age-matched BALB/c and CBA mice. Results from studies using lymphocytes and
21
serum samples from SLE patients are also described and compared with the studies on 
the mouse models. The study included both in vitro and in vivo approaches.
Results from the in vitro studies indicate that T-cell, particularly T-helper, 
functions are severely impaired in the lupus mice. These include abnormal production 
of IL-2, IFN-y and IL-4, inability of T-cells to express functional high affinity IL-2R 
and to proliferate in response to Con A stimulation, confirming and extending previous 
studies by other investigators. Since the stage of development at which these defects 
occur is not clearly understood, efforts have been devoted to analysis of lymphocytes 
from lupus mice at different ages, in relation to the disease activity. Attention has been 
particularly focused on young lupus mice including mice of one week old, before the 
onset of clinical disease. Evidence is given indicating an early onset of the T-helper 
functional defects and the central role of IL-2 deficiency in the defective T-cell 
activation. The hyporesponsiveness of lupus T-cells to Con A is due to the inability of 
T-helper cells to produce IL-2 and this can be bypassed by exogenous IL-2 in vitro. 
Addition of IL-2 during Con A activation restores fully the ability of lupus T-cells to 
proliferate, upregulates IL-2R expression and increases the frequency of IFN-y 
secretors resulting in normalised levels of IFN-y secretion. T-cell phenotype analysis 
indicates that IL-2 preferentially promotes the expansion of the functionally more 
mature single positive cell population while inhibiting the growth of the characteristic 
CD3+CD4"CD8" (double negative) cells in MRL/lpr mice.
Addition of IL-1 during Con A stimulation of T-cells did not restore the IL-2 
production defect in the lupus mice. To assess the function of accessory cells in the 
lupus mice, replacement of the adherent cells from MRL/lpr mice by adherent cells from 
H-2 compatible normal mice also failed to bypass the T-cell activation defect. 
However, some serum factors which affect the growth of the IL-2 dependent CTLL cell 
line were found in sera and plasma from SLE patients with active disease and some 
lupus mice. At high concentrations, these factors inhibit CTLL cell proliferation in
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response to IL-2 but, at low concentrations they synergise with IL-2 to stimulate CTLL 
cells to proliferate. Characterisation of the serum components shows that these factors 
bind to CTLL cells but not to Protein A, and are heat labile but not neutralised by IL-2. 
In addition, serum nitric oxide levels were increased in MRL/lpr mice, but decreased in 
NZB/W mice, compared to the BALB/c controls at all ages.
The study of cytokine mRNA expression by PCR shows that spleen cells freshly 
isolated from both lupus and normal mice do not spontaneously express mRNA for IL-2 
or IL-4 but do express IFN-y. IL-6 mRNA was only detected in the cells from BALB/c 
and MRL/lpr but not NZB/W mice. However, Con A-induced mRNA expression for 
all the above T-cell cytokines was detectable in these mice. There was no increased 
expression for any of these cytokines in the two strains of lupus mice compared to the 
normal controls, although the quantitative information provided by PCR may be limited 
and is to be confirmed. On the contrary, Con A-induced mRNA expression for IL-2 
and IL-4 was clearly reduced in the MRL/lpr and to less degree in the NZB/W mice (25 
weeks old).
To determine the in vivo effects of IL-2 and TGF-p on the development of lupus 
disease in MRL/lpr mice, a non-virulent live S. typhimurium or or mutant has been 
used as a vector to deliver cytokines by oral administration of IL-2 or TGF-p 1 gene 
transfected bacteria. Preliminary results from small scale pilot experiments show that 
TGF-pl suppressed Con A-induced T-cell proliferation, IL-2 and IFN-y production in 
normal and lupus mice. MRL/lpr mice had delayed onset of glomerulonephritis. 
However, TGF-pl-treated MRL/lpr mice later developed increased titres of anti-ss and 
anti-dsDNA and glomerulonephritis. In contrast, MRL/lpr mice treated with IL-2 
showed reduced levels of serum anti-ssDNA, a significant decrease in the abnormal 
double negative cell population, suppressed IFN-y production and reduced
glomerulonephritis.
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In general, the study indicates a crucial role for the Thl functional defect and 
therapeutic potential of IL-2 in SLE. It sheds some doubt on the current clinical 
treatments by non-specific immunosuppressive drugs and favours approaches which 
may enhance the endogenous capacity of the immune system to carry out its proper 
functions in maintaining self-tolerance. The need for new insights into the underlying 
mechanism of the disease and more consideration of the immune deficient aspects of 
autoimmune phenomena as a whole for therapeutic strategies are discussed.
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Chapter 1 
INTRODUCTION
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1 .1  Systemic lupus erythematosus
Systemic lupus erythematosus (SLE), formerly named 'disseminated lupus 
erythematosus', is a non-organ-specific autoimmune disease of unknown aetiology. It 
is one of a group of related systemic rheumatic diseases including rheumatoid arthritis 
and Sjogren's syndrome. The disease has been recognised for centuries and yet has 
been studied in depth only in relatively recent years largely owing to the establishment 
of good animal models.
1 .1.1 Clinical repertoire and the natural history of SLE
SLE is characterised clinically by a multisystem involvement affecting a variety of 
tissues and organs. One of the typical clinical manifestations of the disease is 
erythematosus, the so called butterfly rash. In Latin, the term 'lupus' means wolf and 
it has been used since mediaeval times to described the erythemic ulcerations which can 
'eat away' the face (Morrow and Isenberg, 1987). Many other organs and tissues, 
such as joints, blood vessels, muscles, nerves, kidneys, lung, heart, and spleen may 
also be affected during disease development causing a variety of disorders. 
Glomerulonephritis is a severe complication of the renal involvement which is believed 
to be caused by deposition of immune complexes and complement activation. In 
human SLE, although glomerulonephritis is not necessarily manifested in the clinical 
features of many patients it is one of the major contributions to death (Corriea et al., 
1984). The full spectrum of the disease has been described in details by Morrow and 
Isenberg (1987) illustrating a broad and complex clinical picture. As the disease may 
be presented in many ways, it makes SLE potentially difficult to diagnose. The criteria 
set by the American Rheumatism Association (ARA) for the classification and diagnosis 
of SLE (Tan, 1982; Tan et al., 1983) include the number of clinical manifestations 
which reflect the features of multisystem involvement and non-organ-specificity of the 
disease.
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The disease has a high incidence in young women, particularly in females of 
child-bearing age or after puberty. In general, it has been estimated that approximately 
9 out of 10 SLE sufferers are females suggesting a possible role of sex hormones in the 
disease development. In a SLE mouse model (MRL/Zpr), disease-limiting effects of an 
aromatase inhibitor, 4-OHA (4-hydroxyandrostenedione) which blocks oestrogen 
formation, has been reported (Greenstein et al., 1993). However, there are some 
families in which the disease occurs mainly in males (Lahita et al., 1983). The 
heritability of the disease in humans is still not certain. Several family occurrence 
studies have described a higher incidence of SLE in close family relatives of patients 
(Brunjes et al., 1961), even in twins (Bloch et al., 1976), but results from other reports 
suggest little or no such relationship (Winchester, 1983). Ethnic variation has also 
been observed as another feature of the disease. According to the study by Serdula and 
Rhoads (1979), the prevalence rates per million population at risk are: 241 in ethnic 
Chinese, 204 in mixed Hawaiian, 199 in ethnic Filipino, 182 in ethnic Japanese and 58 
in Caucasian. Among females, the prevalence rates per million may vary from 4000 in 
Jamaica to 232 in New Zealand (Morrow and Isenberg, 1987). Lupus may affect 
young people and it has been reported in children as young as 3 years old. The clinical 
manifestations of juvenile lupus resemble their adult counterpart, except that it is often 
more severe. Although women with lupus may have normal fertility, children bom to 
mothers with lupus have been shown to have an increased risk of congenital heart 
disease (Esscher and Scott, 1979).
Since the cause of the disease is still unknown, clinical treatments for SLE have 
been mainly based upon achieving symptomatic relief rather than cure. There are four 
main groups of drugs including the non-steroid anti-inflammatory drugs (NSAID), the 
anti-malarial and cytotoxic drugs (Klippel, 1992) and corticosteroids (Kimberly, 1992). 
The therapeutic strategies are usually designed for a general suppression of the immune
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system because of the prominent features of B-cell hyperactivity and the non-specific 
organ involvements.
1.1.2 Serological abnormalities
There are many serological abnormalities found in SLE. The most notable and 
widely recognised ones are serum autoantibodies, circulating immune complexes and 
hypocomplementaemia.
A diversity of antibodies to self antigens present in the blood of lupus patients and 
the animal models is one of the most prominent features in SLE. These autoantibodies 
may bind to an extensive array of molecules including nuclear antigens (DNA, RNA, 
RNP, Sm, histones and non-histone chromatin proteins), phospholipids, cytoplasmic 
and cell surface components, and even immunoglobulin G (rheumatoid factor). Among 
them, the anti-nuclear antibodies (ANA) have attracted most attention and therefore 
been most extensively studied. It is now nearly forty years since the coincidental 
discovery of anti-DNA antibodies in the serum of lupus patients by many independent 
research groups and laboratories (Friou, 1957; Cepellini et al., 1957; Miescher and 
Straessle, 1957; Robbins et al., 1957; Seiligmann, 1957). Clinically, anti-dsDNA are 
diagnostic of SLE since they can be detected in majority of lupus patients and rarely 
occur in other conditions (Buskila and Shoenfeld, 1992). In order to understand their 
pathological and pathogenic significance, much effort has been made to analyse 
structurally and functionally the nature of these antibodies.
SLE has been long regarded as a polyclonal autoimmune disease due to the 
variety of antibody specificities detected. However, recent studies using isoelectric 
focusing (IEF) techniquejhave revealed that the anti-DNA antibodies in the sera of SLE 
patients and the mouse models (Stott et al., 1986; 1988, 1990), as well as the serum 
anti-Sm antibodies in MRUlpr  mice (Williams et al., 1986), are clonally restricted. In
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agreement with this notion, the anti-DNA B-cells in the MRUlpr mice were also found 
to be clonally restricted (Shlomchik et al., 1990). More recently, the anti-DNA- 
secreting B-cell clones of SLE patients have been shown to be not only restricted in 
number, but also stable and long lived (Stott, 1992). The findings are striking in 
regard to the wide range of antibody specificities and clinical features of the systemic 
involvement of the disease. Since monoclonal anti-DNA antibodies derived from lupus 
mice and SLE patients exhibit extensive cross-reactivity, a  possibly false impression 
of polyclonal activation is therefore suggested. A study by Raz et al. (1993) showed 
that anti-DNA, but not anti-RNA or anti-histone, antibodies secreted by hybridoma cell 
lines derived from spleen cells of NZB/W FI female mice bound to membrane proteins 
of several different cell types. By opposing the hypothesis of an environmental 
mitogen-driven B-cell polyclonal activation, the evidence indicates an intrinsic 
immunological defect in SLE. It is postulated that such a clonally restricted 
autoimmune response might be due to somatic mutation of clones from anti-non-self to 
anti-self, or otherwise due to some limited number of potentially self-reactive clones 
which escape from a defective immune tolerant mechanism (Stott, 1992).
Circulating immune complexes (CICs) are commonly observed in both SLE 
patients and lupus mouse models. CICs have been shown to consist of nucleic acid 
and serum autoantibodies of corresponding specificity. Three types of CICs identified 
are dsDNA-anti-dsDNA, ssDNA-anti-ssDNA and ssDNA-anti-dsDNA (Brentjens and 
Andres, 1982). It is believed that deposition of immune complexes in tissues, such as 
skin, kidneys, blood vessels and brain, may initiate some inflammatory mechanisms. 
These include complement fixation and recruitment of inflammatory cells resulting in 
tissue damage. There have been many attempts to elucidate the role of immune 
complexes in the pathogenesis of renal damage. DNA antigens and antibodies have 
been demonstrated in immune complexes in kidneys with proliferative and membranous 
lupus nephritis (Agnello et al., 1973, 1976; Andres et al., 1970). The determinants 
responsible for the deposition, in particular the precise location of immune complexes,
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are still not clear. However, antibody avidity and class, antigen/antibody ratios and 
size of DNA have been shown to be important in determining the deposition of immune 
complexes (Morrow and Isenberg, 1987).
Changes in serum complement levels, reduced early reacting components (Cl-4) 
but increased final products (C5-9), are associated with the lupus disease activity. 
This has been suggested to be a consequence of complement activation. Many studies 
have demonstrated that complement is consumed by immune complexes and localised 
in the tissues, particularly the kidney. In addition, in contrast to patients with 
rheumatoid arthritis demonstrating high levels of serum acute phase proteins, C-reactive 
protein (CRP) is low in SLE unless there is a superimposed infection. Other acute 
phase proteins like amyloid P component are elevated in many other autoimmune 
diseases but not in SLE (Pepys et al. 1978). Although the serological abnormalities 
share many common features with other autoimmune diseases, these are well 
recognised outstanding characteristics of lupus.
1.1.3 Immunopathological features and aetiological considerations
i) Adoptive transfer of SLE
The origin of the defect leading to autoaggression in SLE is still an unsolved 
puzzle. However, in the mouse models of SLE, it has been clearly demonstrated that 
lupus is caused solely by a defect within the lymphoid system. The evidence is that the 
disease can be transferred by transplantation of the lymphoid cells (spleen, liver or bone 
marrow cells) between lupus and H-2 compatible lethally irradiated normal mice. On 
the basis of many experimental models, several studies have shown that, as well as its 
transferable nature, many features of disease expression by donors are also adoptable 
by the recipients, such as differences in the onset of clinical disease, the pace of disease 
development and the sex preferences (Theofilopoulos and Dixon, 1985). Conversely,
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lethally irradiated lupus strain of mice (NZB) which received normal bone marrow from 
a H-2 compatible mice has been shown to possess all the characteristics of the normal 
donor (Jyonouchi et al., 1981). Another very important finding was that spleen cells 
from old lupus mice with clear-cut disease do not produce disease in recipients any 
faster than transfer of bone marrow from premorbid mice (Eisenberg et al., 1980). 
Thus, the defect seems to exist at stem cell level and is carried through the animals' life. 
In addition, a similar study by Akizuki et al. (1978) showed that the disease could even 
be transferred into H-2 incompatible nonautoimmune lethally irradiated recipients when 
the lupus mouse (NZB/W) bone marrow cells were pre-treated with anti-Thy 1.2 serum 
plus complement to eliminate differentiated T-cells. These studies indicate that murine 
lupus haematopoietic stem cells or lymphoid processor cells are inherently defective and 
possess all that is necessary for the expression of the disease. A variety of studies has 
been carried out since to determine the exact nature of the lymphoid defect.
ii) Cellular and functional abnormalities of lymphoid cells
Numerous immunological disorders featuring cellular and functional 
abnormalities of lymphoid cells are related in SLE (Tsokos, 1992). The two most 
prominent features are B-cell hyperactivity on one hand reflected by massive 
autoantibody production, and defective T-cell mediated immunity on the other.
B-cell hyperactivity is one of the immunological markers of the lupus disease. B- 
cells from the blood of SLE patients spontaneously secrete large amounts of 
immunoglobulin including antibodies to self antigens in cultures (Jasin and Ziff, 1975; 
Budman et al., 1977). Upon B-cell mitogen stimulation, these cells also secrete higher 
levels of immunoglobulin than cells from normal subjects. SLE B-cell proliferate 
vigoriously in the presence of 50 kD BCGF or a recombinant 12 kD BCGF even in the 
absence of mitogen, although not in the presence of IL-2 and the 20 kD BCGF 
(Delfrassy et al., 1986; Flescher et al., 1990). The B-cell hyperactivity in vitro
31
resembles its in vivo state as indicated by the increased antibody and autoantibody 
levels in the sera from patients. However, in spite of the increased immune activity in 
the B-cell compartment, infection is known to be one of the potential causes for 
disease exacerbation. Although there has not been sufficient evidence to  
suggest a general increase in susceptibility of lupus patients to infections, it has been 
shown that lupus B-cells are indeed unable to respond to some antigens by mounting a 
normal immune response. By sensitising cells with specific antigen in vitro, Pelton et 
al. (1982) showed a decreased production of anti-influenza antibodies by B-cells from 
SLE patients. A B-cell defect per se in lupus is evident.
Owing to the increasing knowledge about the crucial role of T-cells in modulating 
the B-cell response, the importance of T-cell abnormalities in the development of lupus 
disease has become more and more emphasised. Studies on peripheral and thymic T- 
cells have revealed that cellular and functional abnormalities of T-cells exist in SLE 
patients as well as in lupus animal models. The main evidence for the existence of 
defects in the T-cell compartment is the abnormal functional activities of the cells. T- 
cells from lupus patients and several mouse models display severely impaired abilities 
to proliferate and to produce cytokines in response to T-cell mitogens (Kroemer and 
Wick, 1989; Kroemer and Martinez-A, 1991). T-cell lymphopenia is characteristic of 
patients with lupus and its severity correlates with disease activity (Steinberg et al., 
1991). An impaired T-cell-mediated cellular immunity is a prominent immunological 
feature in both human SLE and the animal models. Decreased autologous mixed 
lymphocyte reaction (AMLR), and reduced activities of cytotoxic T-cells and NK cells 
have been common findings in both human lupus and the mouse models (Kuntz et al., 
1979; Theofilopoulos and Dixon, 1985; Theofilopoulos, 1992). On the other hand, 
however, recent studies have identified certain T-cell subsets, T-cells that lack both 
CD4 and CD8 molecules in SLE patient (Steinberg et al., 1991) and in lupus mouse 
models (Datta, 1989) which are not MHC restricted, may provide excessive help to the 
pathogenic autoantibody secreting B-cells. In addition, CD4+DR+ and CD8+DR+ T-
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cells isolated from SLE patients were also reported to support polyclonal IgG 
production and autoantibody synthesis (Linker-Israeli et al., 1990). Therefore, the 13- 
cell hyper-responsiveness is now largely attributed to lack of, or abnormal, T-cell 
regulation.
iii) Environmental and genetic factors
A number of environmental factors, such as drugs, exposure to UV light, and 
viral infections, are able to induce or are associated with the disease. Many viruses 
have been shown to produce various abnormalities found in lupus. Among them, type 
C RNA viral particles have been suggested as an aetiological agent responsible for 
SLE. These particles were not only found in large numbers in a lupus strain (NZB) of 
mice (Mellors and Huang, 1966; East et al., 1967) but also in SLE patients (Strand and 
August, 1974; Panem et al., 1976). However, the basis for the increased sensitivity 
and susceptibility of lupus patients and mice to these environmental influences is not 
clear. Since this virus was later found in some normal strains of mice too, its relation 
to lupus disease has become questionable.
Genetic analysis of disease susceptibility has been used to study the role of the 
major histocompatibility complex (MHC) class I and II antigens in SLE. In human 
SLE, evidence from a large body of studies has established an association of SLE with 
the class II HLA markers DR2 and DR3. Although the association has been found to 
be inconsistent in different ethnic groups and between various studies, C4 null alleles 
are now considered to be a strong genetic determinant which is relatively common in 
various ethnic groups (Pisetsky, 1991). In the MRLIlpr mouse model of SLE, lupus 
disease has been found to be linked with a defect in a gene controlling Fas antigen 
which is a cell surface protein involved in cell apoptosis in the thymus (Watanabe- 
Fukunaga etal., 1992).
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1 .2  Lupus mice: the animal models of SLE
The availability of animal models of SLE has been an enormous boost in studies 
of the disease in the last decades. In particular, several lupus strains of mice have been 
well established and proved to be the best models of the human disease because of their 
similar clinical, serological and immunological characteristics. These mice 
spontaneously develop lupus-like symptoms characterised by vasculitis, arthritis, 
glomerulonephritis and hypergammaglobulinaemia. Previous studies using murine 
SLE models have provided a good understanding of the disease in many aspects and 
results from studies by different investigators show considerable agreement (reviewed 
by: Theofilopoulos and Dixon, 1985; Morrow and Isenberg, 1987; Steinberg et al., 
1991; Theofilopoulos, 1992).
1.2.1 The mouse strains
Among several murine strains, the FI hybrids produced by the mating of New 
Zealand Black (NZB) with New Zealand White (NZW) mice, [(NZB/NZW) FI] 
(NZB/W), have been suggested to be one of the best models of human lupus. The 
NZB (H-2d) is the first described animal model which develops lupus-like autoimmune 
disease (Bielschowsky et al., 1959; Helyer and Howie, 1963). This mouse strain is 
primarily a model for autoimmune haemolytic anaemia. As it manifests many clinical 
features of lupus disease, such as glomerulonephritis, lymphomas, autoantibodies and 
immune complexes, the NZB is also considered to be a lupus-prone strain. The NZW 
(H-2Z) does not develop overt autoimmunity, but its hybrid with the NZB undergoes 
changes very closely resembling human SLE. Therefore, the NZB/W ( H ^ 2) strain 
has been an popular animal model used in many of the previous studies of SLE.
Two other best known lupus mouse models are MRL/MP-llprllpr (MKLIlpr) and 
BXSB/Mp (BXSB) developed by Murphy and Roths (1979) at the Jackson
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Laboratory, USA. The MRL (H-2k) strain originated as a by-product of a series of 
crosses involving several inbred strains AKR/J (H^k), C57BL/6J (H-2b), C3H/Di (H- 
2*0, and LG/J (H-2d/f). During the inbreeding, some of the offspring of the 25th 
generation developed massive generalised lymph node enlargement early in life, while 
others did not. With subsequent inbreeding, one subline that developed 
lymphadenopathy was termed MRUlpr, and the other that did not express the lymphoid 
abnormality was named MRL/n. Although MRLIlpr and MRL/n share at least 89% of 
their genome, a single autosomal recessive gene named lymphoproliferation (Ipr 
mapped to Fas) and possibly from the AKR ancestors, has been suggested to control 
the lymphoproliferation in MRL/Ipr mice. An advantage of the MRL over the NZB/W 
is that, unlike the latter whose H-2^z haplotype is difficult to match with other strains 
of mice in some studies, the MRUlpr is an inbred strain with one Jhomozygous H-2k 
haplotype. It enables studies like the adoptive lymphoid cell transfer where such 
matching is crucial. The BXSB (H-2b) is also a recombinant inbred strain derived from 
a cross between a C57BL/6J (H-2b) female and a SB/Le (H-2b) male. A trait or 
gene(s) on, or linked to, the Y chromosome of BXSB mice derived from SB/Le, was 
found to profoundly enhance autoimmunity in this strain of lupus mice (cited in: 
Theofilopoulos and Dixon, 1985).
The NZ, the MRL and the BXSB are three main types of SLE mouse models. 
Other less known lupus mice include the Moth-eaten (Me) strain developed from a 
mutation (recessive moth-eaten trait) in the C57BL/6J (Schultz and Zurier, 1978), the 
Palmerstron-North (PN) strain derived in New Zealand at the Palmerston North 
Hospital (Walker et al., 1978), and Swan strain that gets its name from Swiss Anti- 
nuclear as it was originally developed from a Swiss line and selected for breeding 
according to ANA positivity (Morrow and Isenberg, 1987).
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1.2.2 Natural history and immunopathological characteristics
Murine SLE parallels its human counterpart in a wide range of clinical, serological 
and immunopathological features and therefore provides a good basis for the studies of 
the disease. Clinically, murine lupus displays features of multi-organ involvement and 
exhibits symptoms resembling the active phase of human SLE at late stages. Many 
manifestations such as skin lesions, serum autoantibodies and immune complexes, and 
glomerulonephritis are found in common among these strains. As m entioned 
previously, one of the findings from the studies of murine lupus is that the disease is 
caused by genetically determined abnormalities of the haematopoietic stem or lymphoid 
cells. These abnormalities are commonly expressed as a generalised B-cell 
hyperactivity leading to hypergammaglobulinaemia, early IgM to IgG switching, 
production of autoantibodies against self antigens, and formation of im m une 
complexes. In contrast to lymphoid system hyperplasia, another common feature of 
lupus mice is, however, early thymic atrophy. The B-cell hyperactivity and the 
early recessive thymic function have been the two most intriguing features consistently 
found in all lupus mice, but their possible link in terms of pathological significance is 
still controversial.
Various SLE mouse models also show strain-related characteristics such as sexual 
preference. Similar to human SLE, the disease that develops in some lupus strains, like 
NZB/W and BXSB, is sex-linked, while others, like NZB and MRL/Ipr, are not. 
Female NZB/W and male BXSB mice display clinical disease in its most severe form 
including glomerulonephritis with heavy proteinuria, but the pathological changes in the 
opposite sex can be less severe and are developed much later. In spite of the general 
feature of female dominance in human SLE, the male preference in BXSB mice is 
interesting because, as mentioned previously, there are some families in which the 
disease occurs mainly in fathers and sons (Lahita et al., 1983).
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The difference in the onset, pace and degree of the disease development between 
strains is another feature of the mouse models. Two forms of murine SLE, the 'early- 
life' and the 'late life' models, have been described by many early investigators 
(Murphy and Roths, 1979; Theofilopoulos and Dixon, 1985; Warner, 1977; Howie 
and Helyer, 1968). The MRLIlpr is a typical early-life disease model. Some 
immunological abnormalities become observable as early as one or two months in the 
mice (Altman et al., 1981). The life span of the animals, both male and female, is 
about 5-7 months according to Morrow and Isenberg (1987), or the mean survival time 
(50% mortality) at 5 months as observed by Theofilopoulos and Dixon (1985). The 
onset and pace of disease development in BXSB male mice is similar to that of 
MRL/Ipr, but the female mice have a much longer life span with a 50% mortality of 
more than 20 months. In comparison, the NZB/W strain is a later-life model. The 
clinical manifestations and detectable serological abnormalities do not normally appear 
until about 4 months of age. The 50% mortality is approximately 8 months for the 
female mice (Theofilopoulos and Dixon, 1985). The differences in the disease onset 
and pace are still not clear, but it has been suggested that, apart from the genetic defect 
that determines B-cell hyperactivity, some kinds of accelerating factors could be 
controlling the development of the disease. These might be exogenous factors such as 
viruses and bacterial products that may activate B-cells (Rook and Stanford, 1992), or 
endogenous factors like female hormones and cytokine disorders (Kroemer and 
Martinez-A, 1991).
1.2.3 Treatment of murine SLE
Regarding the analogies between human SLE and the mouse models, lupus mice 
are valuable animal models for therapeutic experimentation to assess effects of various 
clinical interventions in the disease. Much effort has been made towards the control of 
lupus-like symptoms, serological and pathological changes, and some studies 
concerned the regulation of T and B-cell functions. Similar to treatments in human
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SLE, most of the approaches to the therapeutic studies of lupus mice have been targeted 
at the disease-associated inflammatory processes and hyperactivity of the immune 
system. These include immunosuppressive and cytostatic drugs. Corticosteroids, such 
as methylprednisolone which is still currently the treatment of choice in SLE patients, 
have been tested on NZ mice with some effects in reducing disease symptoms and 
increasing life expectancy (Fan et al., 1979; Fessel, 1980; Isenberg et al., 1982). 
Cytotoxic agents, such as azathioprine (Gelfand and Steinberg, 1972) and 
cyclophosphamide (Chia et al., 1981; McCune et al., 1988) have been shown to 
prevent or to arrest the disease progression in lupus mice. Cyclosporin A is a powerful 
immunosuppressant. It inhibits both spontaneous and LPS-induced anti-DNA antibody 
production by lymphocytes from lupus-prone mice in vitro (Klaus, 1981). However, 
none these immunosuppressive agents cure the disease. Therefore, the control of 
the clinical disease requires continuous use of the drugs, but long-term treatment with 
some of these drugs has been reported to increase malignant tumours in the animals. In 
NZB mice, it has been shown that treatment with azathioprine may cause a considerable 
increase in the appearance of thymic lymphomas (Marrow and Isenberg, 1987). In 
addition, predisposition to infections is a possible side effect of the immunosuppressive 
drugs which may in turn escalate the progression of the disease. Interestingly, in 
contrast to its effect on lupus mice, azathioprine causes leucopenia in human SLE. 
Cyclosporin A has also been reported to induce autoimmune disease in mice (Bucy et 
al., 1993).
On the other hand, paradoxically, some drugs which have immunostimulatory 
rather than anti-inflammatory effects were also reported to be beneficial to the disease. 
For example, N-(2-carboxyphenyl)-4-Chloroanthranilic acid disodium was found to 
have significant effects on increasing 50% survival time of female NZB/W mice 
(Ohsugi et al., 1978). This is in agreement with the observation in the in vitro study of 
lymphocytes frorti SLE patients that isoprinosine, an anti-viral drug w ith
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immunostimulatory activity, enhances T-cell mitogenic responses and IL-2 production, 
but reduces immunoglobulin production (Nakamura e? al., 1983).
There are other forms of experimental treatments which have been more specific, 
being directed primarily against the T, B or accessory cell compartments. Injection of 
prostaglandin E l considerably increases the survival of NZB/W (Winkelstein and 
Kelly, 1980) and MRLIlpr (Izui et al., 1980) mice and protects the mice against 
nephritis, which have been attributed to its selective effect on B lymphocytes. 
However, the treatments did not affect the production of anti-DNA antibodies although 
deposits of immune complexes in the kidneys were reduced in the mice. 
Administration of specific antibodies to CD4 molecules has been shown to prevent and 
reverse spontaneous autoimmune disease in three genetically unrelated strains of lupus- 
prone mice including NZB/W (Wofsy and Seaman, 1985; 1987), BXSB (Wofsy, 
1986) and MRL//pr (Santoro et al., 1988); and in other autoimmune diseases such as 
non-obese diabetic mice (Shizuru et al., 1988), experimental allergic encephalomyelitis 
(EAE) (Waldor et al., 1985), and collagen-induced arthritis (CIA) (Ranges et al.,
1985). However, like those non-specific immunosuppressive drugs, the effect is 
transient unless such treatment is continuously and chronically given. Upon a short 
course of anti-CD4 treatment, even combined with thymectomy, severe autoimmune 
disease still develops with autoantibody levels, proteinuria and mortality comparable 
with the controls, despite significant reduction of CD4+ cells (Connolly et al., 1992). 
Therefore, such a general depletion of T-helper cells also remains questionable both in 
theory and in practice.
Another therapeutic development that has shown disease-limiting effect is the anti­
idiotype suppression. Administration of syngeneic anti-DNA monoclonal antibodies 
(Hahn and Ebling, 1983; 1984) or syngeneic anti-DNA IgG with a synthetic 
immunoadjuvant (Zouali et al., 1985) is able to induce anti-idiotype antibodies which 
suppress the corresponding idiotype. Since anti-idiotypic therapy may have the
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undesired effect of increasing idiotype expression (Hahn and Ebling, 1984), anti- 
idiotypic antibodies conjugated with a cytotoxic agent neocarzinostatin, have been 
reported to eliminate anti-DNA antibody-producing cells selectively (Saski et al.,
1986). Following the demonstration of beneficial effects of this specific treatment on 
lupus mice, similar therapy for treating SLE patients by using a human-mouse or 
human-human hybridoma approach is being developed. In addition, many immune 
regulators such as thymic hormones and cytokines have also been used to treat lupus 
mice. One of the most notable approaches is the in vivo delivery of IL-2 by live 
vaccinia recombinant viruses in MRL!Ipr mice which showed prolonged survival, 
decreased autoantibody levels and absence of glomerulonephritis (Gutierrez-Ramos et 
al., 1990, 1991), although direct injection of recombinanat IL-2 in NZB/W mice 
showed no effect on the disease in an earlier study (Owen et al., 1989)
1 .3  Immune regulation and the role of cytokines
A property that is universal to all biological systems is the need for regulation. 
This also applies to the immune system which may otherwise malfunction and cause 
disease. The mechanism of immune regulation is important not only in the control of 
the magnitude of an immune response once it is initiated, but also to establish a stable,
non self-responsive environment, during the development of the immune system,
which should then be properly maintained throughout.
1.3.1 T-cell-mediated regulation
i) "Help" and "suppression"
Many studies have shown that the regulation of the immune response is a 
complex network involving distinct populations and sub-populations of regulatory 
cells. These cells interact among themselves and with populations of effector cells to 
up-regulate (help) or down-regulate (suppress) the immune response (Hodes, 1989).
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"T-helper", or "T-inducer", refers to a special subset of T-cells important in 
modulating the normal immune response. It is well known that, through specific 
cellular recognition, these cells can provide 'help' for many types of cells by producing 
a viriety of cytokines, or more precisely lymphokines, which are themselves non­
specific immune regulators. In antigen specific, T-dependent responses, T-helper cells 
are known to control the maturation of B cells. After activation, the B cells become 
sensitive to T cell-derived cytokines which drive them to proliferate and differentiate. 
This T-B cell co-operation has been recognised as an essential feature involved in 
imnune regulation. Playing a major role in the T-B cell communication, IL-2, as well 
as nany other lymphokines are a group of non-specific helper T-cell derived cell 
regulators inducible by stimulation either with antigens or mitogens such as 
Coicanavalin A. Numerous evidence has been presented indicating their cell regulatory 
activity (Balkwill and Burke, 1989), and their dysfunctions implicated in the 
pathophysiology of many diseases (Kromemer and Martinez-A, 1991). T-cell help has 
also been demonstrated in other immune responses including T-cell-mediated 
imnunity, such as the generation of cytotoxic lymphocytes (Hodes, 1989).
However, T-cells have been found to have the capacity to suppress immune 
responses as well. T-cell mediated suppression is a phenomenon observed for many 
yea's, but progress in clarifying the cellular nature of the so called 'suppressor cells' 
has been slow and the results controversial (Mitchison, 1989). This is partially due to 
the lack of specific markers necessary for distinguishing such a unique T-cell subset. 
Many immunologists still argue about the existence of suppressor T-cells, but the 
phenomenon of immune suppression has been continuously demonstrated. These 
suppressive regulatory events in the immune system have now largely been ascribed to 
the inhibitory actions of products of helper or inducer cells, such as IL-4, IL-10 and 
TGF-p.
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ii) Cytokines, T-helper phenotypes and their functional properties
Cytokines are peptidic or glycopeptidic mediators secreted by a array of cells that, 
similar to "classical" hormones, exert their effects via specific receptors expressed on 
the surface of target cells but within short distances. Although most cytokines are 
produced by several different cell types, a few of them are specific products of 
lymphocytes also called "lymphokines". Cytokines are well known to be integrated in 
a regulatory network of mutual interactions (Balkwill and Burke, 1989). Their effects 
are pleiotropic in the sense that they participate in induction of many different kinds of 
responses in cells of multiple types. They may induce or suppress the secretion of 
others so regulating each other.
In mice, on the basis of two essentially non-overlapping sets of characteristic 
lymphokines that they secrete, T-helper cells (CD4+) have been phenotypically divided 
into two sub-populations. T-cells that secrete IL-2 and IFN-y are designated as T hl,
and those that secrete IL-4, IL-5, IL-6, IL-7, IL-8 and IL-10 are termed Th2 (Mosmann 
and Coffman, 1989). In addition, ThO is a third T-helper phenotype described 
recently, referring to cells that have the ability to secrete lymphokines overlapping both 
T hl and Th2 subsets (Street et al., 1990), and most of the CD4+ cell clones in human 
have been found to possess the ThO phenotype in their secretion of lymphokines.
The significance of the phenotypic division is mainly about the functional 
property of the different cytokines that are associated with the regulation of various 
immune responses. It is suggested that Th2 cells which produce lymphokines like IL- 
4, IL-5 and IL-6 are associated with B-cell differentiation (Finkelman et al., 1990; 
Harriman et al., 1988), thus regulating humoral immunity. Lymphokines of the Thl 
phenotype are important in the regulation of cellular immunity since they are found to 
be associated with the generation of delayed-type-hypersensitivity responses. Evidence 
has been shown that in some pathological states including both infectious and allergic
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diseases, the spectrum of lymphokine production by the CD4+ cells tends to shift 
towards a Th2 phenotype (Romagnani, 1990). However, such functional division is 
not absolute as IFN-y has also been shown to enhance antibody responses in both mice 
and humans (Snapper et al., 1988); and an effective response by cytotoxic CD8+ cells 
may require regulation and augmentation by a combination of cytokines of both Thl 
and Th2 phenotypes (Carreno et al., 1992).
In fact, many studies have suggested that the functions of 'help' or 'suppression' 
of a given cell type or their derivatives (cytokines) are often relative rather than absolute 
depending on many factors which ensure a dynamically balanced immune system. For 
example, IFN-y may enhance both murine IgG2a and human IgGl responses but it 
inhibits many of the functions of IL-4 on murine B-cells including the capacity of IL-4 
to cause Ig class switching (Paul, 1989). Conversely, although IL-4 synergies with the 
Thl-derived cytokine IL-2 in promoting the IL-2-dependent growth of CTL cells, it has 
also been shown to down-regulate the activity of IL-2 on the induction of lymphokine- 
activated killer cells mediated through monocytes (Brooks et al., 1992). On the other 
hand, cytokines do exert particular and predictable effects on the immune system as 
they interact with defined targets. One way that determines the specificity of different 
cytokine's actions is the expression of specific receptors for each cytokine by target 
cells. It also depends how these receptors are linked to the distinct pathways of 
intracellular signalling that regulate cell behaviour (Swain, 1991).
1.3.2 Interleukin-2 and its central role in immune regulation
In the cytokine family, IL-2 produced by T-cells is believed to provide a universal 
signal for proliferation of antigen or mitogen-activated T-cells through its binding to 
specific cell receptors (Swain, 1991). IL-2 is the first of a series of lymphocytotropic 
hormones and the one best characterised both in terms of molecular biochemistry and 
functions. The production of this 15.5 KD effector glycoprotein is thought to be
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confined to CD4+ periphery T-cells of the inflammatory phenotype (Thl) and certain 
thymocyte subsets. IL-2 was first studied for its key role in supporting clonal 
expansion of T-cells therefore named previously as T-cell growth factor' (Morgan et 
al., 1976). It stimulates T-cells to undergo cell cycle progression via its specific 
receptors (IL-2R). Subsequently, many other important functions of IL-2 have been 
disclosed including modulating activation, functional differentiation and division of B- 
cells, natural killer (NK) and lymphokine activated killer cells (LAK) (Smith, 1988, 
1990). Under normal circumstances, IL-2 acts either as an autocrine growth factor 
(Meuer et a l, 1984) (e.g. Thl and pro-T-cells) or in a paracrine fashion, where specific 
T hl cells release IL-2-containing vesicles in apposition to the contact site with the 
interacting cells (Sitkovsky and Paul, 1988). IL-2 and its mRNA, and signals that 
induce the IL-2 gene transcription are short-lived (Mier and Gallo, 1982). IL-2 is 
subjected to proteolytic process and antagonised by soluble inhibitors (Kucharz et al., 
1988). It is also rapidly cleared by the kidney and has a serum half-live of 3.7 (± 0.8) 
mins after i.v. injection (Donohue and Rosenberg, 1983).
While resting T-cells lack the ability to produce IL-2 and do not express anti-Tac 
reactive components of the IL-2R, exposure to lectin or antigen in the presence of 
accessory cells induces T-cells to release IL-2 (Meuer et al., 1984) and display 
immunoreactive IL-2R (Williams et al., 1985). The interaction of IL-2 with the IL-2R 
promotes progression of T-cells through the S phase of the cell cycle (Gillis et al., 
1977; Leonard, 1992). Studies employing accessory cell depletion have shown several 
stimuli required for induction of IL-2 and IL-2R. Transcription of IL-2 mRNA, 
production of IL-2 protein, and expression of membrane-bound IL-2R are dependent 
upon T-cells receiving signals from antigen in conjunction with co-stimulator from 
accessory cells. IL-1, IL-6 and used to be proposed as the candidates responsible for 
co-stimulation (Hadden, 1988; Majumdar etaL,1990). More recently, an increasing 
number of accessory molecules mediating the process has been identified and many of 
the ligands for the accessory molecules are cell surface proteins expressed on lymphoid
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cells (Hivroz-Burgaud and Cantrell, 1992. The interaction of CD28 molecules of T- 
cells and a B-cell molecule B7/BB1 has now been considered to be the major co- 
stimulatory pathway for IL-2 production (Norton et al., 1992).
The central role of IL-2 in the regulation of the immune system has been well 
documented. It has been established since the early 80s that the presence of IL-2 is 
both necessary and sufficient for the expansion of most T-cells, natural killer cells and 
B-cells following activation. Interference of IL-2 activity, with antibodies to IL-2 or its 
receptors for examples, blocks the development of antibody-secreting B-cells, and the 
development of precursors into cytolytic effectors. Later it was shown that blocking 
IL-2 production in the thymus interrupted T-cell development (Tentori et al., 1988); and 
blocking with anti-IL-2R in vivo prevented the development of virus-specific cytotoxic 
T-cells (Leist et al., 1989). IL-2 may also induce other changes in cell behaviour. It 
stimulates the expression of IL-2R p55 chain (Smith, 1989), as well as up-regulating 
other cytokine receptors on lymphocytes such as that for tumour necrosis factor (TNF)- 
a  (Owen-Schaub et al., 1989).
1.3.3 Immune regulation, tolerance and ontogeny of the immune system
Apart from the function of generating immune responses to foreign antigens, 
another fundamental aspect of the immune system is tolerance to self tissues. In 
healthy individuals, self-reactive B cells and low titre detectable autoantibodies are not 
uncommon. The origin of the self-reactive B cells is not clear but, to maintain 
unresponsiveness to self, the immune system is believed to be capable of preventing 
autoimmunity through specific deletion of self-reactive T and B-cell clones or by 
suppression. The term 'tolerance' defines a state of specific immunological 
unresponsiveness to an antigen which arises after an initial encounter with the antigen 
(Male et al., 1987, Miller et al., 1993). "A state of indifference or non-reactivity 
towards a substance that would normally be expected to excite an immunological
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response" described R.D. Owen (1945) almost 50 years ago. The concept of tolerance 
today includes 'acquired immunological tolerance' that is the unresponsiveness arising 
as a result of administration of exogenous antigen, and 'natural immunological 
tolerance1 or 'self-tolerance' defining the immunological unresponsiveness to 
endogenous antigens.
The mechanism of self-tolerance is crucial in establishing a normal immune 
system, which included clonal deletion of self-reactive immunocytes. The hypothesis 
of Burnet and Fenner, dealing with unresponsiveness to self antigens, stated that all 
anti-self lymphocytes were eliminated before maturity (Burnet and Fenner, 1949). On 
the other hand, autoimmune states can also be regulated by the induction of a state of 
acquired immunological unresponsiveness. The mechanisms of tolerance induction are 
still hypothetical. One mechanism that has been proposed to explain B-cell tolerance is 
exhaustive terminal differentiation which might result in clonal deletion of the B-cell. It 
has been established that many more precursors for a response against a particular 
autoantigen are present in the pre-B-cell pool than in the mature B-cell pool (cited from 
Male et al., 1987). It was therefore interpreted that a process of purging occurs that 
leads to elimination of the autoreactive B-cells during ontogeny. A similar conclusion 
can be drawn when the clonal deletion mechanism is extended to the T-cell repertoire 
where the so called 'thymic negative selection' process is involved to prevent release of 
potentially autoreactive T-cell clones into the circulation. It is now belived that the 
mechanism of T-cell selection is related to the T-cell receptor rearrangements and the 
affinity of the receptors for self-MHC molecules (Lydyard and Grossi, 1993). T-cells 
which may be negatively selected include cells not making successful TCR gene 
rearrangements, and those which have successfully rearranged their genes but have 
produced receptors which either no affinity, or very high affinity for MHC molecules. 
This programed cell death occurs by apoptosis achieved by activating endogenous 
nucleases, causing DNA fragmentation.
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Another mechanism for induction of tolerance has been attributed to T suppressor 
cell activity or, alternatively, immunosuppression. It was first shown by Gershon and 
Kondo (1972) that when animals were given a large dose of sheep red blood cells they 
became tolerant to this antigen. The importance of this finding is that such tolerance 
can only be induced in the presence of T-cell help. Since splenic T-cells could transfer 
this unresponsive state to other mice, the tolerance was suggested to be mediated by T 
suppressor cells. Similar studies have subsequently been demonstrated using different 
antigens. In some early reports, absence of a suppressor T cell subset was suggested 
to lead to B cell hyper-reactivity and to be linked with elevated levels of autoantibodies 
in SLE (Abdou et al., 1976, Bresnihan and Jasin, 1977). Morimoto et al. (1987) 
found that lack of CD4+2H4+ cells, a suppressor-inducer T-helper subset, is 
characteristic in patients with SLE. Although the role of suppressor cells in 
autoimmune diseases still remains controversial, a CD45RClow Th2-like phenotype has 
recently been found responsible for suppression of diabetes in rat (Fowell, 1993). A 
reduced CD4T-cell-mediated suppression of autoantibody response rat RBC has also 
been observed in NZB mice (Roitt, 1993)
The role of cytokines in the induction of tolerance is controversial. The ability of 
IL-2 to modulate tolerance induction is particularly interesting but paradoxical. It has 
been suggested that the presence of IL-2 interferes with the generation of a state of 
tolerance (Male et al., 1987). The reasons are, firstly, the fact that neonatal spleen cells 
do not produce IL-2 following Con A stimulation; secondly, stimuli known to trigger 
IL-2 production (the lectin Con A, and graft-versus-host reactions) block, whereas 
reagents which suppress IL-2 production, such as cyclosporin A and anti-CD4 (L3T4), 
favour tolerance induction; and thirdly, in vivo administration of IL-2 blocks the 
development of tolerance to alloantigens and the generation of antigen specific T 
suppressor cells by haptenated cells. However, the thymus, which is known to be an 
important organ where the tolerisation of T-cells takes place, produces a considerable 
number of peptides influencing T-cell development. These are thymus-derived
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hormones including thymosin, thymopoietin, thymulin and thymus humoral factor, 
some of which have been shown to promote the differentiation of IL-2 producing T- 
helper cells. The role of IL-2 in intrathymic T-cell selection is not clear, but normal 
thymus does not lack CD4+ mature T-cells which are capable of producing IL-2. In 
addition, IL-2 is known to be essential for the maintenance of all T-cell lines. It is 
conceivable that IL-2 might be necessary for the generation of suppresser T-cells which 
is one of the important mechanisms for induction of tolerance. Most recent evidence 
has indicated that IL-2 induces apoptosis in mouse thymocytes (Migliorati et al., 1993).
1 .4  Cytokine regulation in autoimmunity
In normal individuals, the expression and production of cytokines are under tight 
regulatory control. The presence or absence, and decreased or increased activity, of a 
particular cytokine can have profound effects on the regulation of the immune system. 
In the recent years, the role of cytokine regulation in autoimmune diseases, in which the 
immune system is apparently disordered, has been widely studied. In vitro and in vivo 
evidence to date indicates the involvement of cytokine dys-regulation in the 
development of autoimmunity. Abnormal production and defective responsiveness of 
lymphocytes to various cytokines have been demonstrated in many of the autoimmune 
disorders including SLE.
1.4.1 Cytokine disorders in SLE and other autoimmune diseases
As mentioned previously, one of the main T-cell functional abnormalities in SLE 
is the abnormal production of cytokines. A defective IL-2/IL-2R system, in particular, 
has been implicated in the autoimmune phenomena In both human SLE (Linker-Israeli 
et al., 1983; Tsokos and Balow, 1984; Murakawa et al., 1985; Huang et al., 1986, 
1988; Hishikawa et al., 1990) and lupus-prone mice (Altman et al., 1981; Blank et al., 
1981; Wofsy et al., 1981; Theofilopoulos et al., 1985; Santoro et al., 1987; Zubler and
48
Miescher, 1990), it has been shown that there exists a defect in the ability of T-helper 
lymphocytes to produce IL-2. By stimulating T-cells in vitro with different T-cell 
mitogens such as Con A or PHA, or allogeneic stimulator cells, these studies all 
showed a reduced level of IL-2 activity in the cell culture supernatants when compared 
to normal controls. The in vitro IL-2 production defect has also been found to be 
common in some other autoimmune diseases. A similar abnormality is present in 
rheumatoid arthritis (RA) (Combe., 1985), Sjogren's syndrome (Leventhal et al., 
1967) and active multiple sclerosis (Merrill et a l, 1984). In addition, it has been 
demonstrated that T-cells from MRLIlpr mice also lack ability to respond to IL-2. 
Altman (1981) showed that cells from lymph nodes and spleens of 6-month old 
MRL/lpr mice were unable to proliferate in response to Con A even in the presence of 
IL-2. This was later attributed to a defect in IL-2R expression (Wofsy et al., 1984). 
Since IL-2 is known to be required for up-regulation of functional IL-2R expression, it 
is still not clear whether the defect in IL-2R expression is secondary to the defective IL- 
2 activity in the disease. However, in MRL/lpr mice, it has been shown that the 
abnormally accumulated DN T-cells were unable to generate functional IL-2R 
(Rosenburg et al., 1989; Tanaka et al., 1993).
Early studies have suggested that autoimmunity might be regulated in part by IFN 
modulating macrophage la antigen expression resulting in enhanced production of cell 
antigens (Steeg et al., 1982). In organ-specific autoimmune diseases, it was shown 
that IFN-y increases expression of class II MHC antigens leading to inappropriate 
presentation of self antigens, and inhibits IL-4 activity by altering the balance of Ig 
isotype expression or by Fey receptor expression (Bottazzo et al., 1986). It has been 
proposed that the immuneactivating lymphokine may have deterious effects in 
autoimmune diseases (Rosenberg et al., 1984). However, peripheral mononuclear 
cells from patients with rheumatoid arthritis exhibit deficient production of IFN-y in 
vitro (Hasler et al., 1983), and clinical studies indicate that IFN-y has some efficacy in 
the treatment of this disease (Browning, 1989; Machold et al., 1992). In SLE, studies
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on production of IFN-y are not in agreement with each other too. Impaired ability of 
SLE mononuclear cells to produce IFN-y in response to some viruses has been reported 
(Neighbour and Grayzel, 1981; Strannegard et al., 1982). Some studies also showed 
decreased mitogen-induced production of IFN-y in both SLE patients (Tsokos et al., 
1988) and lupus mice (Kofler et al., 1984), but others described normal production of 
IFN-y in the disease (Santoro et al., 1983; Mckenna et al., 1988).
The LPS- and/or IFN-y-triggered in vitro secretion of TNF-a by macrophages 
from several autoimmune-prone strains of mice has been found to be significantly 
lower than that produced by MHC-matched controls (Jacob et al., 1988, 1990; Malave 
et al., 1989). Using restriction fragment length polymorphism (RFLP) technique to 
analyse TNF-a gene, Jacob revealed abnormalities that correlated with the defective 
TNF-a production in the NZW strain of mice, known to carry a gene responsible for 
induction of autoimmune disease. In later studies, although it was shown that many 
normal inbred strains of mice exhibit a similar RFLP too (Richter et al., 1989), a 
polymorphic microsatellite in the TNF-a promoter has been shown to identify an allele 
unique to the NZW mouse strain (Jongeneel et al., 1990).
Moreover, abnormal production of many other cytokines are found to be 
correlated with autoimmune diseases. Linker-Israeli (1983) showed that, apart from 
their inability of IL-2 production in response to PHA or allogeneic Daudi cells, 
peripheral blood mononuclear cells from SLE patients produced lower levels of IL-1 in 
response to phorbol myristic acetate (PMA). This was confirmed by Dinarello (1989) 
who showed that blood monocytes from SLE patients produce less IL-1 than controls 
but, in contrast, monocytes from patients with active RA produced elevated amounts of 
IL-1. Recently, Levine et al. (1993) have shown evidence that IL-1 dysregulation is an 
intrinsic defect in macrophages from MRL/lpr mice. Since IL-1 used to be suggested 
as a co-stimulator required for IL-2 production, the inability of macrophages to produce 
IL-1 was considered to be a possible cause for low in vitro IL-2 production in SLE.
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However, by adding exogenous IL-1 in vitro Linker-Israeli et al. (1983) did not restore 
ability of T-cells from lupus patients to produce IL-2. Defective LPS-induced 
expression of IL -la , IL-ip and IL-6 by peritoneal macrophages has also been 
demonstrated in autoimmune-prone mice (Donnelly et al., 1990). Furthermore, T-cells 
from MRL mouse strain display defective IL-3 production in response to pokeweed 
mitogen (PWM) (MacNeil et al., 1986) and Con A. Santoro (1987) showed evidence 
suggesting that, the defective Con A-induced IL-3 as well as IL-2 production was not 
only in the DN but also in the CD4+ cell subsets in the Ipr-bearing MRL//pr and 
C57BL/6 mice.
1.4.2 Controversy and hypothetical mechanisms
In SLE and other autoimmune situations, B cells are hyperactive, proliferating 
and secreting large amounts of immunoglobulin, as if they were receiving excessive 
stimulatory signals. T-cell help has been shown to be essential for induction of B-cells 
to produce an anti-DNA responses in mouse chimaera models of SLE (Stott et al., 
1988) and in NZB.H-2bm12 mice (Naiki et al., 1992). However, the deficient 
production of IL-2 and other cytokines are difficult to reconcile with the elevated B-cell 
activity. Although the in vitro IL-2 hyposecretion has been consistently demonstrated 
in many studies, there have been different views on its nature. It has been suggested 
that the inability of lupus T-cells to secrete IL-2 might be an outcome of the 
development of the autoimmune lesions (Kroemer and Martinez-A, 1991). 
Paradoxically, autoimmune diseases like SLE (Huang et al., 1988) and multiple 
sclerosis (Adachi et al, 1989; Trotter et al., 1988) associated with defective in vitro IL- 
2 production are reported to have elevated serum IL-2 levels. Huang and his colleagues 
found that sera from 50% of the SLE patients contained higher levels of IL-2 compared 
to normal controls. Most interestingly, he also showed that the ability of lupus T-cells 
to produce IL-2 could be restored when these cells were rested for 2 to 3 days in culture 
before stimulation (Huang et al., 1986). The authors suggested that the in vitro IL-2
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hyposecretion could be due to a transient exhaustion of T-cells that had been over 
activated in vivo. Alternatively, others suggested that the suppressed cytokine activity 
and cell proliferative responses could be a consequence of non-specific immune 
suppression resulted from the hyperactivated immune system. It may therefore reflect 
some kinds of operating negative feedback mechanism that attempts to restore the 
immune homeostasis. In MRL/lpr mice, since the disease is associated with the 
expansion of phenotypically immature and functionally unknown double-negative 
CD3+ lymphocytes, lack of IL-2 activity in culture supernatants of Con A-stimulated 
spleen cells has been attributed to a 'cell dilution' effect by the proliferating non-IL-2 or 
other cytokine secretors (Kroemer and Wick, 1989). Moreover, release of soluble IL- 
2R which prevents function of IL-2 and is elevated in SLE (Cuadrado et al., 1993) and 
other autoimmune diseases such as multiple sclerosis (Greengery et al., 1988), is also 
thought to be a possible cause responsible for the reduced cytokine levels in cultures.
One of the important questions is whether abnormalities in cytokine production or 
responsiveness may predispose to the development of the autoimmune disease. Several 
studies have suggested that deficient IL-2 activity may be intrinsic to SLE lymphocytes 
because the defect was observed in SLE patients regardless of the disease activity or 
corticosteroid therapy (Linker-Israeli et al., 1983; Tsokos and Balow, 1984; Murakawa 
et al., 1985). However, the evidence for a possible intrinsic nature of IL-2 deficiency 
is still lacking. Nevertheless, the defective lymphokine production and responsiveness 
indicate the functional abnormalities of the lymphocytes. Although the original defect 
that causes these functional disorders is still to be clarified, it has led to speculation that 
an imbalance in the normal T-cell-mediated regulatory processes of the immune system 
might cause abnormal B-cell regulation thereby contributing to the development of 
autoimmune diseases.
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1.4.3 Aim and scope of the thesis
The aim of the study was to investigate the mechanisms of immune regulation, 
particularly the roles of cytokine disorders, in the development of lupus disease. The 
study included both in vitro (Chapters 3 to 6) and in vivo (Chapters 7 to 8) approaches 
based on mainly two murine models of SLE. The thesis focuses on the roles of T- 
helper cells and the nature of various lymphocyte functional defects in association with 
different immunological and serological abnormalities, and the characteristic 
pathological changes in SLE.
As part of the in vitro study, the third chapter begins the investigation by looking 
at the abnormal IL-2 production in lupus mice at different ages and the natural history 
of murine lupus disease. This is to determine the onset of this T-helper cell functional 
abnormality and its relationship to the kinetics of disease. Subsequent experiments 
described in the fourth chapter were designed to analyse other functions of T-cells from 
lupus mice, and from SLE patients in selected experiments. These included Con A- 
induced T-cell proliferation, IL-2R expression, production of IFN-y and IL-4, as well 
as mRNA expression of Thl and Th2 phenotypes for IL-2, IFN-y, IL-4 and IL-6. The 
role of T-cell activation co-stimulators including effects of IL-1 and adherent cell 
function was also studied. To understand the role of IL-2 deficiency in the defective T - 
cell functions, the fifth chapter demonstrates the effects of exogenous IL-2 on lupus T- 
cell activation. In addition, the in vitro effects of IL-2 on autoantibody secretion, and 
the responsiveness of different T-cell subsets from MRLllpr mice to IL-2 were also 
discussed. Concerning serological abnormalities in SLE, the sixth chapter describes 
mainly a finding of serum factors which are increased in SLE patients with active 
disease, and in some lupus mice. The serum factors which affect the growth of IL-2 
dependent CTLL cells were partially characterised in an attempt to determine their 
nature and the possible role in the immune disorders.
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Based on the evidence from the in vitro observations, the following two chapters 
explore the possibility of treatment of lupus disease by cytokine intervention. A new 
approach using Salmonella typhimurium aro' mutant as a vector to deliver cytokines in 
vivo was carried out in the small scale pilot studies. The in vivo effects of TGF-pl 
and IL-2 on lupus and normal mice are described in the seventh and the eighth chapters 
respectively.
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Chapter 2 
MATERIALS AND METHODS
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2 .1  Animals and materials
2.1.1 Animals
i)____ Mouse Models
MRL-Mp-/lpr/lpr (MRL/lpr) and [NZBxNZW]Fl (NZB/W) mice, were bred in 
the Glasgow University Animal House from pairs purchased from Harlan Olac Ltd., 
UK Female mice were used in the study. Sex and age matched normal BALB/c and
CBA control mice were also purchased from Harlan Olac Ltd., UK BALB/c mice were
used as controls throughout the study and, in addition, CBA mice were used in selected 
experiments. All mice were kept in the Animal House, Gartnavel Hospital, Glasgow.
The lupus mice were divided into groups according to age. NZB/W mice aged 
between 7 and 9 months or MRL/lpr mice aged between 4 to 6 months were old mice 
which exhibited obvious clinical symptoms with elevated serum autoantibodies. Young 
mice of different ages before the development of overt autoimmune lesions were used at 
3, 2, 1-month and 1-week old as indicated.
iO Rabbits
Two NZB female rabbits (005865, 004896), weighing 2.5 and 3 kg, were 
purchased from Froxfield U.K. and kept in the Animal House, Gartnavel Hospital, 
Glasgow.
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2.1.2 Plasma and serum samples
f)____ Mouse sera
Blood samples were taken from all experimental mouse models including lupus 
strains, MRLflpr and NZB/W, and normal control BALB/c and CBA mice. Ether 
anaesthesia was used and the mouse was bled by common iliac artery puncture prior to 
the removal of its spleen.
ii) Rabbit sera and antisera
Normal rabbit sera and rabbit anti-r-human IL-2 antisera were obtained by 
bleeding the ear vein before and after immunisation with antigen.
iii) Human plasma and sera
SLE plasma and sera were obtained from blood samples from diagnosed SLE 
patients with active disease, kindly provided by Dr J. Hunter in the Department of 
Rheumatology, Gartnavel Hospital. Normal human plasma and sera were obtained 
from healthy donors and provided by the Blood Transfusion Unit, Western Infirmary, 
Glasgow.
All serum and plasma samples were kept at -20°C before assaying. Plasma 
samples were supplied in the presence of anticoagulant either potassium EDTA (BS 
4851 5ml sample container) or heparin (10 i.u./ml).
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2,1.3 Tissue and sections
Freshly isolated mouse kidneys were sliced into halves longitudinally and 
processed as follow for histological and immunocytochemical examinations:
j) Frozen tissue
Blocks of tissue were fast-frozen in liquid nitrogen and kept at -70 °C. 24 to 48 
hours before each assay, 5 pm sections were cut from the frozen tissue, mounted on 
washed plain glass slides, and kept at 4°C.
iil Paraffin-embedded fixative-fixed tissue
Blocks of tissue were fixed in neutral buffered formalin or in Bouin's fixative. 
After being embedded in paraffin wax, 4 pm sections were cut and mounted on washed 
plain glass slides.
2.1.4 Cel 1 li nes and maintenance
i)____ CTLL cell line
The mouse CTLL (cytotoxic T lymphocyte line, Gillis & Smith, 1977) cell line 
was kindly provided by Dr. Richard Grencis at the University of Manchester. The IL-2 
dependent mouse CTLL cells were routinely maintained at 370C/5%CO2 in a 
humidified incubator in RPMI-1640 complete culture medium containing 10%FCS, 
supplemented with r-human IL-2 at 10 ng/ml and 2-mercaptoethanol at 50 piM. The 
cells were passaged regularly and rigorously every 2 to 3 days. To split cells, 80-85% 
volume of the cell culture was replaced with fresh medium that contained IL-2.
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ii) Mink Lung cell line (CCL-64)
The CCL-64 mink lung cell line was kindly provided by Professor F.Y. Liew and 
his research group at the Research Laboratory of Immunobiology, Wellcome 
Foundation, UK. The cells were adherent cells and routinely maintained at 37 
°C/5%C02 in a humidified incubator in RPMI-1640, or DMEM (Dulbecco's Modified 
Eagle's Medium) complete culture medium containing 0.45% glucose and 10% FCS in 
25-cm2 culture flasks. Culture medium was changed every 3 days. Two days before 
each assay, the cells were propagated in a new flask of appropriate size depending on 
cell number required. The cells were detached from culture flasks by trypsinisation 
(Holley et al., 1983). After two washes with warm serum-free culture medium, the 
cells were incubated with 0.025% trypsin in calcium and magnesium free tris buffer 
saline containing 0.5 mM NaiEDTA for 2 to 3 minutes at 37 °C. Cells were then 
suspended by gently patting the wall of the flask and the enzyme activity stopped by 
addition of culture medium which contained 10% FCS. An aliquot of the cells was re­
seeded in fresh culture medium in a new flask or 96-well assay plates.
Both the CTLL and mink lung cell lines have been screened for mycoplasma and 
found to be free of mycoplasma contamination.
2.1.5 Reagents and Chemicals (see Appendix I)
2 .2  Antibody production, quantitation, purification and conjugation
2.2.1 Production of antibodies to rIL-2 in rabbits
i) Antigen preparation
Recombinant human IL-2 (Glaxo) 10 p.g/ml dissolved in PBS, was mixed and 
emulsified with an equal volume of Complete Freund Adjuvant (CFA) for primary 
immunisation, or Incomplete Freund Adjuvant (IFA) for subsequent booster injections,
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in a 10 ml sealed syringe on a Griffin Flask Shaker. After 1 to 2 hours vigorous 
shaking, the antigen emulsion was checked by its ability to form stable droplets on the 
surface of water.
iri Immunisation of rabbits
Prior to the primary immunisation, 5 ml blood was taken from the ear vein of 
each of two normal rabbits (005865,004896), 5 months of age, and the sera were kept 
at -20 °C for assay controls. Each rabbit was injected subcutaneously with the antigen 
at 8 sites, 0.2 ml/site (about 8 pg rIL-2 per animal). Subsequent booster injections of 
the antigen in IFA were given 4 weeks after the primary immunisation and at 2 week 
intervals thereafter. Blood samples were taken immediately before each injection and 
tested for titres of specific antibodies to r-human IL-2 by ELISA. In antisera with high 
titres of specific antibodies, the immunoglobulin fraction was purified by ammonium 
sulphate precipitation.
iiri Titration of antisera
A HRP-conjugated goat anti-rabbit IgG was used to monitor specific antibodies to 
r-human IL-2 raised in the rabbits. r-Human IL-2 (Glaxo) was diluted to 5 pg/ml in 
carbonate coating buffer and 100 pl/well plated on a 96-well Dynatech micro-ELISA 
plate (Immulon 2) before incubation at 4 °C overnight. Although IL-2 concentrations at 
up to 10 pg/ml have been tested for coating, it did not reach saturation (according to a 
preliminary assay of antigen titration). A 5 pg/ml coating concentration was chosen 
because it satisfied the assay purpose of antibody titration. After washing 4 times with 
tris-Tween buffer, the remaining binding sites on the plate were blocked by adding 200 
pi of blocking buffer, 0.5% (w/v) bovine serum albumin (BSA) in PBS, to each well. 
This was incubated at room temperature for 30 minutes, and then washed 4 times in 
tris-Tween buffer. Serial dilutions of the rabbit antisera in PBS were then added to 
each well (100 pl/well, duplicates) and incubated at 4 °C for 2 hours. Negative
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controls were provided by using normal sera taken from the same rabbits before 
immunisation. After incubation, the plates were washed 3 times. 100 pi of the HRP-
conjugated goat anti-rabbit IgG diluted 1:1000 in 0.5% (w/v) BSA in PBS, was added 
to each well and incubated at room temperature for 30 minutes. Following 5 washes in 
tris-Tween buffer, 100 pi of substrate, orthophenylene diamine (OPD, Sigma) diluted 
to 0.4 mg/ml in Mcllwaine's buffer containing 0.32 pl/ml hydrogen peroxide, was 
added and incubated for 30 minutes in the dark at room temperature. The reaction was 
stopped by adding 100 pi per well of 4N sulphuric acid, and the optical density was 
read on a 'Multiscan' spectrophotometer, at 492 nm.
ivl Immune responses of the rabbits to IL-2
Figure 2.1 shows the specific immune responses of the two rabbits. Four weeks 
after the primary immunisation, both rabbits 005865 and 004896 showed an immune 
response to the antigen given. The antiserum titres increased linearly after subsequent 
boost injections and reached a peak level at week 8, 2 weeks after the second boost 
injection. Rabbit 004896 was killed at 9 weeks due to a serious skin infection around 
the sites where antigen was injected.
2.2.2 Quantitation of autoantibodv production in the mouse models
i) Quantitation of anti-ssDNA and anti-dsDNA antibodies by ELISA
Calf thymus DNA (Sigma), single (ss-) or double (ds-) stranded, was used as 
antigen. To obtain ssDNA, the calf thymus DNA at 1 mg/ml in borate buffered saline 
(BBS, pH 8.5) was boiled for 10 minutes and put on ice. dsDNA for antigen coating 
was prepared by SI nuclease digestion and phenol extraction (Sambrook et al., 1989) 
before using for coating plates. The dsDNA used in this study was kindly prepared 
and given by Dr. R. Quinn in the department.
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Fi2ure 2 .1  Immune responses of rabbits to r-human IL-2. Serum samples 
taken from 2 rabbits (R5865, R4896) at different time points after immunisation with IL- 
2 were assayed by ELISA. One rabbit (R4896) was killed at 9 weeks after the primary 
immunisation because of severe skin infection. The titration curves show specific 
antibody titres in serum samples diluted at 1:3200.
A 96-well Dynatech micro-ELISA plate (Immulon 2) was used in the assay. 
Before antigen coating, the plates were treated with poly-L-lysine (Sigma) 50 pg/ml in 
BBS, 100 pl/well incubated at 37 °C for 1 hour then at 4 °C overnight. After 3 washes 
in BBS containing 0.02% Tween-20, ssDNA or dsDNA diluted 10 pg/ml in BBS was 
coated, 50 pl/well, onto the plates. The plates were incubated 3 hours at 37 °C or 
overnight at 4 °C and unbound antigen was washed off 4 times with BBS-Tween. 
Remaining binding sites on the plates were blocked by adding 200 pi of blocking
buffer, 0.5% (w/v) bovine serum albumin (BSA) in BBS, to each well. This was 
incubated at room temperature for one hour, and the plates were either stored with 
BSA/BBS in the wells at -20 °C or used for immediate assaying.
After 3 washes with BBS-Tween, serial dilutions of standard and test samples in 
diluent, 2% BSA/ BBS/0.05% Tween-20 (for anti-dsDNA 10% normal goat serum 
was added), were then added to the plates (50 pl/well, duplicates) and incubated at 4 °C 
overnight. After incubation, the plates were washed 3 times with BBS-Tween and 
blotted dry. An alkaline phosphatase conjugated goat anti-mouse immunoglobulin 
antibody (y-chain specific, Sigma) was used as a detector antibody, 1/1000 diluted in 
the diluent and incubated at room temperature for 30 minutes. Following 5 washes 
with BBS-Tween, the substrate, p-nitrophenyl phosphate (p-NPP, Sigma) 1 mg/ml in 
the p-NPP substrate buffer (see Appendix I), 50 pi per well, was added and incubated 
for 30 to 45 minutes in the dark at room temperature. The reaction was stopped by 
adding 100 pi per well of 1 M sodium hydroxide, and the optical density was read on a 
'Multiscan' spectrophotometer, at 492 nm.
For titration purposes, pooled sera from MRL//pr mice (5 months) was used as a 
standard for anti-ss and -dsDNA antibody quantitation. The sera had been shown in 
preliminary assays to have high titres of anti-ss and -dsDNA antibodies. For each 
assay, a series of two-fold dilutions of the standard serum from 1/50 to 1/102,400 was 
included in parallel with test samples. One titration unit (T.U.) is arbitrary defined as
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the amount of antibody present in a fixed dilution of the standard serum, which is 
1/10,000 for anti-ssDNA and 1/1,000 for anti-dsDNA antibodies in the study. From 
the standard curve of OD against dilutions, the equivalent dilution ( 1/x) of standard 
serum giving the same OD as the test sample was read off. Let the dilution of the test 
sample be 1/D. Therefore:
4
No. of T.U. in sample = —IQ— X D (anti-ssDNA) ------------------  (1)
X
3
No. of T.U. in sample = -1 0 -  X D (anti-dsDNA) ------------------  (2)
X
ii) Determination of the frequency of autoantibodv secreting cells bv FT JSPO T  assay
The assay was based on the method developed by Czerkinsky et al.(1988) to 
determine the frequency of antibody secreting cells. This technique was modified in the 
present study to detect autoantibody secreting cells.
Calf thymus ssDNA or dsDNA was prepared as previously described for the 
ELISA above, and diluted in 20x SSC (see Appendix I) at 10 pg/ml. The antigen was 
coated, 100 pl/well, onto a sterile Millipore Millititer 96-well plate (5THA 096NS) with 
HA 0.45 pm nitrocellulose membrane fixed to bases of wells. After 1 hour standing at 
room temperature, the plate was emptied, blotted dry and baked at 80°C for 2 hours. 
After coating, the plates were washed 3 times with PBS containing 0.05% Tween-20. 
Remaining binding sites on the plates were blocked by adding 200 pl/well of 
0.5%BSA/PBS and incubated at 37 °C for 30 minutes. Following 3 washes with PBS, 
the plates were pre-filled with culture medium (50 pl/well) and kept in an incubator at 
37°C/5% C02 until the cell suspension was ready. Splenic lymphocytes were washed 
and diluted in culture medium at the required concentrations of viable cells. lO* to 106 
viable cells per well in 100 pi culture medium were incubated overnight (16 hrs) at
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37°C/5% C02. The assay was carried out under sterile conditions until this step. The 
plates were then rinsed 5 times followed by immersing in PBS-Tween for 5 minutes.
A HRP-conjugated rabbit anti-mouse IgG (at 1/200, the Laboratory) and an 
alkaline phosphatase conjugated rabbit anti-mouse IgM (at 1/400, the Laboratory) were 
used as detecting antibodies. After an one hour incubation at 37°C, the plates were 
washed 4 times with PBS-Tween (without azide), immersed in 0.05 M tris buffered 
saline (TBS, pH 8.0) for 5 minutes and dried using aMillipore vacuum water pump 
system.
5-bromo-4-chloro-3-indoyl phosphate (BCIP, Sigma) and p-nitroblue tetrazolium 
chloride (NBT, Sigma) were used as substrate for alkaline phosphatase; and 3-amino- 
9-ethyl carbazole (AEC, Sigma) was used as substrate for horseradish peroxidase. To 
prepare these substrates, BCIP (3mg) and NBT (6mg) dissolved separately in 0.2ml 
dimethylformamide (DFM) were added to 20 ml of 0.1 M NaHC03 containing 1 mM 
MgC12 (pH 9.8). AEC (5mg) was dissolved in 0.4 ml DMF and added to 19 ml 
0.05M NaOAc (pH 5.0). The relevant substrates were filtered and added to the wells 
(100 pl/well) followed by a 20 to 30 minute development at room temperature. To stop 
the reaction, the plates were rinsed with PBS and blotted dry on paper towel. The 
number of spots was counted using a Carl Zeiss stereo zoom microscope. The spots 
were clearer and easier to count when the membrane of the plate was completely dry 
(i.e. when left overnight at room temperature).
2.2.3 Antibody purification
D____ Ammonium sulphate precipitation of immunoglobulins
The whole procedure was carried out at 4 °C. To 1 ml cold serum, an equal 
volume of saturated ammonium sulphate (Fisons) was added dropvvise with slow 
stirring for 1 hour. After centrifuging at 10,000 g for 10 minutes, the pellet was
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resuspended in 10 ml 50% saturated ammonium sulphate and centrifuged as before. 
The pellet was then dissolved in 1 ml distilled water and dialysed with 3 changes in 
PBS. The sample OD was read at 280 nm and the immunoglobulin concentration 
calculated:
Concentration of IgG (mg/ml) = OD280nm X dilution
1.3
iil Protein A column separation of human serum IgG
To characterise the unknown serum factor(s) found in SLE patients (Chapter 6), 
which affected the IL-2 dependent CTLL cells growth, a protein A column was used to 
separate IgG from other serum proteins.
Protein A coupled to Sepharose 4B fast flow (Sigma) in suspension form was 
loaded in an 1ml syringe with a glass bead at the bottom end of the column. The 1ml 
protein A column has a capacity for IgG binding of 35 mg. After a continuous wash 
with 10 times the column volume of PBS (0.02% sodium azide), 0.4 ml of serum 
sample was loaded and eluted with PBS. Protein concentration in the eluent was 
determined by its optical density measured at 280 nm. Unbound proteins (first peak) 
were collected in a series of tubes (0.2 ml/tube). Following a thorough wash with PBS 
until E280 = 0, the IgG fraction (second peak) was eluted from the column with 0.1 M 
glycine/HCl (pH 2.8), and 0.2 ml fractions collected in a series of tubes containing 20 
pi of 3 M tris (pH 8.5). Sample fractions in the first or the second peak giving high 
OD were pooled, dialysed in PBS (no azide) with 3 changes at 4 °C, and the final 
protein concentration in the samples measured. After each use, the column was washed 
with 0.1 M glycine/HCl, 2 M urea, and then PBS extensively. The Protein A column 
was stored in PBS containing 0.02% sodium azide at 4°C for reuse.
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iii) Antiserum absorption bv liver powder
All antisera and the fluorescein conjugates used in the immuno-staining for 
immune complexes in mouse kidney tissue sections were pre-absorbed with sheep or 
donkey liver powder to remove non-specific binding antibodies and proteins. To 2 
grams of sheep or donkey liver powder (Sigma) in an universal, 20 ml PBS were 
added and mixed gently to dissolve. The suspension was then spun at 1000 g for 5 
minutes at 4  °C and the pellet resuspended in fresh PBS. The washing was repeated, 
about 3-5 times, until the supernatant became colourless. The washed liver powder 
was then resuspended in 20 ml cold PBS and 2 ml suspensions aliquoted in small flat- 
bottom bijou bottles. Finally, these were spun again at 1000 g for 5 minutes and the 
pellets stored at -20 °C for serum absorption. To an aliquot of washed liver powder in 
a small bijou bottle, 1 ml antiserum from the same species was added and mixed gently 
to suspend. The bottle was well sealed and rotated on a Matburn mixer for 1 hour at 
room temperature. The suspension was spun at 1000 g for 5 minutes and the 
supernatant transferred to a fresh aliquot of washed liver powder to repeat the 
absorption procedure once. The absorbed serum was stored in aliquots at -20 °C.
2.2.4 Antibody conjugation
i) Fluorescein-antibodv conjugation for B-cell marker in FACS analysis
Equal amounts of the IgG fractions of rabbit anti-mouse IgG (£chain, 5563) and 
anti-mouse IgM (RC406/8/9) were combined to give a protein concentration of 11.58 
mg/ml. At a ratio of 1:20, FITC (fluorochrome isothiocyanate) powder was added to 
the immunoglobulin preparation and mixed at 4 °C overnight. The mixture was then 
applied onto a G-25M Sephadex column (Pharmacia, UK) preabsorbed with 2 ml 0.5% 
BSA in PBS, and eluted with PBS. Two colour bands were visible in 5 minutes. The 
first one (conjugate) was collected in a series of 10 tubes, 0.5 ml/tube; and the second 
band (unbound fluorochrome) discarded. Samples from tubes 4-6 showing strong 
yellow green colour were therefore combined. To determine its fluorescein/protein
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molar ratio, the conjugate was diluted 1:50 in PBS and the OD measured at 280 and 
495 nm. The molar ratio of the conjugate was 0.97.
iil Antibody biotinvlation for IL-2 ELISA
The IgG fraction, isolated from the rabbit anti-rIL-2 (005865, the Laboratory) by 
ammonium sulphate precipitation, was diluted at 5 mg/ml in PBS. At a biotin/protein 
molar ratio of 200:1, 5 mg IgG was mixed with 2.13 mg of biotin (long arm, Sigma) 
pre-dissolved in 100 pi of dimethylformamide. The reaction took 2 hours at room 
temperature followed by extensive dialysis in PBS. The conjugate was stored at 4 °C.
2 .3  Cell culture and stimulation
2.3.1 Mouse spleen cell preparation
Under ether anaesthesia, mouse spleens were aseptically removed and immersed 
in 5 ml serum-free Hanks' Balanced Salt Solution (HBSS, Gibco)y then transferred 
into 10 ml fresh HBSS containing 1% FCS in a plastic universal. The spleen tissue 
was forced through a sterile tea strainer into a petri dish in the buffer by the rubber 
plunge of a lOml-syringe. Using the syringe without needle, the cell suspension was 
drawn up and down 3 times. Finally, this was expelled through a 21-gauge needle into 
a conical centrifuge tube and allowed to settle for 2-3 minutes. The resulting cell 
suspension was transferred into a 25ml-universal bottle and centrifuged at 1300 g for 5 
minutes. After 3 washes with the Hanks' buffer, the spleen cell pellet was 
resuspended in 10 ml RPMI-1640 containing 10% FCS. Cell viability was determined 
by staining dead cells with 0.05% trypan blue.
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2.3.2 Cell culture
RPMI-1640 (Gibco, UK) was used for all cell cultures. This medium was 
supplemented with heat inactivated (56 °C, 30 minutes) foetal calf serum (5%), 
penicillin (50 U/ml), streptomycin (50 pg/ml) and 2-mercaptoethanol (50 pM). Mouse 
spleen cells were cultured in 25-cm2 culture flasks {Nunc, U.K.Ltd.) at 106 viable 
cells/ml in 10 ml culture medium with and without addition of Con A (2.5 p.g/ml,
SIGMA, U.K.) at 37 °C/5%C02. Samples were collected at intervals and tested for 
IL-2R cell surface expression, cell proliferation and cytokine activity in the medium.
2.3.3 T-cell activation
Polyclonal activators, or mitogens, are widely used as agents to activate T and B 
lymphocytes. When it was established that lymphocytes could be separated into T and 
B-cells, it was discovered that Concanavalin A (Con A) and phytohaemagglutinin 
(PHA) stimulated T-cells (Stobo et al., 1972); whereas lipopolysaccharide (LPS) 
stimulated B-cells (Andersson et al:, 1972). These mitogens induce effector functions 
and the cellular requirements for mitogen-induced responses have been shown to be 
similar to those of antigen specific induction (Habu and Raff, 1977; Hadden, 1988).
In the present study, Con A has been used to assess T-cell functions in lupus 
disease. To obtain optimum conditions for in vitro mitogen stimulation of mouse 
lymphocytes, the optimal concentration of Con A was determined. The effect of Con 
A-induced T-cell activation was evaluated by the T-cell proliferative responses and IL-2 
production (see Chapter 3, Fig.3.1). The Con A concentration of 2.5 pg/ml in medium 
containing 5% FCS was chosen for T-cell activation in subsequent experiments in the 
study. In selected experiments, PHA (5 /^g/ml) was also used to stimulate T-cells in 
cultures.
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Recombinant human IL-2 (kindly donated by Dr. J.G. Shields), recombinant 
human IL-1, recombinant mouse IL-4 and recombinant mouse IFN-y were used to test 
effects of exogenous cytokines on the in vitro mitogenic activation of lupus and normal 
T-cells. Cells were cultured in 25-cm2 flasks with or without Con A plus various 
concentrations of IL-2 or the other cytokines. Proliferative responses from day 0 up to 
day 7 were determined by 3H-thymidine incorporation and lymphocyte surface IL-2 
receptor expression by 'FACS' analysis.
2.3.4 Lymphocyte proliferation assay
A tritiated thymidine incorporation assay was used to measure the rate of cell 
DNA synthesis. Stimulated and unstimulated mouse spleen cells were pulsed in 24-well 
plates (0.5 ml/well, Falcon, USA) with tritiated thymidine (0.5 p,Ci/well, Amersham 
International, UK) for 3 hours and harvested on to glass fibre filters. Incorporated 
radioactivity was determined in 'Ecosint A' scintillation fluid using a liquid scintillation 
counter and calculated as means (cpm) of duplicates.
2 .4  Cytokine assays
2.4.1 Cytokine quantitation
i) Quantitation of IL-2 bio-activitv (CTLL bio-assay)
The CTLL bio-assay was used to measure IL-2 activity in culture supernatants, 
and to study serological abnormalities in SLE (Chapter 6). The concentration of IL-2 in 
samples was determined by its ability to induce CTLL cell proliferation. After 3 
washes with HBSS containing 1% FCS, the indicator cells, 4X103 viable cells per 
well, were incubated with serial dilutions of test or control samples in complete culture 
medium containing 10% FCS in 96-well plates (Nunc, UK Ltd) for 24 hrs at 
370C/5%CO2 and pulsed with 3H-thymidine (0.5 pCi/well, Amersham International,
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UK) for the last 4 hours. The cells were then harvested on to glass fibre filter paper 
and the incorporated radioactivity was measured using a 'Beta Plate' scintillation 
counter (Pharmacia UK). The IL-2 concentration was determined by comparison with 
a standard curve using r-human IL-2 at 50% maximum or, if lower, on the linear part 
of the curve of thymidine uptake (cpm) in every assay, and expressed as equivalent 
activity. The assay sensitivity has a detection limit below 10 pg/ml (±2SD). Figure 
2.2a shows a typical rIL-2 standard curve. The IL-2 dependent cell line has been tested 
and showed no response to r-mouse IL-4 or IL-4 synergistic effect.
ii) IL-2 Q u a n tita tio n  b y  ELISA
A 'sandwich' ELISA method was designed to quantify soluble immunoreactive 
IL-2 present in biological samples. This included a mouse monoclonal antibody (1E2, 
in ascites kindly provided by Dr. C.D. Benjamin, Biogen) to r-human IL-2 as capturing 
antibody for coating, and a rabbit polyclonal antibody (005865, IgG fraction, the 
Laboratory) to r-human IL-2 used as a detecting antibody. Since the r-human IL-2 
exhibited high cross-reactivity in promoting the growth of mouse CTLL cells (IL-2 bio­
assay), the human IL-2 ELISA was also intended to measure IL-2 in the mouse system. 
Two assay systems were developed:
IL-2 ELISA I
In this system, the 1E2 monoclonal antibody was used as a capture antibody for 
coating and the polyclonal rabbit anti-human IL-2 antibody as detector antibody. To 
determine the sensitivity of the assay, the system was first of all optimised. Briefly, 
1E2 antibody, 3 to 30 pg/ml, was diluted in carbonate-bicarbonate buffer (pH 9.6, 
Appendix I) and coated on a 96-well Dynatech micro-ELISA plate (Immulon 2) 
overnight at 4 °C. After coating, the plates were washed 3 times with PBS containing 
0.05% Tween-20 (PBS-T) and blotted dry. Remaining binding sites on the plates were 
blocked by adding 200 pl/well of 2%BSA/PBS-T and incubated at room temperature 
for 1 hour. Following 3 washes with PBS-T, a wide range of concentrations of r-
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human IL-2 in RPMI-1640 containing 5%FCS was added, 100 pl/well, and incubated 
at room temperature for 3 hours. The plates were then rinsed 3 times followed by a 1 
hour incubation at room temperature with detecting antibody, the rabbit anti-human IL- 
2 antibody at various concentrations (from 5 to 100 pg/ml tested) in antibody diluent 
(2%BSA/PBS-T). The plates were washed again 5 times and incubated at room 
temperature for 1 hr with a goat anti-rabbit IgG alkaline phosphatase conjugated 
antibody (Sigma), at 2 pg/ml (1:1000) in the same diluent. The enzyme substrate was 
p-nitrophenyl phosphate (p-NPP) tablets (Sigma), 1 mg/ml dissolved in 1 M tris buffer 
containing 3 mM MgCl2. The enzyme substrate reaction was carried out at room 
temperature for 30 to 60 minutes and stopped by addition of 1 M sodium hydroxide 
(100 pl/well). Optical density was read on a 'Dynatech MR 700' ELISA reader at 410 
nm. Negative controls were culture medium alone during antigen incubation, and 
replacement of the second antibody with normal rabbit serum.
IL-2 ELISA II
The procedure of System II was basically the same as that of System I except the 
coating antibody was replaced by the polyclonal rabbit anti-human IL-2 antibody. In 
addition, the biotinylated same rabbit antibody (see 2.2.4ii) was used as the detector 
which was followed by an HRP-conjugated avidin amplification. Orthophenylene 
diamine (OPD, Sigma) diluted to 0.4 mg/ml in Mcllwaine's buffer containing 0.32 
pl/ml hydrogen peroxide, was used as the enzyme substrate, developed in the dark at 
room temperature. The reaction was stopped by adding 100 pi per well of 4N 
sulphuric acid, and the optical density was read at 492 nm.
However, although both the IL-2 ELISA Systems I and II were able to detect r- 
human IL-2 at nanogram levels, it showed no detectable cross-reactivity to murine IL-2 
in the culture supernatants of Con A activated mouse spleen cells. Figure 2.2c is a 
representative IL-2 standard curve derived from the ELISA System II using r-human 
IL-2.
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iii) IFN-y ELISA
A sensitive ELISA method has been developed to quantify murine IFN-y. The 
assay employed a rat monoclonal antibody (R46AT) to mouse IFN-y and a rabbit anti- 
mouse IFN-y polyclonal antibody. r-Mouse IFN-y was used as the standard to 
quantify IFN-y concentrations in test samples.
R46AT rat monoclonal antibody at 10 pg/ml diluted in PBS was coated, 50 
pl/well, onto a 96-well Dynatech micro-ELISA plate (Immulon 2) overnight at 4°C . 
After coating, the plates were washed 3 times with PBS containing 0.05% Tween-20 
(PBS-T) and remaining binding sites on the plates were blocked by adding 150 pl/well 
of PBS containing 10% FCS and incubated at room temperature for 30 minutes. Serial 
dilutions of IFN-y standards (0 to 10 ng/ml) and test samples were prepared in RPMI- 
1640 containing 10% FCS. The samples, 50 pl/ml, were incubated at room 
temperature for 2 hours after 3 washes of the plates with PBS-T. The plates were then 
rinsed 6 times followed by a 1 hour incubation at room temperature with detecting 
antibody, the rabbit anti-mouse IFN-y antibody, 100 pl/well at 5 pg/ml in PBS-T
containing 5% FCS. The plates were washed again 6 times and incubated with an 
alkaline phosphatase-conjugated goat anti-rabbit IgG antibody (Sigma) at 2 pg/ml 
(1:1000) in the same diluent at room temperature for 1 hour. The enzyme substrate was 
p-nitrophenyl phosphate (p-NPP) tablets (Sigma), 1 mg/ml dissolved in 1 M tris buffer 
containing 3 mM MgCl2. The enzyme substrate reaction was carried out at room 
temperature for 30 to 60 minutes and stopped by addition of 1 M sodium hydroxide 
(100 pl/well). Optical density was read on a Dynatech MR 700 ELISA reader at 410 
nm. Negative controls were culture medium alone during antigen incubation, and 
replacement of the second antibody with normal rabbit serum. The assay has a 
detection limit below 0.1 ng/ml (± 2SD). Figure 2.2d shows a typical r-IFN-y standard 
curve.
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iv) IL-4 ELISA
A sensitive ELISA method has been developed to quantify murine IL-4. The 
assay employed a rat monoclonal antibody (Clone BVD4-1D11, IgG2b Phamingen) to 
mouse IL-4 and a biotinylated rat anti-mouse IL-4 monoclonal antibody (Clone BVD6- 
24G2, IgG l, Phamingen). Recombinant mouse IL-4 was used as standard for 
quantification of the cytokine in test samples.
Purified antibody BVD4-1D11 at 2 ^g/ml diluted in 0.1 M NaHC03 was coated, 
50 [xl/well, onto a 96-well Dynatech micro-ELISA plate (Immulon 4) overnight at 4 °C.
After coating, the plates were washed 3 times with PBS containing 0.05% Tween-20 
(PBS-T) and remaining binding sites on the plates were blocked by adding 150 pl/well 
of PBS containing 10% FCS and incubated at room temperature for 30 minutes. Serial 
dilutions of rIL-4 standards (0 to 10 ng/ml) and test samples were prepared in RPMI- 
1640 containing 10% FCS. The samples, 50 pl/ml, were incubated at room 
temperature for 2 hours after 3 washes of the plates with PBS-T. The plates were then 
rinsed 6 times followed by a 1 hour incubation at 37 °C with detecting antibody, the 
biotinylated rat anti-mouse IL-4 monoclonal antibody (BVD6-24G2), 100 pl/well at 1 
p-g/ml in PBS-T containing 10% FCS. The plates were washed again 6 times and a 
extravidin-peroxidase, at 2 p-g/ml in the same diluent, was incubated at 37 °C for 1 
hour. After further extensive washes (X 8), TMB Microwell Peroxidase Substrate 
(Dynatech) solution, 100 /d/well was finally added. The reaction was developed at RT 
for 30 minutes and the optical density read on a Dynatech MR 700 ELISA reader at 
492 nm. Negative controls were culture medium alone during antigen incubation. The 
assay has a detection limit below 0.05 ng/ml (± 2SD). Figure 2.2e shows a typical r- 
IL-4 standard curve.
vl TNF-q ELISA
XT22.11 monoclonal antibody at 10 p,g/ml diluted in carbonate-bicarbonate 
buffer (pH8.5) was coated, 100 pl/well, onto a 96-well Dynatech micro-ELISA plate
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(Immulon 2) overnight at 4 °C. After coating, the plates were washed 3 times with 
PBS containing 0.05% Tween-20 (PBS-T) and remaining binding sites on the plates 
were blocked by adding 200 pl/well of PBS containing 20% FCS and incubated at 
room temperature for 30 minutes. Serial dilutions of r-mouse TNF-a standards (0 to 
100 U/ml) and test samples were prepared in RPMI-1640 containing 10% FCS. The 
samples, 100 pl/ml, were incubated at room temperature for 2 hours after 3 washes of 
the plates with PBS-T. The plates were then rinsed 8 times followed by a 1 hour 
incubation at room temperature with detecting antibody, the rabbit anti-mouse TNF-a 
antibody, 100 pl/well at 10 pg/ml in PBS-T containing 5% FCS. The rest of the 
procedure was the same as that of IFN-y ELISA including the goat anti-rabbit IgG 
alkaline phosphatase conjugated antibody (Sigma) and the enzyme substrate 
development (see 2.4.1iii). The assay has a detection limit below 4 U/ml (±2SD). 
Figure 2.2f shows a typical r-TNF-a standard curve.
vil TGF-B bio-assav (MvILu)
Two days before assaying, the CCL-64 mink lung cells (Wellcome, UK) were 
propagated in new flasks and the cells were detached from the culture flasks by 
trypsinisation (see 2.1.4). After washing, the cells were seeded in 96-well flat bottom 
culture plates at 105 cells per well. After an overnight incubation at 37°C/5% C02, 
non-adherent cells were removed by washing with warm plain culture medium once, r- 
human TGF-{32 was used as the standard in every assay. Samples were incubated with 
the cells in 100 \x\ complete culture medium in triplicate wells overnight in a cell culture 
incubator. Cells were washed again twice and pulsed with tritiated thymidine (0.5 
pCi/well, Amersham International, UK) overnight. Finally, the cells were washed 
once with plain medium, dissolved in 1 N sodium hydroxide at 100 pl/well for 30 
minutes and harvested on to glass fibre filter paper. Incorporated radioactivity was 
measured using a 'Beta-Plate' scintillation counter (Pharmacia, UK). Figure 2.2b 
shows a typical r-TGF-p2 standard curve.
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Recombinant cytokines as well as the specific antibodies used in the IFN-y and 
TNF-a ELISA assays, and the Mink lung cell line used in the TGF-{3 bioassay were 
kindly provided by Professor F.Y. Liew. Recombinant human TGF-p2 was kindly 
provided by Dr Paul Garside.
2.4.2 Determining frequency of cvtokine-secreting cells bv ELISPOT assays
The ELISPOT technique (Hutching et al., 1989) was also introduced in the study 
to quantify the frequency of IFN-y and IL-2-secreting cells in vitro. This is a 
'sandwich' assay and the assay protocol was a combination based principally on the 
ELISPOT assay for detection of autoantibody secreting cells and ELISAs for 
quantitation of IFN-y and IL-2, which have been described previously (see 2.2.2ii, 
2.4. lii & iii).
Briefly, the R46AT rat anti-murine IFN-y at 10 pg/ml, or the 005865 rabbit anti­
human IL-2 antibody (IgG fraction, at up to 100 ng/ml), diluted in PBS were used as 
capture antibodies for coating, 100 pi/well, onto a sterile Millipore Millititer, HA 0.45 
pm nitrocellulose membrane based, 96-well plate (5THA 096NS). After incubation 
overnight at 4 °C, the plates were washed 3 times with PBS and remaining binding 
sites on the plates blocked by adding 150 pl/well of RPMI-1640 containing 10% FCS 
and incubated at 37 °C for 30 minutes. Unstimulated and Con A-stimulated mouse 
spleen cells were washed and cultured, 104 to 106 viable cells per well in 200 pi 
culture medium, at 37 °C/5% C02 for about 16 hours. The plates were then rinsed 5 
times and immersed in PBS-Tween for 5 minutes. The procedure was followed by a 1 
hour incubation at room temperature with detecting antibodies, the rabbit anti-mouse 
IFN-y antibody at 5 pg/ml or the biotinylated rabbit anti-IL-2 antibody at 10 pg/ml, 100 
pl/well in PBS-T containing 10% FCS. After washing the plates 5 times, enzyme 
conjugates: a goat anti-rabbit IgG alkaline phosphatase conjugated antibody (Sigma), at
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2 (Ag/ml; or avidin-alkaline phosphatase conjugate (Vector Laboratory) at 1/5000, were 
added. The conjugates were diluted in PBS-T containing 10% FCS and incubated for 1 
hour at room temperature. Finally, the plates were washed 5 times with PBS-Tween, 
immersed in 0.05M tris buffered saline (TBS, pH 8.0) for 5 minutes and dried using a 
Millipore vacuum water pump system..
5-bromo-4-chloro-3-indoyl phosphate (BCIP, Sigma) and p-nitroblue tetrazolium 
chloride (NBT, Sigma) were used as substrate (see 2.2.2ii) to generate an insoluble 
colour product, blue spots on the nitrocellulose membrane. After the membrane was 
dry, the number of spots was counted using a Carl Zeiss stereo zoom microscope.
2.4.3 Cytokine assay evaluation
The CTLL IL-2 bio-assay showed high sensitivity and consistency in detecting 
both the r-human and nature murine IL-2 in Con A-stimulated spleen cell culture 
supernatants. The long term maintenance of the CTLL cell line by the pure recombinant 
IL-2 might explain why these cells do not response to IL-4. This assay has, therefore, 
been used to detect and to quantify biologically active IL-2 throughout the study. The 
assay has a upper detection detection limit which is an equivalence of about 1000 pg per 
ml of the r-human IL-2 used in the study. It was noted that IL-2 at concentrations 
above the upper limit had strong over-dose inhibitory effects on the growth of these IL- 
2 dependent CTLL cells (Fig. 2.3), although IL-2 used in the cultures of mouse spleen 
cell at much higher doses still showed stimulatory effects (see Chapter 5). Therefore, 
all samples tested for IL-2 activity were assayed at least in serial doubling dilutions 
from undiluted up to 1:256. In addition, the possibility of IL-2 inhibitors (see Chapter 
6) present in the test samples might have interfered, to some extent, with the results.
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Figure 2 .3  High dose inhibitory effects of IL-2 on the CTLL ceil line.
CTLL cells, at 4 X 103 cells per well in a 96-well plate, were incubated with different 
concentrations of r-human IL-2 in culture medium containing 10%FCS for 24 hours and 
pulsed with 3H-TdR, 0.5 p id  per well, for the last 4 hours. Cells in the cultures 
containing IL-2 over 1000 pg per ml had reduced thymidine incorporation. Data shown 
are means (±SD) of duplicate cultures.
Using antibodies specific for r-human IL-2 in an highly optimised IL-2 ELISA 
assay, it was able to detect r-human IL-2 at a concentration below 0.1 ng/ml (Fig.2.2c). 
However, it failed to detect mouse IL-2 in the spleen cell culture medium by ELISA 
(both the system I and II), and IL-2 secreted by viable Con A-stimulated mouse spleen 
cells in ELISPOT assays. Although human IL-2 showed strong biological cross­
reactivity in supporting growth of the mouse CTLL cells, the antibodies raised in 
mouse and rabbits specific for r-human IL-2 did not appear to cross-react 
immunologically (or react very weakly) with mouse IL-2. In addition, the antibodies 
were also found to block only weakly function of r-human IL-2 in the CTLL assay.
The ELISA assays for IFN-y and IL-4 showed high sensitivity in detecting both 
recombinant and mouse spleen cell-derived cytokines with reproducible results. The 
T N F -a ELISA is also a reproducible assay but detected no TNF-a in all culture 
supernatants of Con A-stimulated mouse spleen cells from normal and lupus mice, 
suggesting negative effect of Con A in the induction of TNF-a production. The IFN-y 
ELISPOT assay detects readily IFN-y secretion by Con A stimulated mouse spleen 
cells. However, the attempt of using same antibodies as that used in the IL-4 ELISA 
assay has failed to detect IL-4 secretion by the IL-4 ELISPOT technique presumably 
due to the low amount of the cytokine secreted in cultures. The TGF-p bio-assay also 
showed high sensitivity in the cytokine detection. TGF-p neutralising antibody has not 
been used in the MvILu bio-assay to determine the specificity of the assay in the present 
study, but this has been demonstrated elsewhere (Wellcome Lab, UK).
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2 .5  FACS analysis of cell surface markers and receptor expression
2.5.1 Analysis of IL-2R (CD25) expression on T and B-cells
Surface IL-2R positive cells were detected by using a monoclonal rat anti-mouse 
CD25 antibody (IgG2a, Clone AMT13, Boehringer Mannheim, Germany) specific for 
mouse IL-2R a-chain conjugated with R-phycoerythrin (PE). Pan-T cell marker was a 
hamster anti-mouse CD3 FITC-conjugated monoclonal antibody (IgG, Clone 145- 
2C11, Boehringer Mannheim, Germany). Pan-B cell marker was a mixture of rabbit 
anti-mouse IgG Kappa-chain (MR11 and MR13, the Laboratory) and rabbit anti-mouse 
IgM (RC406/8/9, the Laboratory), which were conjugated with FITC (see 2.2.4i).
To label the cells, approximately one million splenocytes, stimulated and 
unstimulated, were incubated with the conjugated anti-CD25 antibody (1 pg in 100 pi) 
as well as the T or B-cell marker at 4 °C for 30 minutes. Contaminated red cells were 
lysed with 1ml of 0.144M ammonium chloride in 17 mM Tris buffer (pH 7.2) for 5 
minutes at room temperature. The cells were then washed twice with cold PBS and 
resuspended in 1ml of PBS containing 0.5%BSA. IL-2R cell surface expression was 
analysed using a Becton & Dickinson fluorescence-activated cell sorter (LYSYS II 
program). 104 viable cells were analysed from each sample. The number of CD25 
positive cells is expressed as '% cell frequency'. The fluorescence intensity indicates 
density of IL-2R expressed on the cell surface. To eliminate non-specific binding, cells 
were preincubated, prior to antibody staining, with 0.5%BSA/PBS containing 0.02% 
sodium azide and 1% normal rat serum. An isotype control, rat myeloma IgG2a 
conjugated with R-phycoerythrin and FITC (Caltag, USA), was used to identify false 
positivity due to Fc binding. Propidium iodide, which stains dead cells, was used at 1 
pg/ml to assess cell viability, and to eliminate dead cells during acquisition which might 
otherwise interfere with subsequent analysis.
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2.5.2 T-cell phenotyping
To study T-cell phenotype changes in the disease development of lupus mice, the 
expression of functional T-cell markers CD4, CD8 and CD3 were analysed by using 
antibodies to these markers. The antibodies used in the analysis were: PE-conjugated 
rat anti-mouse L3T4 (CD4) (4 pi/test, Becton & Dickinson), FITC-conjugated or 
biotinylated rat anti-mouse Lyt 2 (CD8) (4 pi/test, Becton & Dickinson), and the pan-T 
cell marker hamster anti-mouse CD3 FITC-conjugated (Clone 145-2C11, 0.5 pg/test, 
Boehringer Mannheim, Germany). Mouse spleen cells were dual-labelled as follow:
Unstimulated and stimulated cells were washed 2 times with ice-cold PBS 
containing 0.1% sodium azide. For each sample, cells were prepared in 3 separate 
tubes, about one million cells per tube. Cells in each of the 3 tubes were incubated for 
30 minutes at 4 °C, with 2 of the above antibody conjugates at different combinations: 
anti-CD4 (PE) + anti-CD8 (FITC), anti-CD4 (PE) + anti-CD3 (FITC), anti-CD8 
(biotin) + anti CD3 (FITC). Cells labelled with antibodies of the third combination 
were further incubated with PE-conjugated avidin (Vector Laboratory). The cells were 
then washed twice with cold PBS and resuspended in 1ml of PBS containing 
0.5%BSA for FACS analysis.
2 . 6  PCR-assisted cytokine Message Amplification Phenotyping 
(MAPPing)
The rapid, highly sensitive technique developed by Brenner et al (1989) to 
simultaneously analyse the array of cytokine messenger RNAs made by small numbers 
of cells has been modified to study cytokine gene expression in lupus mice. The 
technique incorporates a micro-procedure for isolating total cellular RNA, reverse 
transcription of mRNA to produce cDNA (complementary DNA), and enzymatic
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amplification of cytokine-specific DNA fragments using the polymerase chain reaction 
(PCR).
One day before the operation, double distilled water (ddH20), TE buffer, 
microtubes (1.5ml and 0.5ml) and pipette tips were autoclaved.
2.6.1 Cellular RNA extraction
i ]____ Cell preparation
Mouse spleen cells were prepared as described previously (2.3.1). Spleen cells 
from 3 to 5 mice of the same strain and age were pooled. The splenic lymphocytes 
used for cellular RNA extraction included cells that were freshly isolated from mouse 
spleens and cells cultured without added stimulus (unstimulated), and those that were 
subsequently stimulated in vitro. For T-cell activation, spleen cells were cultured in 
25cm2 culture flasks, at a density of 1 x 107 viable lymphocytes per millilitre, in RPMI- 
1640 complete culture medium containing 5% FCS with or without Con A (2.5 pg/ml, 
Sigma). Cell samples were collected into 1.5ml microtubes, 2 x 107 cells/sample, at 0 
(freshly isolated), 3, 6, 9 and 16 hours of incubation and pelleted by centrifugation for 
5 minutes at 1300 g, 4 °C. After contaminated red cells were lysed by exposure to 
distilled water for 30 seconds, the cell pellets were washed with ice-cold PBS twice and 
stored at -70 °C until all samples were ready for RNA extraction.
ii) RNA extraction
Total cellular RNA preparation was performed using a RNAzol™ B method 
(Chomczynski and Sacchi, 1987). To the cell pellet of each sample, 0.8 ml of 
RNAzol™  B tBiogenesis) was added to lyse the cells, and the cellular RNA was 
solubilised by passing the lysate a few times through a blue-tip pipette. To each tube, 
80 pi of chloroform (Sigma) was added and the mixture was shaked vigorously for 15 
seconds with the tube tightly covered. The samples were allowed to stand on ice for 5
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minutes followed by centrifugation at 12000 g for 15 minutes at 4 °C. The colourless 
upper aqueous phase, which contained purified soluble RNA , was transferred into 
fresh tubes. The RNA was then precipitated by addition of an equal volume (about 0.4 
~  0.5 ml) of anhydrous isopropanol (Sigma) and the samples stored for at least 15 
minutes at 4 °C. After centrifugation at 12000 g for 20 minutes at 4 °C, RNA 
precipitates formed a white-yellow pellet at the bottom of the tube and the supernatant 
was removed. To wash the pellet, 1.5 ml cold 75% ethanol was added. After a brief 
vortexing, the samples were repelleted at 7500 g for 8 minutes and the supernatant 
removed. The RNA samples in the residue ethanol was finally dried under vacuum for 
10 minutes (not completely dry) at room temperature, resuspended with 50 pi of ice- 
cold TE buffer (10 mM Tris, ImM EDTA, pH 7) and heated at 90 °C for 5 minutes. 
RNA concentration was determined by its optical density at 260 nm and 280 nm and 
estimated as follow:
RNA (pg/ml) = [(62 X O D 260nm) - (36 X O D 280nm)] X dilution factor
RNA samples were kept at -20 °C up to 1 month, or at -70 °C for longer periods.
2.6.2 mRNA reverse transcription
cDNA was synthesised by mRNA reverse transcription. Three micrograms of 
total cellular RNA in each sample were reverse transcribed using either oligo-dTi5 or 
random hexanucleotides as primers in a 20-pi reaction. The reaction mixture contained 
20 units of RNasinR RNase inhibitor (Promega), 0.8 pg of oligo-dTi5 (Promega) or 
0.09 units of random hexanucleotides (Gibco BRL), 0.25 mM each dNTP (dATP, 
dCTP, dGTP, dTTP), 4 pi of 5x RT buffer (250 mM Tris-HCl pH 8.3, 375 mM KC1, 
15 mM MgCh), 10 mM DTT and 200 units Moloney murine leukemia virus (M-MLV) 
reverse transcriptase (Gibco BRL). The RNA sample was heated at 90 °C for 5 
minutes and quickly chilled on ice to break up secondary structures and aggregates
81
before addition to the reaction mixture (Innis and Gelfand, 1990). Samples were then 
mixed by spinning for 1 minute at 7500 g and standing at room temperature for 5 to 10 
minutes. The reaction was carried out at 37 °C for 1 hour, and stopped by heating at 
75 °C for 10 minutes then chilling quickly on ice.
2.6.3 cDNA PCR-amplification
i) Primers
Murine IL-2, IFN-y and p-actin specific primer pairs were synthesised by
Genosys (USA) according to primer sequences designed by Ehlers et al. (1992) for IL- 
2, IFN-y, IL-4 and IL-6; and by Barral-Netto et al. (1992) for p-actin (Table 2.1).
Table 2.1 Oligonucleotide sequences of cytokine primers for PCR
IL-2 (320bD)
sense 5'-ATG-TAC-AGC-ATG-CAG-CTC-GCA-TCC-TGT-GTC-A-3'
antisense 5'-AGT-CAA-ATC-CAG-AAC-ATG-CCG-CAG-AGG-TCC-A-3'
IFN-v f388btrt
sense 5,-GAA-AGC-CTA-GAA-AGT-CTG-AAT-AAC-T-3'
antisense 5’-ATC-AGC-AGC-GAC-TCC-TTT-TCC-GCT-T-3'
IL-4f351bo)
sense 5'-ACA-AAA-ATC-ACT -TGA-GAG-AGA-TC A-T -3'
antisense 5'-AGT-AAT-CCA-TTT-GCA-TGA-TGC-TCT-T-3'
IL-6f600bDl
sense 5'-CTG-GTG-ACA-ACC-ACG-GCC-TTC-CCT-A-3'
antisense 5'-ATG-Cn -AGG-CAT-AAC-GCA-CTA-GGT-T-3'
B-actin (420bD)
sense 5'-GAC-TTC-GAG-CAG-GAG-ATG-GCC-AC-3'
anti sense 5'-CTA-CAC-CTA-GTC-GTT-CGT-CCT-C-3'
ii) PCR-amplification
The conditions of the PCR assay were optimised in different preliminary 
experiments, including concentrations of magnesium, dNTPs and primers, as well as 
temperature for cDNA denaturation, primer annealing and extension. The results 
showed that these conditions were important in obtaining sensitive amplification with
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high specificity. In particular, it was found that the concentration of magnesium used 
in the PCR reaction was crucial, which was optimal at about 1.5 mM within a narrow 
range between 1 to 2 mM under the following conditions.
All procedure was performed on ice unless where indicated otherwise. An aliquot 
of 2 microlitres of the heat-chill-treated cDNA (equivalent to 0.3 pg of total cellular 
RNA) was amplified in a 0.5ml microtube in the presence of 0.2 pM final concentration 
of upstream and downstream specific primers (Table 2.1), 0.1 mM each dNTP, 1.25 
units Thermus aquaticus thermostable (Taq) DNA polymerase (Promega), and PCR 
buffer containing 1.5 mM MgCh, 50 mM KC1,10 mM Tris-HCl, and 0.1% Triton X- 
100) in a final volume of 50 pi. Samples were then mixed by spinning for 1 minute at 
7500 g, and overlaid with a drop of light mineral oil (Sigma) to prevent evaporation 
during thermal cycling. PCR was performed in a DNA thermal cycler (Tecline PHC-3, 
UK) for 30-35 cycles: (1) denaturing for 1 minute at 94 °C; (2) primer annealing for 2 
minutes at 56 °C; and (3) primer extending for 3 minutes at 72 °C. At the end of the 
programme, the primer extension was allowed a further 8 minutes at 72 °C.
iiil Analysis of amplification products
After amplification, the mineral oil was removed. The PCR reaction product was 
visualised by electrophoresis of 10 pi of the reaction mix (equivalent to 30 ng of total 
cellular RNA origin) at 80 mA for 45 minutes in 1% agarose (Electrophoresis grade, 
Bethesda Research Laboratory, USA) in 0.5 x tris-borate-EDTA (TBE, see Appendix 
I) buffer containing 0.5 pg/ml ethidium bromide. One microgram of lkb DNA ladder 
(Gibco BRL, UK) was run in parallel as m.w. markers giving bands at 12216, 11198, 
10180, 9162, 8144, 7126, 6108, 5090, 4072, 3054, 2036, 1636, 1018, 517, 506, 
396, 344, 298, 220, 201, 154, 134 and 75bp, for size estimates of the products. 
Negative controls included amplification of a sham reverse transcription without Taq 
DNA polymerase to assess any contribution of contaminating genomic DNA in the
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RNA samples; and amplification of a reaction mix with no added cDNA to assess 
contamination by plasmid or other sources of DNA.
2 .7  Kidney histopathology and immunohistochemistry
2.7.1 Preparation of tissue sections
i)____ Crvostat sections
Cryostat sections were prepared from the frozen kidney tissue for 
immunofluorescence staining of immune complex deposition. 24-48 hours before 
screening, 5 pm cryostat tissue sections were cut and stored at 4 °C (see 2.1.3). After 
30 minutes at room temperature, the sections were washed in PBS in a Coplin jar on a 
shaker with 2 changes of PBS over 20 minutes. The section were then fixed in cold 
ether ethanol (50: 50) for 10 minutes and followed by 20 minutes in methylated spirits.
iO Paraffin sections
5 pm thick Bouin's-fixed, paraffin-embedded kidney tissue sections were 
dewaxed in xylene for 8 minutes, rehydrated through graded alcohols and into water. 
For histopathological examination, the sections were stained by the periodic-acid Schiff 
technique (Lendrum et al., 1962) and examined by light microscopy. To detect kidney 
immune complex deposition, the dewaxed paraffin sections were processed for 
immunofluorescence staining.
2.7.2 Immunofluorescence staining
Alcohol-fixed cryostat or dewaxed paraffin sections were rinsed in PBS for 10 
minutes, and treated with pontamine sky blue 0.5% (w/v) in PBS, pH 7.4, for 20 
minutes which stains the elastic tissue red and diminishes background. This was 
washed off by flooding with PBS. To reduce nonspecific reaction, the sections were
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blocked with 2% (w/v) BSA in PBS. Excess BSA was drained off, and the sections 
were incubated with the detecting antibodies at 1:10 diluted in 2% BSA/PBS, 30 
minutes for cryostat sections or 1 hour for paraffin sections, in a full humidity 
environment at room temperature. To detect immune complexes, a FITC-conjugated 
sheep anti-mouse IgG (Sapu) was used to detect autoantibody binding; and a goat 
(Fab)2 anti-mouse C3 antibody (Cappel, USA) was used to observe complement 
activation, which was followed by a FITC-conjugated donkey anti-goat/sheep IgG 
antibody (Sapu) at 1:20 in the same diluent. To assess autofluorescence and non 
specific staining, sections which were incubated with diluent alone or with normal goat 
serum were included as negative controls. Sections were washed in PBS after each 
antibody incubation. All antisera used for the staining had been pre-absorbed with 
normal sheep or donkey liver powder to minimise non-specific binding (see 2.2.3iii). 
Finally, the sections were mounted in 'Citifluor' mounting fluid and examined using a 
fluorescence microscope.
2 .8  Measurement of serum nitric oxide (NO) levels
2.8.1 The nitrate reductase assay (Bartholomew. 1984)
i)____ Nitrate fNQ3i) —> Nitrite (NQ2i) conversion
Nitric oxide has a very short half-life and is rapidly converted to nitrate (N03‘) in 
plasma. To measure serum NO levels, a conversion of N03- to N02* by nitrate 
reductase must first be carried out. To convert, 30 pi of the serum sample was 
incubated with an equal volume of reaction buffer containing 5 mg/ml NADPH, 41.5 
mg/ml FAD, 0.5 M KH2P04 and 35 mg/ml of the nitrate reductase (Sigma) added 
immediately before used. The conversion was carried out at 37 °C for 2 hours in a 96- 
well ELISA plate. NO standards were also run in parallel with the test samples.
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ii) NO quantitation
A Disibi Chemiluminescence NO Analyser (Model 2107) was used to measure 
NO concentration in the serum samples. A boiling solution containing 75 ml of 
concentrated acetic acid, 25 ml 6% sodium iodide (kept dark until used) in distilled 
water (dH20) was added to a round bottomed flask. Once the analyser had stabilised 
(about 1/2 hour), nitrite N02-standards were injected starting with the highest dose. 
The standard and test samples were propelled through the system by a flow of nitrogen, 
after being boiled off from a mixture of acetic acid/sodium iodide. Oxygen, extracted 
from air was converted to 03 in the reaction chamber at 42 °C. Breakdown of the 03 to 
02 excited N02-. On its return to ground state, light was evolved. A reading of each 
sample at its peak value was taken and allowed to return to baseline before adding the 
next sample. All measurements were recorded in conjunction with a background 
reading which was subtracted from the sample reading.
For NO quantitation, standards were prepared from known amounts of stock 
N03- and N02- and run in parallel with test samples in every assay. The standards 
were made up freshly in dH20 every 6 weeks, including 300, 100,30, and 10 pM for
both N 03‘ and N 02\ All standard and test samples were assayed in triplicate and 
calculated as mean and standard deviation. For the negative control, the serum sample 
was replaced by distilled water in the same buffer. Figure 2.4 shows typical standard 
curves for both nitrate and nitrite. The assay had a detection limit below 5 pM. Sample 
NO level was estimated from the N03- and N02- standard curves.
2.8.2 The Greiss method (Green et al.. 1982: Drapier and Hibbs. 1988)
i)____ Preparation of the Greiss solution
The Greiss solution was prepared fresh immediately before use. The solution 
was obtained by mixing equal volume of 0.1% alpha-naphtyl-amine in distilled water 
(Solution A) and 1% sulfanilamide in 5% phosphoric acid (Solution B). Both of the
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stock Solutions A and B were kept in dark (light sensitive) at 4 °C up to a maximum of 
2 months.
ii) NO quantitation bv the Greiss reaction
To 50 /d per well of test samples in 96-well ELISA plates, an equal volume of the 
Greiss solution was added. After 10 minutes of development at room temperature, the 
plates were read by an ELISA reader at 550 nm. Sample NO levels were estimated by 
the nitrite standard curve which was established by doubling dilutions of a sodium 
nitrite stock solution (10 /<g/ml) in every assay. For NO quantification by the Greiss 
reaction, nitrite secretion in culture supernatants were measured directly. However, for 
measurement of serum samples, the conversion procedure described in Section 2.8. Ii 
was also carried out before assaying.
2 .9  The construction of BRD509/TGF-pl and BRD509/IL-2
The S. typhimurium mutant used in the present study, BRD509, was an aro A " 
aro D~ double mutant strain derived from S. typhimurium SL1344 (Salmonella 
Genetic Stock Centre, Calgary, Canada). Mouse cytokine cDNA (TGF-pl and IL-2) 
was purchased from DNAX, UK. The expression plasmid pKK-TGF-pl and pKK- 
IL-2 were constructed by Dr D-M Xu in the Department, using commercially available 
expression vehicle pKK-233-2 {Pharmacia, Uppsala, Sweden).
2.9.1 The construction procedure (brief)
The procedure for the construction has been described previously in detail by 
Strugnell (1992). Briefly, the leading sequence of the cytokine cDNA was deleted and 
the cDNA reconstructed by PCR to make it suitable for expression in Salmonella. 
Table 2.2 shows the primer sequences used in the PCR reconstruction for murine TGF- 
(31 and IL-2. The DNA fragments derived were then purified by the standard method
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and inserted into the expression vector pKK-233-2. The recombinant plasmids were 
screened by restriction enzyme mapping and the positive plasmid were transformed into 
E. coli strain TGI. The expression of TGF-fJl and IL-2 was then determined by 
western blot. A brief outline of the molecular construction and transformation is 
illustrated in Figure 2.5 (provided by D-M Xu).
Table 2.2 
Primer sequences for cytokine cDNA reconstruction
TGF-61
sence 5'-CTGCAGAGCTCACGGCACCCCATGGCCCTGGATACCAAC-3'
anti-sence 5'-GGCGGGGGCGGGGCCAAGCTTGCCGGGAGGGGCGGG-3!
IL-2
sence 5l-ACAC^TGTGC^CCTTGGATCCATGGCACCCACTTCAAGC-3,
anti-sence 5'-CATATTTATCATCTGCAGACTAGTAGTTAC-3'
2.9.2 Propagation of the Salmonella bacteria for treatment of mice
One day before the treatment, the cytokine gene transfected and the wild-type 
bacteria were grown statistically overnight in 500 ml L-broth bulk cultures from a 
starting OD of 0.05 to a final OD of 0.2 (about 108 bacteria per ml). The bacteria were 
then harvested and concentrated by centrifugation at room temperature, for 7 minutes at 
9000g (Beckman centrifuge, JA10 rotor), and the pellet resuspended in small volume 
of PBS, at 5 X 1010 per ml. For oral treatment of mice, 1010 live Salmonella per dose 
in 0.2 ml of the bacterial suspension was given to each mouse by a gavage tube. In 
addition, aliquots of the bacterial samples were also assessed for cytoplasmic 
expression of the cytokines by bio-assays.
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i i i r ..............i-------
Deletion of the leading sequence by PCR
Ligation
Ptac
PKK233-2
IL-2TGF-IPtac Ptac
PKK/IL-2
N /
Transformed into E.Coli and identified by Western blot and bioassays
\U
Preparation of the plasmid from the postive clone and 
transformation of the plasmid into S. typhimurium BRD 5 0 1 0
\U
Transduction of the plasmid from BRD5010 into S. typhimurium Aro A",Aro D" 
BRD 509 by phage22 and identification of the ampicillin resistant colonies were 
identified by Western blot and bioassays
Figure 2.5 Diagram illustrating a brief procedure for the 
construction of BRD509/cytokines
(provided by D-M Xu, the Department)
2.9.3 Extraction of cytoplasmic cytokines expressed bv S. typhimurium
To confirm the expression of TGF-|31 and IL-2 in the gene transfected S. 
typhimurium, the cytokines were isolated from cytoplasm of the bacteria following an 
extraction procedure. To extract, 108 bacteria in 1 ml culture were centrifuged at 
12000g for 2 mins and 200 pi of 7M urea added. After a 4 h incubation at RT, the 
samples were centrifuged at 12000g for 5 mins and the supernatants collected. 1.02 ml 
of saturated ammonium sulphate was then added to the supernatant, and mixed at 4 °C 
overnight. Precipitated proteins were spun down at 4 °C, 12000g for 5 mins, and 
resuspended in 100 pi of RPMI 1640. The suspension was left at 4 °C for 1.5 hrs 
before being tested by the MvILu TGF-0 bioassay for TGF-P activity, or by the CTLL 
IL-2 bioassay for IL-2 activity.
2.10 Statistical analysis
The Mann Whitney Test was the only statistical method used in the study. 
Results which were subjected to the test are indicated (P value) and described in each 
of the figure legends as appropriate.
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Chapter 3
Early, progressive IL-2 defect 
and the natural history of disease kinetics of murine lupus
90
3 .1  Introduction
The early finding of the in vitro mitogen-induced IL-2 hypoproduction in SLE has 
led to many contradictory interpretations over its in vivo significance for the 
development of lupus disease (Kroemer and Martinez-A, 1991). It is not clear whether 
or how this T-cell defect might be contributing to the origins of abnormalities leading to 
B-cell hyperactivation and autoaggression. The nature of the T-cell functional defect 
therefore remains to be clarified.
Murine SLE is a good model of human SLE as most of the immunological 
abnormalities apparently fundamental to the human disease also appear to be operative 
in the mouse (Theofilopoulos and Dixon, 1985). There are many advantages of using 
lupus mice over the human system to study the disease development. Firstly, unlike 
studies in human system, the mouse system may have less problems in the 
interpretation of results due to clinical diagnosis or treatment, such as drug effects. 
Secondly, some lupus mouse models like MRLIlpr and BXSB are inbred mutant 
strains. These mice are, in theory, genetically identical in spite of some individual 
variations due to environmental influences or the stochastic process of mouse 
generation. Another important aspect, thirdly, of using the mouse models is the natural 
history of murine lupus. Like other animal disease models, lupus mice start to develop 
clinical disease only at certain ages. It offers opportunities to study any existing defects 
in the mice not only during but also before the development of the clinical disease. In 
addition, although most of the serological and histopathological abnormalities are 
common to all SLE mouse models, the onset of the disease differs considerably 
between strains. However, these strain-dependent differences in disease onset allow 
analysis of the relationship or possible link between disease kinetics and those 
experimentally found immunological or physiopathological changes.
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To study the nature of the previously reported in vitro IL-2 hypoactivity in SLE, 
the first two questions addressed in the present study were: "whether the cytokine 
system is indeed defective in lupus mouse models;" and if so, "at what stage of the 
disease development does it occur ?"
3 .2  Con A-induced IL-2 production in normal and lupus mice
3.2.1 Determination of the optimum concentration of Con A for T-cell activation
The ability of T-cells to produce IL-2 was assessed by in vitro T-cell mitogen 
stimulation. Con A was used throughout the study, and the optimum concentration for 
stimulation of T-cell proliferation and IL-2 production was determined. Figure 3.1 
shows the dose-dependent response of BALB/c splenic T-cells to Con A measured by 
secretion of IL-2 and incorporation of 3H-thymidine. The results indicate that the 
optimum dose of Con A depended on the concentration of foetal calf serum (FCS) 
added in the culture medium. To induce IL-2 secretion, the optimum concentration of 
Con A is 2.5 and 5 pg/ml in cultures containing 5 and 10% FCS respectively (3.1a,
arrows). Although for a peak proliferative response Con A was optimum at 0.625 - 
1.25 and 2.5 - 5 pg/ml in cultures containing 5 and 10% FCS respectively, the T-cells 
responded well to a relatively broader range of Con A concentration (3.1b). At 2.5 
pg/ml it induced satisfactory T-cell proliferation in either culture conditions containing 5 
or 10% FCS. Considering both IL-2 production and cell proliferation, therefore, Con 
A was used at 2.5 pg/ml, in cultures containing 5% FCS, for the in vitro mouse T-cell 
activation in all subsequent experiments.
3.2.2 Kinetics of Con A-induced IL-2 production
In adult mice, similar kinetics of Con A-induced IL-2 production were observed 
between the two lupus strains and BALB/c control mice according to repeated time 
course studies. In the culture supernatants of Con A-stimulated mouse spleen cells
92
>■ -t—'
>'j-juro
CM
1
( U/ ml )(pg/ ml )
3200
2400
1600
800
Co
ro
L_o
C l
L_ouc
CCTD
Xro
— 0 — 5% FCS
10% FCS
Figure 3 ,1  Con A dose-response curves for T-cell activation. Spleen cells 
from BALB/c mice were cultured at 106 cells/ml in RPMI complete culture medium 
containing 10 or 5% of FCS in the presence of different concentrations of Con A as 
indicated, (a) IL-2 activities presented in the culture supernatants were measured at 24 
hrs by the CTLL assay; (b) cell proliferative responses were determined at 48 hrs by 
tritiated thymidine incorporation. Data are shown as the means of triplicates. The peaks 
of the responses were indicated by arrows.
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from these 3 strains, IL-2 activity was detectable after 2h, and it increased rapidly and 
normally reached a peak at 24h. However, individual variations exist particularly in the 
lupus strains. An earlier fall or sustained levels of the IL-2 activity were seen in some 
cases (Fig.3.2). However, peak IL-2 production by spleen cells from CBA mice 
appeared to be relatively late, at between 48 and 72h (Fig.3.3). IL-2 activity was 
undetectable in the culture supernatants of spleen cells without Con A stimulation. In 
addition, there were age-related differences in the kinetics of IL-2 production between 
young mice. The peak IL-2 activity was delayed by 1 to 2 days in mice under 2- 
months old, compared with mice of 3 months or older (Fig.3.4).
Therefore, to determine IL-2 production by spleen cells from different strains and 
ages, the results presented were IL-2 activity detected at its peak time point, for each 
age and strain of mouse.
3.2.3 IL-2 activity in old NZB/W and MRLIlpr mice with clinical disease
MRLIlpr is a typical early-life lupus disease mouse model with a 50% mortality 
rate (female and male) at 5 months of age (Theofilopoulos, 1992). In contrast, NZB/W 
mice develop disease later, and the 50% mortality rate is at 8 and 12 months for the 
female and male mice respectively. According to their age at peak disease activities, the 
mice chosen for this experiment were female MRLIlpr of 4-6 months and female 
NZB/W of 7-9 months. All of the mice used in the experiment showed various degrees 
of clinical manifestations including skin lesion, enlarged spleens, and tumours 
(M RUlpr strain, due to lymphoproliferation).
IL-2 activity, determined by the CTLL bioassay, was significantly reduced in 
culture supernatants of Con A-stimulated spleen cells from old lupus mice (Fig.3.5). 
In spite of considerable individual variation and strain differences, the IL-2 hypoactivity 
in lupus mice was consistently found to be highly significant in every experiment, in
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Figure 3 .2  Kinetics of Con A-induced IL-2 secretion by spleen cells 
from BALB/c, NZB/W and MRL/lpr mice. Spleen cells from 2 mice of each 
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in the culture supernatants were measured at 0, 2, 4, 8, 24, 48, 72 and 96 hrs by the 
CTLL assay.
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Figure 3 .4  Kinetics of Con A-induced IL-2 secretion in young BALB/c, 
NZB/W and MRL/lpr mice. Spleen cells from 2 mice of each strain and age group 
were pooled and cultured at 10^ cells/ml in RPMI complete culture medium containing 
5% of FCS in the presence of Con A (2.5 ptg/ml). Culture supernatants were collected at 
daily intervals and IL-2 activities measured by the CTLL assay.
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Figure 3 . 5  Defective Con A-induced IL-2  production in old lupus mice 
with active disease. Spleen cells from individual mice of each strain and age group 
were cultured at 106 cells/ml in RPMI completed culture medium containing 5% of FCS 
in the presence of Con A (2.5 ^g/ml). IL-2 activities were measured at daily intervals 
and data shown are means (±SD) of the peak values obtained for each mouse. Number 
of mice in each group is indicated on the top of each column.
comparison to the sex-age-matched BALB/c and CBA control mice (P<0.01). Since 
the data shown were the peak IL-2 activity present in the culture supernatants, the 
defective IL-2 production by lupus T-cells was not due to kinetic differences from 
control mice or between strains. There was no spontaneous IL-2 secretion by the 
spleen cells cultured without Con A detected in both the lupus and the normal control 
mice.
3.2.4 IL-2 deficiency: its early onset in lupus mice
To determine whether the IL-2 defect found in old lupus mice was a consequence 
of the autoimmune lesions, the next step of the study was to assess T-cell function in 
mice of different ages from as young as 1-week old, preceding the onset of disease 
activity. However, IL-2 hypoactivity was evident in all age groups studied except the 
1-week old mice (Fig.3.6). Relatively higher IL-2 activity was noted in cultures from 
younger NZB/W mice than in old NZB/W mice and both young and old MRUlpr strain 
mice. In general, the older the mice the greater the difference observed between the 
control and the lupus mice.
IL-2 activity was not measurable in culture supernatants of Con A stimulated 
spleen cells from 6-day old BALB/c mice though low levels of IL-2 (<30 pg/ml) could 
be detected in the two lupus strain mice at the same age (Fig.3.6). This was due to a 
lack of T-cells in mouse spleens (CD3+ < 4%) at this very early age (see Figs.3.8, 
3.9).
3 .3  The age-related lupus disease activities: serological changes, 
cellular abnormalities and clinical manifestations
As mentioned previously, the onset and age relation of the disease in many lupus 
models have been well studied with considerable agreement between different
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laboratories (Theofilopoulos and Dixon, 1985; Theofilopoulos, 1992). In the present 
study for the purpose of confirmation, some aspects of the possible pathological 
activities of the disease in the lupus mice used were studied.
3.3.1 Autoantibody production
Screening of anti-nuclear antibodies (ANA) has been a basic laboratory test for 
many years and the presence of these antibodies is a standard criterion for the diagnosis 
of SLE. Although there has been some controversy regarding the correlation between 
the autoantibodies and lupus disease activity, the dsDNA binding test has remained the 
single the most important laboratory test for SLE as approximately 75%, or higher 
depending on the assay methods used, of patients with the disease are seropositive 
(Morrow et al., 1982; Buskila and Shoenfeld, 1992). As in human lupus, serum 
autoantibodies to an extensive array of molecules including the nucleic acids can be 
detected in different strains of lupus mice. These antibodies vary in their life span, time 
course and specificities (Stott et al., 1990). As one of the indicators of disease 
development, autoantibody production may reflect the characteristic B-cell 
hyperactivation, autoaggression and onset of the disease.
Sera taken from lupus and normal mice at different ages were assessed for the 
production of antibodies against ss- and ds-DNA. The results showed low detectable 
levels of anti-ss and ds-DNA in normal BALB/c mice, but an age-dependent significant 
increase of autoantibody production was found in both MRLllpr and NZB/W mice 
(Fig.3.7). High levels of anti-ss (>1000 TU average) and anti-ds (>200 TU average) 
DNA antibodies were detectable in MRL/lpr mice of 3 months or older. In the NZB/W 
strain, the increase of serum autoantibody titre appeared to occur much later (after 6 
months), and the levels of the anti-ssDNA were relatively lower compared with 
MRLllpr mice. Variations in the serum autoantibody levels were observed especially in 
the 4 to 6 month old MRL/lpr mice, ranging between 1000 to 100,000 TU and 50 to
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Figure 3 .7  Serum  levels of anti-ssD N A  (a) an d  an ti-d sD N A  (b) 
antibodies in BALB/c, NZB/W and M RL/lpr mice at d ifferent ages. A total 
of 59 serum samples from BALB/c (19), NZB/W (19) and M RL/lpr (21) mice of 
different ages were titrated for anti-ss and anti-dsDNA by ELISA. Data are shown as the 
mean values (±SD) obtained from individual sera in different age groups. The relative 
levels (low, intermediate or high) of the autoantibodies were assigned arbitrarily as 
indicated in the graphs. Number of mice in each group is as follow:
Age g roups 1
BALB/c
NZB/W
MRL/lpr
4-6 7-9 (mo)
10
4
10
2000 TU for anti-ss and ds-DNA respectively. However, in the young lupus mice, 
normal or only slightly increased levels of serum anti-DNA antibodies (anti-ssDNA < 
100 TU; anti-dsDNA < 20 TU average) were observed at least until 4-month old in 
NZB/W, and until 2 month old in MRUlpr mice. Intermediate levels of anti-ssDNA 
(100 - 1000 TU average) were detected in the 2-month old MRLllpr mice. The 
observations have also been confirmed by results from ELISPOT assays specific for 
antibodies to ss and ds DNA.
3.3.2 Ly mphoproliferation
Lymphoproliferation is another feature of murine lupus, particularly in MRUlpr 
mice. Old lupus mice show enlarged spleens and lymph nodes. Figure 3.8 shows age- 
dependent changes in total numbers of spleen cells and CD3+ cells in NZB/W and 
MRLllpr mice. The lymphoproliferation begins at 3 months in MRL/lpr mice with a 
massive increase in the total and CD3+ cell number (3-7.5 fold), peaking at 4 to 6 
months. In NZB/W mice, the lymphoproliferation was only moderate (about 2 fold at 
the peak) and it appeared much later at 7 to 9 months. However, there was no evidence 
for such lymphoproliferation in young lupus mice until 4 and 2 months of age in 
NZB/W and MRUlpr strains respectively. The average total number of spleen cells and 
CD3+ cells were within the normal range of the BALB/c controls.
Figure 3.9 shows that there was a gradual increase in the percentage of splenic 
CD3+ cells in young mice between 1 week and 2 months in all three strains. It peaked 
at 2 months (open arrow), and then declined before a relatively constant level was 
established after 3 months in BALB/c and NZB/W mice. However, the percentage of 
CD3+ cells expanded rapidly after 3 months and reached a second peak at 4-6 months 
(solid arrow) in MRL/lpr mice.
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Figure 3 .8  Flow cytom etry analysis of the total num ber of splenic cells 
and  the num ber of CD3+ cells in BALB/c, NZB/W and M R L /lpr mice of 
different ages. Freshly isolated spleen mononuclear cells were stained with a hamster 
anti-mouse CD3 antibody conjugated with FITC and 104 viable cells were analysed in 
each sample using a Becton & Dickinson cell sorter. Data are shown as means of 
individual mice in each of the age groups.
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Figure 3 .9  Age-dependent changes in the percentage of splenic CD3+ 
cells in BALB/c, NZB/W and MRL/lpr mice. The open arrow indicates a peak 
of percentage CD3+ cells in all three mouse strains at 2 months of age, while the closed 
arrow points at a second peak that appears only in the MRL/lpr strain of 4 months of age 
or older. Data are shown as the mean values (±SD) obtained from individual mice. 
Number of mice in each group is as follow:
Age groups_______ lwk lm o 2mo 3mo 4-6mo 7-9mo
BALB/c 6 4 2 3 8 2
NZB/W 6 2 2 1 2 5
MRL/lpr 6 2 3 6 10 2
3.3.3 T-cell phenotypical abnormalities in MRUlpr mice
A spontaneously proliferating abnormal CD3+ subset, the so called 'double 
negative' (DN) cells, which lacks the functional T-cell markers CD4 and CD8, is a 
prominent feature in MRUlpr mice. By using monoclonal antibodies specific to mouse 
T-cell markers, the percentage of the 4 T-cell subsets, CD3+CD4+, CD3+CD8+, 
CD3+CD4+CD8+ and CD3+CD4'CD8_, in spleens of MRL//pr mice of different ages, 
was studied by FACS analysis. Figure 3.10 shows that this phenotypic abnormality 
peaks at 5 to 6 months. However, it does not become significant in the spleens of 
young MRL/lpr mice until 3 months of age. The DN cells made up less than 5% of 
total CD3+ cells in 6-month old BALB/c and NZB/W mice.
3.3.4 Immune complex deposition and development of glomerulonephritis
Glomerulonephritis in SLE is believed to be due to immune complex deposition 
and complement activation. It is the major cause of pathology and death, therefore 
reflecting severity of the disease. Figures 3.11 and 3.12 show typical results from 
histological and immunocytochemical studies of the renal changes in 3 and 5 months 
MRL llpr mice. Pathological changes were prominent in the kidneys of 5-month old 
MRL/lpr mice and included severe focal glomerulonephritis, pyelonephritis, vasculitis, 
urinary protein casts, mesangial proliferation and adhesion (Fig.3.1 lc). Deposition of 
immunoglobulin and complement (C3) on the glomerular basement membrane was 
readily detectable (Fig.3.12a, 6, C). In the 3-month old MRL//pr, although 
pyelonephritis was also observed , these other pathological changes were
much less severe or not detectable.
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Figure 3 .1 0  Age-dependent changes in the num ber of the double negative 
(a) and o th er (b) T-cell populations in spleens of M R L /lpr mice. F resh ly  
isolated spleen mononuclear cells were counted for total cell number. The cells were then 
dual-labelled with a rat anti-mouse CD4 or a rat anti-mouse CD8 monoclonal antibodies 
and a pan-T cell marker. All antibodies were pre-conjugated with either R-PE or FITC. 
104 viable cells were analysed in each sample using a Becton & Dickinson fluorescence- 
activated cell sorter. All cells gated for analysis were CD3+. Data are shown as average 
total number of cells per spleen. At least three mice were included in each of the age 
groups.
Figure 3 .11  Renal h istopatho log ical changes in 3 and 5 m onths old 
MR L/ l p r  mice. Representative photomicrographs of kidney sections from: a), a 
BALB/c mouse showing normal renal structure, and b). a 3-month old MRLUpr mouse 
showing relatively normal structure of glomeruli [G] and Bowman's space [A];  compared 
with c). a 5-month old MRL llpr mouse showing an enlarged and severely damaged 
glomerulus with cellular hyperplasia, focal glomerulonephritis &! and thicken Bowman's
capsule ['crescent' like change,n Z,] with little Bowman's space. PAS stain, X480.
Figure 3 .1 2  Im m unofluorescen t s ta in in g  of re n a l im m une com plex  
deposition in a 5-month old MRL/lpr  mouse. Representative photom icrographs 
of kidney sections showing specific staining o f mouse C3 (a, b) and IgG (c) (frozen 
sections), (b) a low power graph (x 100) showing strong positive staining for mouse 
IgG in many glomeruli, (a) and (c) high power graphs (x 400) showing strong 
fluorescent staining is mainly located at the glomerular lacis region (mesangial cells). 
Negative control (d) is a kidney section from the same mouse incubated with normal goat 
serum (x 400).
3 .4  Summarising remarks
The study so far has demonstrated that there exists an early, progressive IL-2 
deficiency in NZB/W and MRLIlpr mice. The results show that the T-cell defect exists 
not only in old lupus mice with overt clinical disease but also in young mice as early as 
4 weeks or younger. In aged MRLIlpr mice, IL-2 hyposecretion may be partially due 
to dilution of CD4+ cells by the proliferating DN cells. However, spleen cells from 
NZB/W and especially from young MRLIlpr mice are also unable to produce IL-2 
although expression of CD4 is normal in these mice. Preceding disease activity, this 
defect exists in young mice at a stage before the rise of serum autoantibodies, lymphoid 
hyperplasia and kidney pathology. The abnormal IL-2 secretion is not due to kinetic 
difference of T-cell activation between strains. Although young mice of one to two 
month old display late responses to the stimulation, reduced IL-2 activity were detected 
at every time point in the lupus strains compared to age-matched normal mice. IL-2 is 
known to be crucial in modulating the maturation, functional differentiation, activation 
and clonal expansion of T-cells (Toribio et al., 1989). In conjunction with other 
cytokines, IL-2 also plays an important role in the regulation of B-cells and other cell 
types such as NK effector cells. The observation that the T cell defect precedes B-cell 
hyperactivity emphasises its significance in relation to autoimmunity. It is conceivable 
that such an early impaired T-helper function may disturb the normal development of 
the immune system resulting in immune regulatory disorders and failure.
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Chapter 4
The defective T-cell activation in lupus disease
4.1 Introduction
In contrast to B-cell hyperactivity, an impaired T-cell mediated immunity is 
another feature in SLE. The defective Con A-induced IL-2 production suggests a 
functional abnormality of the Thl phenotype. Although the early onset of the IL-2 
defect emphasises its role in the abnormal T-cell functions, defects in other cell 
compartments or phenotypes have also been reported in the disease (Tsokos, 1992). It 
is therefore necessary to have a detailed analysis of other functional activities of lupus 
T-cells, including their ability to proliferate, to express cytokine receptors and to 
produce other characteristic lymphokines of T-cells. In addition, the role of co­
stimulators in the defective lupus T-cell activation is not well understood. Complete T- 
cell activation are known to require co-stimulatory signals provided by accessory cells. 
In the absence of the co-stimulative signal, T-cells make only a partial response, and 
more importantly, to enter an unresponsive state, called 'clonal anergy' in which the T- 
cells are incapable of producing its own growth hormone, IL-2 (Schwartz, 1990). 
Production of IL-1, an important co-stimulator for T-cell activation derived mainly from 
adherent cell populations, has been shown to be deficient in lupus disease (Linker- 
Israeli, 1983; Steinberg et al.t 1991). In order to investigate the nature of the defect in 
lupus T-cell activation, the effect of exogenous IL-1 and the function of lupus adherent 
cells was also assessed. Finally, to identify whether any defect at the level of cytokine 
gene transcription could be involved in the defective cytokine production found in lupus 
mice, mRNA expression for the characteristic T-cell-derived lymphokines, including 
IL-2, IFN-y, IL-4 and IL-6, was analysed and described in this chapter.
4 .2  Con A-induced lupus T-cell proliferative responses
The optimum concentration of Con A (2.5 pg/ml) for T cell activation in the 
mouse has been determined in the preliminary experiments (Chapter 3). In agreement 
with previous findings, the Con A-induced proliferative response of T-cells was
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deficient in old NZB/W and MRL//pr mice with clinical disease. Although freshly 
isolated unstimulated lupus spleen cells usually show higher thymidine uptake than the 
controls, they responded poorly (in general below 50% of the thymidine uptake by cells 
from control mice) to subsequent Con A stimulation. Figure 4.1 shows the defective 
proliferative responses of splenic T-cells from old MRUlpr (8 month) and NZB/W (10 
months) mice, in comparison to BALB/c (10 months) control mice. The time course 
study also confirmed that the reduced T-cell proliferative response was not due to 
kinetic difference between strains. The Con A-induced T-cell proliferation in mice of 2 
months or older usually peaked between 2 to 3 days after stimulation, and exceptionally 
some delay was observed in the lupus strains.
The defective T-cell proliferation was also observed in young lupus mice. 
MRUlpr mice begin to display such a proliferative defect as young as 4 weeks old and 
it is progressive with age. Although this early proliferative defect could sometimes be 
observed in young NZB/W mice too, it is not consistently established in most of the 
cases until 6 months (see Chapter 5). A reduced cell proliferative response is often 
associated with low IL-2 activity in the culture which is usually below 1 ng per ml 
(peak activity).
T-cells from SLE patients also showed abnormal proliferative responses to Con 
A. Fig.4.2 shows the Con A-induced proliferation of T-cells from peripheral blood of 
3 SLE patients with active disease, in a whole blood cell culture. The cells were 
stimulated with a wide range of serial concentration of Con A, but no response was 
observed in the samples from two patients while the other showed a relatively enhanced 
response in comparison to the normal control.
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Figure 4 .2  Con A -induced p ro lifera tiv e  responses of T-celis from  
peripheral blood of normal and SLE patients. Blood samples from 3 SLE 
patients with active disease were diluted 1:1 with RPMI containing 5% FCS and cultured 
in 96-well culture plates (0.2 ml/well) in the presence of different concentrations of Con 
A. After 48 hrs of stimulation, the cultures were pulsed with 3H-thymidine (0.5 
/aCi/well) for further 6 hrs and the incorporated radio-activity measured using a Beta Plate 
scintillation counter. Data are presented as means of triplicates. Control: blood sample 
from a normal donor.
4 .3  IL-2 receptor expression
Optimum Con A-induced T-cell (CD3+) IL-2R (a  chain, CD25) expression in 
mice was found between two to three days of stimulation. This was indicated by the 
frequency of CD3+ cells expressing IL-2R and the density of cell surface IL-2R 
expression (mean fluorescence intensity). Figure 4.3 shows representative results 
from a 6-day time course study on Con A-induced T-cell IL-2R expression and CD3+ 
cell proliferation in BALB/c mice. There was no significant difference in the kinetics of 
Con A-induced T-cell IL-2R expression between a 4-month and an 8-month old mouse 
tested. It was noted, in addition, that the peak IL-2R expression (a & b) occurred 
immediately before T-cell division (c & d). After 2 to 3 days of Con A stimulation in 
culture, a rapid increase in the percentage (d) and number (c) of CD3+ cells and, 
reduced T-lymphoblasts (c), was accompanied by a sharp decline in the T-cell IL-2R 
expression (a, b).
Surface expression of IL-2 receptor (CD25) on freshly isolated unstimulated splenic 
CD3+ T-cells was under 6% in all mice studied, except the one week old BALB/c mice, 
with no significant difference between the lupus and the control strains. T-cells from the 
one week old BALB/c mice showed relatively higher CD25 expression (14.113.47 %) than 
lupus mice of the same age, i.e. 3.4 ±0.99% in NZB/W and 2.9 ±1.1% in MRLIlpr. In 
addition, IL-2R expressing splenic T-cells cultured without Con A was under 10% of total 
CD3+ cells and with low density.
However, Con A-induced T-cell surface IL-2R expression was significantly 
decreased in old lupus mice compared with the age-sex-matched control BALB/c and CBA 
mice (Fig.4.4a). Figure 4.4b shows typical FACS profiles of the Con A-induced T-cell 
IL-2R expression in lupus (MRL//pr) and normal control (BALB/c) mice. The defective 
Con A-induced IL-2R expression was also evident in young lupus mice (Fig.4.5), both in
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Fieure 4 .4  Defective surface IL-2R (CD25) expression by splenic T- 
cells from  old lupus mice with active disease. Spleen cells freshly isolated as 
well as cells cultured with and without Con A (2.5 ^g/ml) for 3 days were analysed by 
FACS using specific antibodies to mouse CD25 and CD3. (a) Percentage of total CD3+ 
cells expressing CD25 (cell frequency) in lupus and age-sex-matched BALB/c or CBA 
control mice. The ages and number of mice in each group are indicated in brackets, (b) 
Typical FACS profile of CD25 expression by Con A-stimulated splenic CD3+ cells from 
5-month old MRL/lpr and BALB/c mice. Isotype control: rat myeloma IgG2a R-PE 
conjugated. Cells gated for the analysis were >95% viable after 'PI' exclusion.
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Figure 4 .5  Con A-induced IL-2R expression by splenic T-cells from  
young mice. Spleen cells from individual lupus and normal control mice of different 
ages were stimulated with Con A (2.5 pig/ml) in cultures for 60 hrs before being analysed 
by FACS. Data are expressed as means (±SD). These include percentage of total CDS^ 
cells expressing CD25 (a), and percentage average fluorescein intensity of the control 
BALB/c mice (b). CD25 expression on cultured cells without Con A was under 10% 
(not shown).
terms of frequency of T-cells expressing IL-2R, and average density (relative fluorescence 
intensity).
4 .4  T-cell activation co-stimulators
4.4.1 Effects of exogenous IL-1 on IL-2 production
Due to the availability at the time of study, the IL-1 used in the experiment was 
also a r-human protein (Wellcome Laboratory, UK). The effects of exogenous IL-1 on 
T-cell activation in lupus mice were examined by adding r-human IL-1 during initial 
Con A stimulation. Spleen cells were cultured at 106 cells/ml with or without Con A 
(2.5 pg/ml) and serial concentrations of IL-1, at 0, 50, 100 and 200 ng/ml. Culture 
supernatants were collected at daily intervals, and IL-2 production measured by the 
CTLL assay. No significant effect of exogenous IL-1 was observed on IL-2 
production in either lupus or normal mice (Fig.4.6). The mice used in this experiment 
were 3 month old. Results shown were peak IL-2 activity present in the culture 
supernatants (all at 24h).
4.4.2 Adherent cell function in MRUlpr mice
Adherent and non-adherent spleen cells from MRLIlpr and H-2 haplotype 
compatible normal CBA mice (H-2k) were separated by plastic adhesion in 25cm2 
culture flasks, at 37°C, 5%CC>2 in complete culture medium containing 5% FCS for 2 
hours. Non-adherent cells were collected by gentle pipetting and rinsing once with 
warm medium. The cells were then spun down, resuspended in the original volume of 
fresh medium and counted. Non-adherent cells obtained by this method made up about 
66 to 79% of the total spleen cells in the original cultures. Adherent cells were washed 
twice more with warm medium. In different combinations, the non-adherent cells from 
MRLUpr and CBA mice were recombined or exchanged with the adherent cells in
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F igure  4 . 6  E f fe c t s  o f  e x o g e n o u s  r IL -1  on C o n  A - i n d u c e d  I L - 2  
secret ion.  Spleen cells from 2 mice (3-month old) of each strain were pooled and 
cultured in the presence of Con A (2.5 ^g/ml) with various doses of r-human IL-1. 
Culture supernatants were collected at daily intervals and assayed by the CTLL bio-assay. 
Results shown are peak IL-2 activity (24 hrs) obtained in a 3-day time course.
appropriate flasks, and cultured in the presence of Con A. At daily intervals, culture 
supernatant samples were collected for measurement of IL-2 production and the cell 
proliferation assessed by thymidine incorporation. T-cell IL-2R expression was tested 
at 60h. Mice used in these experiment were 4 to 5 months old.
Results from the first experiment showed that, in normal CBA mice, non­
adherent spleen cells alone responded relatively poorly to Con A. The ability of T-cells 
to proliferate and to produce IL-2 was much reduced without the presence of adherent 
cells (Fig.4.7). Lupus T-cells from MRL///?r mice, however, responded equally poorly 
to Con A either with or without adherent cells from the same strain, compared to that of 
normal CBA mice. Replacement of lupus adherent cells with the adherent cells from 
CBA mice did not restore the ability of lupus T-cells to proliferate or to produce IL-2. 
Surprisingly, it was noted that the proliferative response of non-adherent cells from 
CBA mice was completely suppressed when these cells were cultured with adherent 
cells from MRLllpr mice (Fig.4.7a, *). This was found to be in contrast to a 
significantly enhanced IL-2 activity detected in the culture supernatants (Fig.4.7b, *).
However, results from 4 subsequent repeat experiments were not consistent 
(Fig.4.8). They failed to reproduce the conflicting suppressive and stimulatory effects 
of lupus adherent cells on normal T-cell activation. In spite of similar procedures and 
culture conditions, the T-cell proliferative response in the control groups (Fig.4.8a, 
groups I and II) also varied considerably. This was not due to the cell separation 
procedure as shown by the control cell cultures with and without separation procedure 
in the same experiment.
From results of the 5 separate experiments, the only phenomenon that appeared to 
be clear and consistent was that adherent cells from normal CBA mice were not capable 
of restoring the ability of lupus T-cells either to proliferate, to produce IL-2 or to 
express IL-2 receptors (Fig.4.8c, Group VI).
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Figure 4 .7  A nalysis of ad h eren t cell functional activ ity  in Con A- 
induced T-cell proliferation (a) and IL-2 secretion (b) in norm al and  lupus 
mice (Experiment 1). Before Con A stimulation, mouse spleen adherent and non­
adherent cells were separated by adhesion to plastic. The two types of cells from the H-2 
compatible MRL/lpr and CBA mice were then re-grouped by different combinations as 
indicated by the key to symbols and Con A at 2.5 /<g/ml was added. Cell proliferative 
responses and IL-2 activity in the culture supernatants were assayed at daily intervals and 
the data shown are peak responses observed. Arrows indicate a suppressed proliferative 
response (a) of CBA splenic T (non-adherent) cells by the adherent cells from a 4 -month 
old MRL/lpr mouse in contrast to the enhanced IL-2 activity detected in the culture 
supernatants (b).
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Figure  4 . 8  A na ly s i s  of  a d h e r e n t  cell f u n c t i o n a l  ac t iv i ty  in C o n  A- 
i n d u c e d  T-cell p ro l i fe ra t ion  (a), IL-2 secre t ion (b) a n d  I L -2 R  e x p r e s s io n
(c) in no rm a l  a n d  lupus  mice (Experiments  2 to 5). The procedure for cell 
separation, re-combination group and stimulation, and the subsequent functional 
assessments was same as that descnbed for the Experiment 1 in Figure 4.8. The data of 
cell proliferation (a) shown are mean value obtained from results of the 4 repeat 
experiments (±2SD). The data of IL-2 secretion (b) were from the Experiment 2 only. 
Additionally, in Experiment 4 at day 3, the cells were also assessed for IL-2R (CD25) 
expression by FACS (c). All mice used were 4 to 5-month old.
4.5  Other T-cell derived lymphokines
4.5.1 Production of IFN-y
The IL-2 defect indicates a defective Thl cell function in lupus mice. Since IFN-y is 
also produced by the Thl subset, the ability of splenic T-cells from lupus mice to produce 
this lymphokine was therefore assessed. Immuno-reactive IFN-y in cell culture 
supernatants was quantitated by a sensitive ELISA method (Chapter 2). In a time course 
study, Con A-induced IFN-y secretion peaked at 3 days in BALB/c mice. In NZB/W mice, 
the IFN-y activity in culture supernatants declined after 2 days of stimulation. However, in 
MRLUpr mice, it was relatively level throughout 1 to 5 days with a gradual increase 
(Fig.4.9). As shown in Figure 4.9, Con A-induced IFN-y production was relatively 
reduced in 4-month old lupus mice, especially the MRUlpr strain, compared to BALB/c 
mice of the same age. No significant spontaneous secretion of IFN-y by unstimulated 
cultured spleen cells was detected.
A modified ELISPOT assay has also been developed for detection of IFN-y secreted 
by viable culture cells in the present study. It enables determination of the frequency of the 
cytokine secretors, and is a semi-quantitative assessment of IFN-y secretion on an
individual cellular basis. Insoluble membrane-bound immune complexes formed by the 
secreted IFN-y and the specific antibodies were visualised by cleavage of the substrate 
(BCIP-NBT) by the conjugated alkaline phosphatase. This resulted in dark blue colour 
spots on the membrane which varied in size with a condensed centre and diffuse edge. The 
spots were readily counted at low magnification (2 X 12.5) under a stereo zoom 
microscope. According to results from the ELISPOT assay, IFN-y hyposecretion in old 
lupus mice was not due to less IFN-y secreted per cell, as shown by the size of spots 
(Fig.3.10c, d), but due to a reduced frequency of IFN-y secretors (Fig.3.10a, b). The 
frequency of Con A-induced IFN-y secreting cells was 1:1585 (±215) in a group of 4-
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Figure 4 . 9  Kinetics of Con A-induced IFN-y production by spleen cells
from BALB/c, NZB/W and MRL/lpr mice. IFN-y activities in the supernatants of 
Con A-stimulated and unstimulated mouse spleen cell cultures at 0, 2, 4, 6, 8, 24, 48,
72, 96 and 120 hrs were measured by mouse IFN-y specific ELISA. Data are expressed 
as means of triplicates.
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Figure 4 .1 0  ELISPOT analysis of Con A -induced IFN-y secretion b y  
spleen cells from normal and lupus mice (age: 20 wks). Spleen cells from 
BALB/c (a, c) and MRL/lpr (b, d) mice were stimulated with Con A (2.5 /^g/ml), and
washed before a further incubation for 16 hrs at a cell concentration of 1 X 1CP cells per 
well in 96-well nitrocellulose membrane based plates pre-coated with a rat anti-mouse
IFN-y antibody. Results presented are representative microphotographs at low (X 9) and
high (X 32) magnifications showing decreased frequency of IFN-y secretors from a 20- 
week MRL/lpr mouse (b) compared with that of a sex-age-matched BALB/c mouse (a),  
and no significant difference in the size of the spots between the two strains (c, d).
month old MRL/lpr mice, which was 2.65 times lower than that of BALB/c control mice 
(1:594 ±115).
Therefore, subsequent experiments were carried out to look at the defect of IFN-y 
production in lupus mice of different ages. However, the reduction of IFN-y production in 
lupus mice was found to be inconsistent and not well established until 6-9 months old in 
both NZB/W and MRL/lpr mice (Fig. 4.11). Con A-stimulated spleen cells from the 1- 
week old lupus and BALB/c mice did not secrete detectable level of IFN-y. In the one 
month age group, MRL/lpr mice but not NZB/W mice showed reduced IFN-y production, 
compared to BALB/c controls. In addition, it was observed that spleen cells from three 1- 
year old NZB/W mice which had no clinical symptoms produced levels of IFN-y 
comparable to that of BALB/c mice of the same age (Fig. 4.11, arrow). Also, in selective 
experiments, considerable strain difference in the production of IFN-y was observed 
between the control BALB/c and CBA strains. Con A stimulated spleen cells from 5- 
month old CBA mice produced significantly higher levels of IFN-y (228 ± 170.9 ng/ml, n 
= 5), compared to BALB/c mice of the same age (43.2 ± 17 ng/ml, n = 8).
4.5.2 Production of IL-4
Con A-induced production of IL-4 by mouse spleen cells in cultures was measured 
by an ELISA method developed to study Th2 cell functional activity in lupus mice. The 
detection limit of the assay was below 10 pg/ml (±2SD). Figure 4.12 shows the kinetics 
of IL-4 production by Con A-induced spleen cells from 4-month old BALB/c and lupus 
mice. Both NZB/W and M RL/lpr mice showed reduced IL-4 production, although 
increased IL-4 secretion was observed at the earlier time points in NZB/W mice. In 
\06l06M RUlpr mice, the IL-4 production was almost completely suppressed. The results 
indicate that IL-4 production is also deficient in lupus mice at this age.
106
1 0
□  BALB/c 
NZB/W 
■  MRL/lpr
1 wk 1 mo 2 mo 3 mo 4-6 mo 7-9 mo ^  1 Y
Age of mice
* no MRL/lpr mouse this group
Figure 4 .1 1  Con A -induced  IFN-y production  by spleen cells from
BALB/c, NZB/W and M RL/lpr mice at different ages. IFN-y activities in the 
supernatants of Con A-stimulated mouse spleen cell cultures were measured at daily 
intervals and data shown are means of the peak values obtained for individual mice in 
each group, except the one-week old groups in which spleen cells from 6 mice of each 
strain were pooled. In the one-year old mouse group, NZB/W mice showed no sign of 
lupus disease activity. Number of mice in each group is as follow:
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Figure 4 . 12  Kinetics of Con A-induced IL-4 production by spleen cells 
from BALB/c, NZB/W and MRL/lpr mice. IL-4 activities in the supernatants of 
Con A-stimulated mouse spleen cell cultures at 2, 4, 8, 24, 48, 72, 96 and 120 hrs were 
measured by mouse IL-4 specific ELISA. Data are expressed as means of triplicates.
The IL-4 ELISPOT assay, which used the same antibodies as in ELISA, failed to 
detect IL-4 secretion by individual cells in cultures.
4 .6  T-cell derived cytokine gene expression
The PCR-assisted cytokine message amplification phenotyping (MAPPing) 
technique involved a reversed transcription of total cellular mRNA followed by PCR 
amplification of the cDNA using specific primers for each cytokine. The conditions of the 
PCR assay were optimised in preliminary experiments (see Chapter 2, Section 2.6).
Expression of cytokine genes in freshly isolated and Con A-stimulated spleen cells 
from lupus mice was studied to determine which lymphokines might be transcribed by 
these cells in vivo, and in vitro after stimulation. Time course study showed some kinetic 
delay of the Con A-induced cytokine gene transcription in the lupus mice, particularly IL-2 
and IL-4 in MRL/lpr mice, and IL-6 in the NZB/W mice. However, the relative peak 
expression for all these cytokines appeared between 6 to 9 hours after stimulation in all 
three strains of mice (Fig.4.13). The results showed no significantly detectable mRNA 
expression in the unstimulated cells for either IL-2 (Fig.4.13a) or IL-4 (Fig.4.13c) in both 
lupus and normal control mice. However, compared to control BALB/c, Con A-induced 
mRNA expression for IL-2 was considerably, and for IL-4 moderately, reduced in the 
MRL/lpr strain, but only marginally reduced in NZB/W mice. Low levels of IL-6 mRNA 
were detected in freshly isolated spleen cells from BALB/c and MRUlpr, but not NZB/W 
mice (Fig.4.13d). After Con A stimulation, the NZB/W mice also seem to have a relatively 
low level of IL-6 mRNA expression. In contrast, a considerable amount of IFN-y mRNA 
was detected in the splenic lymphocytes from mice of the three strains not only of the Con 
A-stimulated cells but also the unstimulated cells (Fig.4.13b). The mRNA expression for 
IFN-y was very much comparable between the control BALB/c and lupus mice, except for 
a marginal decrease in the MRL/lpr strain (Fig. 4 .13b).
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Figure 4 .1 3  PC R -assisted analysis of the k inetics of Con A -induced 
cytokine mRNA expression by spleen cells from  BALB/c, NZB/W  and 
M R L /lpr mice (age: 25 wks). Total RNA was extracted from mouse spleen cells 
unstimulated (0 hr) and Con A-stimulated for 3, 6, 9 and 15 hrs. After reverse
transcription, specific messages for IL-2 (a), IFN-y (b), IL-4 (c), IL-6 (d) and (3-actin 
control (e) were amplified by PCR subjected to 35 cycles. RNA samples extracted from 
mouse T h l (WEP 999) and Th2 (WEP 988) cell clones (malaria specific), and CTLL 
cells were run in parallel to establish the cytokine expression patterns of the cells (f) and 
to confirm the specificity of the primers. The negative controls shown were samples 
amplified without cDNA templates. M: 1Kb DNA markers.
The oligonucleotide sequence of each of the cytokine primers was described in the 
Materials and Methods chapter. Each pair of these cytokine primers had been tested on 
RNA samples extracted from Con A stimulated murine Thl (WEP999, Wellcome, UK), 
Th2 (WEP988,Wellcome, UK) and CTLL cell clones to confirm the specificity of primers 
and the PCR amplification (Fig.4.130- It shows that only one of the 4 different cytokine 
message could be detected in each of the three T-cell clones. The Thl cells expressed IL-2, 
Th2 cells expressed IL-4 and CTL cells expressed IFN-y alone. No IL-6 mRNA was
detected in any of the T-cell clones, though it could be readily detected in the Con A- 
stimulated mouse spleen cells (Fig.4.13d). The mRNA expression for p-actin was tested 
to assess the integrity of the RNA preparations from each of the original samples, and also 
gave positive control signals in each case. To some extent, it reflects semi-quantitatively 
the experimental error as well as the accuracy of the test. There was no false positivity 
detected in the negative controls in which sham reverse transcription reactions were run 
without enzyme, or without DNA.
In the study, it was taken into account that the conventional PCR technique does not 
produce sufficient information for quantitation. As a complementary measure, the final 
PCR-amplified cytokine cDNA was therefore examined by serial dilutions. Figure 4.14 
shows the 6-hour (optimum) Con A-induced cytokine mRNA expression in such a semi- 
quantitative way. The results suggest that there is no significant difference (less than 2 
folds) in the amount of PCR-amplified IL-2, IFN-y, IL-4 and IL-6 gene transcripts 
between lupus and normal mice except for an 8 fold reduction of IL-2 gene expression in 
NBZUlpr mice.
The overall results show that Con-induced mRNA expression for IL-2, IL-4, IL-6 
and IFN-y were all detectable in spleen cells from both normal and lupus mice. There was 
no increased expression of these cytokines at transciptional levels in either the stimulated or 
unstimulated spleen cells in the two lupus strains of mice of 6 months old. Although the
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Figure 4 .1 4  Sem i-quantitative  analysis of the P C R -am p lified  cy tok ine  
mRNA expression by spleen cells from  BALB/c, NZB/W  and M R L /lp r
mice. Cytokine mRNA expression for IL-2, IFN-y, IL-4 and IL-6 in the mouse spleen 
cells after 6 hrs of Con A stimulation was partially quantified by serial dilution of the
PCR-am plified products, in comparison to the p-actin controls of each of the 
corresponding samples.
quantitative information derived from the PCR assay might be limited, the reduction of Con 
A-induced IL-2 mRNA expression in the MRL/lpr mice is clear.
4 .7  D iscussion
T-cell mitogens such as Con A and PHA are known to induce normal T-cells to 
enter 'G l' phase from a resting ’Go' phase of the cell cycle, resulting in enlargement of 
the cells and synthesis of protein and RNA. However, DNA synthesis occurs only 
when a second signal, IL-2, is present (Hadden, 1988; Majumdar et al., 1990). The 
failure of T-cells from lupus mice to respond to Con A might be controlled by this 
second signalling process. The defective IL-2 production is apparently accountable for 
the inability of lupus T-cells to proliferate which prevents a complete cell cycling upon 
mitogen stimulation. In addition, it was observed that the proliferative defect appeared 
earlier in the MRL//pr, later in the NZB/W and progressive with age in both strains. 
This correlates with the degree of IL-2 hypoactivity found in the two mouse strains at 
different ages.
Hadden (1988) suggested that the second signalling process might be initiated by 
IL-1 produced by adherent accessory cells resulting in production of IL-2 by primed T 
lymphocytes. Thus, the inability of lupus T-helper cells to respond to an activation 
signal by secreting IL-2 could be due to either a defect in the accessory cell function or 
a defect in the T-helper cell itself. However, addition of IL-1 did not correct the defect 
in IL-2 production. It is possible that human IL-1 might not be physiologically active 
for mouse, but previous studies using human IL-1 also failed to restore the defect in T - 
cell activation in human SLE (Linker-Israeli, 1983). Furthermore, since replacement of 
lupus adherent cells with normal adherent cells did not correct the defect in Con A- 
induced IL-2 production either, it suggests that the defective lupus T-cell activation 
could not be simply attributed to a lack of co-stimulative signal from adherent cells. 
More recent studies showed that responsiveness to IL-1 is restricted to memory CD4+
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cells which are mainly IL-4 but not IL-2 secretors (Luqman et al., 1992), but a different 
APC-derived signal has been proposed for triggering IL-2 synthesis and secretion by 
T-helper cells of Thl phenotype. It is now suggested that the co-stimulative signal 
responsible for IL-2 secretion is mainly generated by interaction of CD28 molecule on 
T-cells with the B-cell restricted B7/BB1 ligand (Norton et al., 1992; Costello et al., 
1993). The present study did not rule out the possibility of a defect within this co­
stimulation, because no attempt was made to separate and to replace B-cells in the 
cultures.
Stimulation of T-lymphocytes with antigen or mitogen results in the expression of 
surface IL-2 receptor molecules that, upon interaction with IL-2, promote clonal 
expansion of T-cells (Smith, 1980). Con A-induced T-cell IL-2 receptor expression are 
defective in NZB/W and MRL/lpr mice. This is in agreement with Zubler's (1986) 
finding in human SLE patients. Since IL-2 is known to be capable of upregulating 
expression of its own receptors (both a  and p-chains) resulting in enhancement of the 
frequency of IL-2 responsive cells (Reem et al., 1985), it is conceivable that the 
inability of lupus T-cells to express IL-2R may also be due to IL-2 deficiency. 
However, It has been shown that the abnormally expanded DN population in MRL/lpr 
mice does not express IL-2R (3-chain (p75) therefore is unable to generate functional 
high-affinity IL-2R (a  and p-chains) (Rosenberg, 1989). Although this has been 
controversial as study by Gutierrez-Ramos et al (1989) demonstrated a 75-kDa IL-2 
binding molecule identified on the surface of Ipr T-cells, a most recent report (Tanaka et 
al., 1993) favours Rosenberg's finding. It was interesting to note that a rapid decline 
in the IL-2R expression of activated normal T-cells occurred almost immediately after 
cell division. This might be due to the release of IL-2R after activation, or a transient 
inability of these post-activated or dividing cells to express IL-2R. However, it is not 
clear, whether this phenomenon might be reflecting any kind of in vivo post-activated 
state of a dominated T-cell population in lupus mice.
1 1 0
IFN-y is another characteristic Thl-derived lymphokine, which has also been 
involved in autoimmune phenomenon. Results from early studies on production of 
IFN-y in SLE have been contradictory and inconclusive (Santoro etal., 1983; Kofler et 
al., 1984, Umland et al., 1989). In the present study, Con A-induced IFN-y 
production by lupus T-cells was decreased in old lupus mice possibly due to reduced 
frequency of the secretors, in spite of individual variation and strain differences. 
However, unlike the deficient Con A-induced IL-2 production, the IFN-y production 
defect is not consistently established in young lupus mice. Since IFN-y were not only 
secreted by Thl cells (CD4+) but also by CD8+ and other cells, the production of such 
a cytokine could be more complex and may not only reflect Thl function. In addition, 
kinetic studies are often necessary to provide a basis for a valid comparison between 
mouse models of different strains and ages. The difference in IFN-y production 
between lupus and normal mice, which peaked at 3 days, would not have been 
observed if the samples had been taken up to 24 hours only like in an earlier study 
(Umland, 1989).
IL-4 is produced by T-helper cells of the Th2 phenotype. Production of IL-4 may 
reflect functional activity of Th2 cells. Although IL-4 is known as a B-cell growth 
factor it also has pleiotropic effects on other cell types such as T-cells, mast cells and 
macrophages (O'Garra et al., 1988). Evidence has been recently shown that this Th2- 
derived lymphokine may down-regulate IL-2 activity via its action on monocytes 
(Brook et al., 1992), and it can also suppress production of IFN-y by human 
mononuclear cells (Peleman et al., 1992). Since liver of MRL/lpr mice contain 
interleukin-4-producing lymphocytes and accessory cells that support the proliferation 
of Th2 helper T lymphocyte clones (Magilavy et al, 1992), an increased Th2 functional 
activity could explain the defective Thl phenotype. However, the present study shows 
that Con A-induced IL-4 production was also deficient in lupus mice.
I l l
The present study on cytokine mRNA expression demonstrates that gene 
transcription for IL-2, IFN-y, IL-4 and IL-6 can all be induced in lupus mice.
However, compared to normal mice, Con A-induced expression of some of these 
cytokines was reduced to different extent in the lupus mice. The results were largely in 
agreement with Umland's study {1989) on MRL/lpr and BXSB mice using the RNase 
protection assay to assess gene expression for IL-2, IL4 and IFN-y. The reduced 
mRNA expression for IL-2 and IL-4 in MRL/lpr mice might suggest that the deficient 
production of the cytokines is due to some defect at gene transcriptional level. 
However, in NZB/W mice, IL-2 and IL-4 genes are expressed comparably to control 
BALB/c mice although production of these cytokines is also defective, suggesting that a 
different mechanism might be involved. It is worth pointing out that, in the 5-month 
old MRL//pr mice, although Con A-stimulated spleen cells showed reduced levels of 
IL-2 and IL-4 mRNA it might have been a cell dilution effect if the spleen enlargement 
(3-7.5 times) due to lymphoproliferation was taken into account. These together with 
the quantitative limitation of the assay are in general inadequate to provide any 
conclusive answer to whether the defect responsible for the reduced cytokine 
production was in the gene or post-transcriptional levels. The significance of the 
reduced expression of IL-6 mRNA in NZB/W mice is also not clear. Nevertheless, it is 
important to know that there is no enhancement of the cytokine mRNA expression, 
particularly in freshly isolated spleen cells, in lupus mice. This suggests that T-helper 
cells are not in a generally activated state in vivo. Further study of cytokine gene 
expression in young mice will be more informative.
Collectively, all the results described here have further confirmed the functional 
abnormalities of lupus T-cells and their defective responses to activation. The origin of 
the defect causing these T-cell abnormalities is not yet revealed, but it is clear that the 
early, progressive IL-2 deficiency would have prevented the normal process for T-cell 
activation.
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Chapter 5
Effects of exogenous IL-2 and other cytokines on T-cell 
activation in lupus mice and a SLE patient in vitro
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5.1 Introduction
The results presented in the previous two chapters have demonstrated a deficient 
IL-2 activity accompanied by various abnormal T-cell functions in SLE. The causes 
responsible for these T-cell abnormalities remain to be elucidated. The defective IL-2 
activity found in young lupus mice which have not yet developed symptoms of 
autoimmune disease suggests the possible intrinsic nature of the Thl functional defect. 
However, it is well established that IL-2 stimulates activated T-cells to proliferate by 
binding to specific cell-surface receptors. Since Con A did not induce lupus T-cells to 
express normal levels of IL-2R, it is necessary to identify whether the defective T-cell 
activation is simply due to a lack of IL-2 or also because of these other T-cell defects 
such as the inability of cells to express IL-2 receptors. The next important question to 
be answered is, therefore, "can lupus T-cells respond normally to IL-2 ?" In other 
words, if the lupus T-cells were not able to produce sufficient endogenous IL-2 upon 
activation, could it be by-passed by addition of exogenous IL-2 allowing a normal Con 
A response ?
5 .2  Effects of exogenous cytokines on proliferative responses 
of T-cells from lupus mice and a SLE patient
5.2.1 Dose-dependent effects of IL-2 on old lupus mice
The defective proliferative response of splenic T-cells from lupus mice to Con A 
stimulation was completely restored by addition of recombinant IL-2 to the cultures 
(Fig. 5.1). The IL-2 effect was dose-dependent (Fig. 5. Id, 0  and 5 to 10 ng/ml was 
sufficient to restore the response to that of the BALB/c or CBA control cells (Fig. 5. lc, 
e). The effect was synergistic since the same dose of IL-2 alone did not stimulate the 
cells to proliferate although at higher doses it had a marginal effect (Fig. 5.1a, b). IL-2 
alone has been tested at up to 30 ng/ml in all strains with similar results. Exogenous
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Figure 5 .1
Dose-dependent exogenous IL-2 effects on Con A-induced lupus T-cell 
proliferative responses. Spleen cells from lupus and sex-age-matched normal 
BALB/c or CBA mice were cultured (106cells per ml) with or without Con A (2.5 ^g/ml) 
and various amounts of r-human IL-2 as indicated. Cell proliferation was measured at 
daily intervals by the proliferation assay. The lupus mice, NZB/W at 35-weeks and 
MRL/lpr at 21-weeks, were at their peak stages of disease development (50% mortality: 
NZB/W ~8 months; MRL/lpr ~4 months). Cells were cultured with medium alone, or 
with increasing doses of rIL-2 at 0.1, 1, or 10 ng/ml in the absence of Con A (a, b); or 
with Con A alone (c-f), Con A plus rIL-2 at 0.1, 1 or 10 ng/ml (c, d) or Con A plus IL-2 
at 5, 10, 20 or 30 ng/ml (e, f).
IL-2 did not significantly affect the mitogenic responses of T-cells from normal 
BALB/c and CBA mice other than a slight prolongation of cell proliferation (Fig. 5.1c, 
e).
5.2.2 Effects of IL-2, IL-4 and IFN-y on young lupus mice
The effects of exogenous IL-2 on T-cell activation was also determined in young 
lupus mice of different ages. The defective Con A-induced T-cell proliferation was 
evident in M RUlpr mice as young as 4 weeks old and it is consistent and progressive 
with age (Fig.5.2c, f, i. closed triangles). This is in comparison with the responses of 
T-cells from sex-age-matched normal BALB/c mice (Fig.5.2a, d, g). Although the 
early proliferative defect could sometimes be observed in young NZB/W mice too (not 
shown), it was not consistently established in most of the cases until 6-8 months 
(Fig.5.2b, e, h; Fig.5.1d).
Recombinant IL-2 was used at 10 ng/ml in these subsequent experiments. Figure
5.2 also shows typical patterns of the exogenous IL-2 effects (closed circles) on the 
proliferative responses of splenic T-cells from young lupus and control mice between 1 
to 12 weeks of age. In the lupus mice of 4-weeks or older, addition of r-IL-2 during 
Con A stimulation by-passed the IL-2 hypoproduction defect where it existed, and 
induced the T-cells to proliferate in full. Again, these mouse spleen cells from both 
lupus and normal strains did not spontaneously proliferate in the absence of Con A 
(Fig.5.2, open triangles), and only marginally responded to IL-2 alone (open circles). 
In the one week old mouse group, BALB/c spleen cells did not respond to Con A 
stimulation even in the presence of exogenous IL-2 (Fig. 5.2j). Since less than 4% of 
cells in the spleens from the one-week old mice of the three strains were CD3+, the 
inability to respond to Con A stimulation is probably due to a lack of T-cells at this very 
early stage. However, although these early spleen cells from lupus mice also remained
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hand comer of each individual graph.
unresponsive to Con A alone, their T cells showed earlier responsiveness to exogenous 
IL-2 during Con A stimulation (Fig. 5.2k, 1).
Figure 5.3a shows effects of exogenous IL-2 on the proliferative response of T- 
cells from a 3 month old MRL/lpr mouse, by using supernatants from cultures of Con 
A stimulated (24h) BALB/c spleen cells as a source of IL-2. The natural murine IL-2 
derived from BALB/c spleen cells (supernatant used neat) also effectively restored the 
lupus T-cell proliferative response to Con A (close triangles). In addition, it was noted 
that the culture supernatants of Con A-stimulated (24h) spleen cells from the 3-month 
old MRUlpr mice had certain suppressive effects on the proliferative response of spleen 
cells from a BALB/c mouse (close circles). Exchange of spleen cell culture 
supernatants between a 3 months old NZB/W and a BALB/c mouse 24 hours after Con 
A stimulation did not affect the subsequent thymidine uptake by the cells, and the 
young NZB/W mouse showed a normal proliferative response to Con A (Fig. 5.3b).
To determine effects of other cytokines on the T-cell activation, recombinant 
murine IL-4 and IFN-y were also tested on spleen cells from MRLllpr and BALB/c
mice. At 10 ng per ml, while IL-2 significantly enhanced the proliferative response of 
lupus cells to Con A, the effect of IL-4 was only marginal and IFN-y had no effect 
(Fig.5.4). The immunoreactivities of the recombinant mouse IL-4 and IFN-g used in 
the experiments have been confirmed by the specific ELISA techniques, but no efforts 
were made to determine their bio-physiological activities.
5.2.3 Effects of IL-2 and IL-1 on spleen cells from a SLE patient
A human spleen from a SLE patient (female, 47 years old) with active disease 
was kindly provided by Dr M Fields, Department of Medidne, Royal Infirmary, 
Glasgow. The spleen was surgically removed due to its hyper-hemocidal activity 
resulting in thrombocytopenia in the patient.
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Fieure 5 .3  Effects of supernatants from  Con A -stim ulated spleen cell 
cultures as the source of IL-2 on subsequent T-cell proliferation in n o rm a l 
and lupus mice. Spleen cells (106 cells per ml) were stimulated with Con A for 24 
hrs followed by exchange of culture supernatants between normal (BALB/c) and lupus, 
MRL/lpr (a) or NZB/W (b), mice (closed symbols). The proliferative responses were 
measured by 3H-thymidine incorporation and compared with the control cell cultures in 
which supernatants were unchanged (open symbols).
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Figure 5 .4  Different effects of r-hum an IL-2, r-mouse IL-4 and r-m o u se  
IFN -y on Con A-induced mouse T-cell proliferation. Exogenous cytokines 
were used at 10 ng per ml. Proliferation of the spleen cells pooled from 2 mice (4 month 
old) in each strain, stimulated or unstimulated, were all measured at 3 days by 3H- 
thymidine uptake. Data shown are means (±SD) of duplicate cultures.
Cells were prepared from the spleen as previously described for dealing tissue 
from mouse spleens, and stimulated with Con A (2.5 pg/ml) or PHA (5 pg/ml) in 96- 
well cell culture plates. The cell cultures were supplemented with recombinant human 
IL-2 or IL-1 at various concentrations. After 66 hours of incubation at 37°C, 5%C02, 
the cultures were pulsed with 3H-thymidine for 6 hours and the incorporated 
radioactivity measured. No significant effect of exogenous IL-1 (0-100 ng/ml tested) 
was observed on the proliferative responses of the cells to Con A or PHA (Fig. 5.5a). 
In addition, the cells did not respond to IL-1 alone either. However, similar to its 
effects on mouse spleen cells, IL-2 enhanced proliferative responses of lupus spleen 
cells from the SLE patient to both of Con A and PHA. It was noted with interest that 
unlike the mouse, the human lupus splenocytes responded strongly to IL-2 alone at 
high doses. At doses above 10 ng/ml, there was a much higher rate of increase of the 
IL-2 stimulating effects in the cultures with IL-2 alone compared to cultures with IL-2 
and either Con A or PHA. At the highest dose (100 ng/ml) of IL-2 tested, there was 
even a 2-fold higher thymidine uptake by the cells cultured with IL-2 alone compared to 
cells cultured with the same dose of IL-2 in the presence of mitogen (Fig. 5.5b).
5 .3  Effects of IL-2 on mouse T-cell IL-2R expression
IL-2 dependent recovery of the T-cell response is also illustrated by the surface 
IL-2 receptor (CD25) expression on T-cells (CD3+). Figure 5.6 shows that exogenous 
IL-2 restores the responsiveness of splenic T-cells from lupus mice to Con A by 
increasing frequency and density of IL-2 receptor expression. Recombinant IL-2 
significantly upregulates IL-2R expression on T-cells from lupus mice of both strains 
despite some kinetic delay. It was noted that the frequency reached normal levels at day 
3 (Fig. 5.6a, b), but the average density of surface IL-2R was still below normal (Fig. 
5.6c, d). In addition, the effect of exogenous IL-2 on old lupus mice was relatively 
poor compared to young mice, particularly in the MRL//pr strain. Figure 5.7 shows
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Figure 5 .6  Effects of exogenous IL-2 on resto ring  ability  of T-cells 
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to Con A-stimulation. The results shown are from a three-dav time course and rIL-2 
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Figure 5 .7  Typical flow cytom etry profile showing effects of IL-2 o n  
Con A-induced T-cell IL-2R expression on young and old mice. Spleen 
cells from BALB/c (a, b), NZB/W (c, d) and MRL/lpr (e, f) mice were stimulated with 
Con A (2.5 pig/m\) in the presence (red filled profile) or absence (green open profile) of 
IL-2 (10 ng/ml) for 3 days, before being labelled with a R-PE conjugated rat monoclonal 
anibody specific to mouse CD25. Pan-T cell marker is a FITC-conjugated hamster anti­
mouse CD3. All cells gated for the analysis are CD3+ and viable, -ve: isotype negative 
control.
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typical FACS profile of the effects of exogenous IL-2 on Con A-induced T-cell IL-2R 
expression in young (2 to 3 months) and old (5 to 8 months) NZB/W, MRL//pr and 
BALB/c mice.
The effect of exogenous IL-2 on IL-2R expression by splenic B-cells in the 
cultures was marginal and no significant difference was observed between normal and 
lupus mice.
5 .4  Effects of IL-2 on Con A-induced IFN-y secretion 
in M RL/lpr mice
As previously described in Chapter 4, Con A-induced IFN-y production was 
reduced in older lupus mice because of decreased frequency of IFN-y secretors. This 
may also be attributed to the IL-2 deficiency as it can be restored by addition of 
exogenous IL-2 in vitro (Fig 5.8). Supplementing IL-2 during Con A stimulation 
increased IFN-y secretion by upregulating the frequency of IFN-y secretors. The effect 
was synergistic because IL-2 alone did not stimulate IFN-y secretion in both BALB/c 
and MRL/lpr mice.
5 .5  Effects of IL-2 on autoantibody production by mouse 
spleen cells in cultures
Figure 5.9 shows that spleen cells from old lupus mice spontaneously secrete 
autoantibodies into cell cultures, but the autoantibody secretion is not significantly 
enhanced by addition of IL-2, at least in the short term (6 day) cultures. Although the 
result was just from one experiment and is to be confirmed, it shows exogenous IL-2 
did not have an accountable effect on either young (3 month old) MRL/lpr mice which 
secreted low levels of antibodies, or old (8 month old) NZB/W mice which secreted 
high levels of antibodies to ss or dsDNA.
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Figure 5 .9  In  vitro spontaneous production  of anti-ssDNA and  anti- 
dsDNA antibodies by spleen cells from  lupus mice and the effects of Con 
A (2.5 ng/m l)  and rIL-2 (10 ng/ml) on the autoantibody titres. Spleen cells 
from BALB/c (6 months), MRL/lpr (3 months) and NZB/W (8 months) mice were 
cultured with or without Con A (2.5 ^g/m l) and/or IL-2 (10 ng/ml) as indicated. 
Antibodies to ss and dsDNA present in the culture supernatants undiluted were measured 
at day 5.
5 .6  T-cell subsets and the IL-2 responders in vitro in 
M RL/lpr  mice
To assess the in vitro effects of exogenous IL-2 on the abnormal DN T-cells in 
M RUlpr mice, and the phenotypes of the IL-2 responders, stimulated and unstimulated 
(freshly isolated) spleen cells from MRUlpr mice were analysed by using specific 
antibodies to T-cell surface markers. Figure 5.10 shows a selective expansion of CD8+ 
lupus T-cells with a sharp decline in the percentage of abnormal CD3+CD4"CD8" cells, 
from 64.94 to 14.32%, after 3 days of Con A stimulation in the presence of exogenous 
IL-2. There was a 5-fold increase in total number of CD3+ cells compared to cells in 
the original cultures at day 0, while the absolute number of DN cells remained 
unchanged. The results indicate that these DN cells did not proliferate in respond to IL- 
2 in vitro.
5 .7  D iscussion
One of the arguments discounting the primary importance of the IL-2 defect was 
the failed attempt of earlier investigators to restore lupus T-cell activation by exogenous 
IL-2. Using IL-2 preparations derived from cultures of Con A-stimulated spleen cells 
of C3H/St mice and rats, previous investigators (Altman et al., 1981) were not able to 
correct the defective response of lymph node and spleen cells to Con A in old MRUlpr 
mice. The authors attributed this to an inability of lupus T-cells to respond to IL-2. 
However, a later study by Warrington et al. (1989) using limiting dilution analysis 
techniques showed that addition of exogenous IL-2 during the initial step of mitogen 
stimulation might increase precursor frequencies of IL-2 responders of peripheral blood 
lymphocytes from SLE patients. In agreement with Warrington's observation, the 
present study has demonstrated clearly that exogenous IL-2 by-passes the in vitro
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activation defects in NZB/W and MRL//pr mice, and enhances the proliferative 
response in the SLE patient.
Under the in vitro culture conditions, exogenous IL-2 is capable of restoring the 
ability of lupus T-cells to respond to Con A or PHA, to proliferate, to express IL-2R 
and to secrete IFN-y. In contrast, normal T-cells from BALB/c and CBA control mice 
are activated by the mitogen and undergo complete cell cycling in the absence of 
exogenous IL-2 as they are able to secrete sufficient endogenous IL-2. The 
experimental evidence indicates that IL-2 deficiency is the major and prime cause of an 
unsuccessful T-cell activation induced by the T-cell mitogens. Therefore, many of the 
T-cell functional abnormalities in lupus disease may be secondary to the IL-2 
deficiency. The results also indicate that T-cells in lupus mice and the SLE patient are 
highly responsive to exogenous IL-2 when the first signal is generated by Con A. 
These cells do not appear to be in an 'exhausted' unresponsive state as suggested 
previously by other investigators (Huang et al., 1986; 1988). Majority of the cells 
from lupus mice are not in an activated state either as they do not respond to IL-2 alone. 
Spleen cells from one week old mice did not respond to either Con A or IL-2 alone. 
This could be explained by the lack of T-cells, especially T-helper cells at this early 
stage. However, it is not clear why T-cells from both lupus strains had an increased 
response to Con A plus IL-2 when compared to cells from BALB/c mice of same age. 
Presumably, these cells, which should have been eliminated during normal thymic 
selection, might have escaped the immune control process and were released to 
peripheral lymphoid organs.
Exogenous IL-2 is able to upregulate IFN-y secretors of old lupus mice to 
produce normal levels of IFN-y also suggesting the secondary nature of the abnormal 
IFN-y production, but not a lack of precursors. However, addition of exogenous IL-2 
in short-term cultures does not enhance the autoantibody secretion. Response to 
exogenous IL-2 during T-cell activation resulted in selective expansion of the mature
1 2 0
CDS4* cell population but not the immature DN cells from MRUlpr mice in cultures. It 
suggests that a normal T-cell activation which requires IL-2 may be important in 
limiting proliferation of the self-reactive DN cells which provide factors supporting 
production of autoantibodies (Datta, 1989) and are related to disease progression.
Before recombinant IL-2 was available, the only source of IL-2 was the 
conditioned medium derived from stimulated lymphocyte cultures (Morgan et al., 
1976). It contains not only IL-2 but also many other complex biological components 
including suppressive factors for IL-2. The measurable IL-2 in the culture supernatants 
is also a residual activity remaining after consumption by the stimulated cells. One of 
the possible explanations for the previous failure in restoring lupus T-cell activation 
might be that the level of exogenous IL-2 in the supernatant was inadequate to elicit a 
full response. The present study has shown that a minimum concentration of IL-2 of 5 
to 10 ng/ml is required to restore T-cell responsiveness, which is two to three times 
more activity than is normally detected in cultures of Con A stimulated normal spleen 
cells. An IL-2 preparation from stimulated BALB/c spleen cells tested in the present 
study was used without dilution and this also showed effects on lupus T-cells. In 
addition, the IL-2 effect peaked at 3 days and it had only a marginal effect at 2 days 
(Fig.5.3a). However, in Altman’s study, the IL-2 preparation was only tested at 1:10 
dilution in the 'MLR' assay, or at a maximum of 1:2 dilution in the proliferation assay 
but measured at 48 hours. In addition, the present kinetic study has shown that Con A- 
induced IL-2 secretion by mouse spleen cells normally peaks at 24 hours and decline 
rapidly thereafter (Chapter 3, Fig.3.2a). The crude IL-2 used in Altman's study, which 
was derived from rat spleen cell cultures, was taken 48 hours after Con A stimulation. 
It might not necessarily contain peak IL-2 activity. Therefore, it is not surprising that 
there was no significant effect observed.
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The significance of the finding that spleen cells from the SLE patient responded 
more strongly to IL-2 alone at high doses than to IL-2 plus Con A or PHA is not clear. 
It is likely that the majority of the potential IL-2 responders might have been B-cells 
which were hyperactive and bearing IL-2 receptors. When T-cells were activated in the 
presence of T-cell mitogen and exogenous IL-2, the significantly lower thymidine 
uptake, compared to cells cultured with IL-2 alone at the same dose, suggests the 
presence of suppressive factor(s) as a consequence of T-cell activation. In mice, in 
spite of the incomplete T-cell activation, culture supernatants derived from Con A- 
stimulated MRL/lpr spleen cells also showed a suppressive effect on the proliferative 
response of cells from BALB/c mice. In addition, the effect of IL-2 on recovery of IL- 
2R expression was poorer in old lupus mice which is possibly due to other defect(s) 
developed along with the disease activity. These support the hypothesis that some 
mechanism of feedback suppression might be operative during the development of 
lupus disease, reflecting attempts of the immune system to restore homeostasis 
(Kroemer and Martinez-A, 1991). As a consequence, it may also nonspecifically 
suppress IL-2 activity even further.
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Chapter 6
Serological abnormalities in SLE
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6.1 Introduction
There has already been a multitude of serological abnormalities found in both 
human SLE and the mouse models, with common features in many aspects as well as 
differences between species or strains. Among them, production of a variety of 
autoantibodies, and the presence of circulating immune complexes (ICs) with reduced 
levels of complement components are the main but complex manifestations which have 
been studied in detail for many years (Morrow and Isenberg, 1987; Theofilopoulos and 
Dixon, 1985; Buskila and Shoenfeld, 1992). Recently, nitric oxide and cytokines that 
induce nitric oxide synthesis have been suggested to play a role in autoimmune process. 
Elevated levels of reactive nitrogen intermediates (RNI) have been reported in sera of 
patients with rheumatic disease (Miesel and Zubler, 1993).
In this chapter, an unknown serum factor or factors, discovered in human sera 
and plasma and increased in SLE patients with active disease, is described. The 
factor(s) have adverse effects on the proliferation of IL-2 dependent CTLL cells, and 
does not appear to be either immunoglobulin (IgG) or an IC. Similar inhibitor(s), but 
with lower titre, were also found in some sera from MRUlpr mice. In addition, serum 
levels of nitric oxide (NO) in BALB/c, CBA, NZB/W and MRUlpr mice were analysed 
during the study.
6 .2  SLE serum factors affecting the growth of IL-2 dependent 
CTLL cells
The initial aim of this study was to measure IL-2 activity in serum and plasma 
samples by the CTLL IL-2 bio-assay. In the CTLL assay, IL-2 activity is determined 
by its ability to induce CTLL cell proliferation (Chapter 2). The attempt to measure IL- 
2 in either sera or plasma by the bio-assay, however, repeatedly failed due to the 
presence of an inhibitor in the serum or plasma samples. No positive IL-2 activity was
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detected in any of the untreated serum or plasma samples by CTLL cell growth. On the 
contrary, the cells incubated with serum or plasma samples showed even lower 
thymidine uptake compared to cells cultured in medium alone (negative controls). The 
inhibitory effect was concentration dependent and the unknown inhibitor was found at 
higher concentrations in SLE sera. To understand the role of this serum factor in the 
defective IL-2 activity in lupus disease, the purpose of the follow-up study was to 
investigate the nature of the serum factor that inhibits the growth of IL-2 dependent 
cells.
6.2.1 Concentration dependent effects on CTLL cell proliferation
To determine activities of the CTLL cell growth inhibitor in SLE, serial dilutions 
of the serum and plasma samples from SLE patients with active disease as well as 
normal donors were cultured with the indicator cells in the presence of a fixed amount 
of human r-IL-2. IL-2 was used at 100 pg/ml in the assay because the growth of CTLL 
cells at this dose is sensitive to changes of IL-2 activity according to IL-2 standard 
curves established in preliminary experiments. It normally gives about 40 to 80% of 
maximum thymidine incorporation, which is within the most linear part of the IL-2 
standard curves (Chapter 2, Fig.2.2a). Surprisingly, the results revealed not only a 
significantly higher inhibitory titre but also a potential stimulatory activity in the sera 
and plasma from SLE patients at different dilutions compared with normal human sera 
and positive control samples without added serum.
Figure 6.1 shows the concentration-dependent but opposite effects of SLE sera 
on CTLL cell proliferative responses to IL-2: (i) at low dilutions - -  inhibition; (ii) at 
high dilutions - -  stimulation. The serum factor(s) inhibit the IL-2-induced CTLL cell 
growth at high concentrations. Although the inhibitor(s) could be found in the sera 
from both normal and SLE patients, it was significantly higher in the latter (up to 8 
fold). The effect of inhibition disappeared at 1:32 to 1:64 for samples from normal
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individuals, but at 1:256 or even higher dilutions for samples from SLE patients. 
Although the activity at high titre could occasionally be found in normal sera, group 
studies confirmed that the difference between the SLE patients and normal controls was 
highly significant (at 1:64, P < 0.001, Fig.6.2). In addition, what is a more interesting 
finding is some stimulatory activity of SLE sera at low concentrations on the CTLL cell 
growth. As shown in both Figures 6.1 and 6.2, serum samples from SLE patients, at 
dilutions between 1:512 to 1:4096, enhanced thymidine uptake by the IL-2-induced 
CTLL cells. The stimulatory effect was synergistic as the cells incubated with the 
samples but without IL-2 showed only growth suppression. In the samples from 
normal controls, this cell growth enhancer was not detectable, or only marginally so. 
The difference between the SLE sera and normal controls was also highly significant (at 
1:1024, P <  0.001, Fig.6.2).
The CTLL cell growth modulators were also found in plasma samples and results 
were similar to that of sera. There was no correlation between the titres of the inhibitor 
and stimulator in each of the individual samples. Freezing and thawing were found to 
degrade their activity, particularly the stimulatory effect In addition, a similar inhibitor 
with increased titres, but no stimulator, was also observed in the sera from some 
MRUlpr mice. However, the titres were low and only 2 out of 4 MRL/lpr mice tested 
(6 months old) showed about 2-fold increased activity in comparison with BALB/c 
controls (Fig.6.3).
6.2.2 Functional characterisation of the SLE serum factors
The serum factors were partially characterised to study their nature and the 
mechanism of interaction by which they influence the IL-2 dependent growth of the 
CTLL cells. Serum samples from SLE patients which showed high levels of both the 
inhibitory and stimulatory activities, and from normal donors as controls, were selected 
for the characterisation. The results show that: (i) the inhibitory effect is not neutralised
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Figure 6 .3  The CTLL cell growth inhibitor(s) in mouse sera. Serial 
dilutions of serum samples from four 6-month old MRUlpr mice were tested in the assay 
as described in Figure 6.1 for human samples. Normal control was pooled sera from 
BALB/c mice of same age. Positive controls (+ve) were CTLL cells cultured with IL-2 
alone at 100 pg per ml without test serum. Data shown are means of duplicated cultures.
by IL-2; (ii) the inhibitor binds to CTLL cells, (iii) is heat labile and (iv) does not bind 
to Protein A.
In the first experiment, CTLL cells were cultured with a fixed concentration 
(1:32) of plasma samples, and different doses of r-human IL-2. By increasing the dose 
of the IL-2 added, at up to 20 ng/ml, it did not neutralise the inhibitory effect of SLE 
plasma on the CTLL cell proliferation (Fig.6.4a). The normal control plasma did not 
have a significant inhibitory effect at a 1:32 dilution compared to the no serum controls, 
but it enhanced the cell proliferation when higher doses of IL-2 were added. In the 
second experiment, a serum from a SLE patient was tested at 1:50, 1:100 and 1:1000 
(Fig.6.4b). IL-2 which was used at 0.8, 4,20, 100 and 500 ng/ml had no effect on the 
inhibitory activity of human SLE serum on the growth of CTLL cells at any of the 
serum dilutions.
However, pre-absorption of the serum samples with viable CTLL cells removes 
the inhibitory effect. The degree of absorption was cell concentration-dependent (Fig. 
6.5). The number of cells required to absorb the serum factor varied from sample to 
sample, which reflects different levels of activities in the sera. Incubation of 4 X 107 
CTLL cells in 1 ml of neat SLE serum for 30 minutes at 37 °C eliminated the inhibitory 
activity fully in most samples tested. As indicated in Figure 6.5, the inhibitory effect 
could also be eliminated by pre-heating the samples prior to cell culture. In all SLE 
serum samples tested, the inhibitor was completely inactivated after 40 minutes 
incubation at 60 °C. AH pre-absorbed and pre-heated samples were tested at the low 
dilutions only to determine effects of cell absorption and heating on the serum 
inhibitory activity. The results shown in Figure 6.5 were combined data from two 
similar experiments in which samples were used at 1:50, but sample dilutions at 1:25 
and 1:32 were also tested with consistent agreement. No attempt has been made to 
assess the effects of these pretreatments on the stimulatory activity in the samples, 
which is present at high dilutions of the untreated SLE sera (Figs.6.1 and 6.2).
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samples expressed as percentage of the positive controls (cells cultured with IL-2 alone at 
100 pg/ml).
To identify the unknown serum factor(s), Protein A-Sepharose which binds 
specifically to human IgG, was used to separate serum IgG molecules from other 
components. Two human sera (0.4 ml each), one SLE and one normal control, were 
fractionated by the Protein A column (IgG binding capacity: 35 mg). The SLE serum 
was from a patient with active disease and has been tested in the previous experiment 
showing both the inhibitory and stimulatory activities. Details of the fractionation 
procedure have been described in Section 2.2.3ii, Chapter 2.
Figure 6.6 shows the serum protein levels in the sample fractions separated by the 
Protein A column. For each serum sample, the first peak represents the amount of 
unbound proteins and the second peak records the amount of IgG eluted from the 
Protein A column by glycine-HCl (pH 2.8). For each peak, adjacent fractions giving 
an OD of 0.2 or higher at 280 nm diluted at 1:20 in PBS, were combined. The total 
protein recovered in the first and second peaks from the SLE serum was 24.5 mg, 
about 59.2% of the original amount of protein (41.4 mg in 0.4 ml serum). The rest of 
the sample fractions containing low or no proteins were therefore discarded.
After dialysis in PBS buffer at 4 °C, extensive precipitation appeared in the 
sample of the second peak from the SLE serum. The precipitated proteins were then 
removed by centrifugation. The soluble form of IgG remaining in the supernatant was 
about 52.8% of the total IgG. The actual amounts of soluble proteins recovered in each 
sample for the first and second peaks respectively were, 18.65 and 2.65 mg for the 
SLE serum and, 18.19 and 3.70 mg for the control serum. All samples were adjusted 
to a final volume of 0.7 ml (dilution factor: 1.75). In addition, samples of unseparated 
sera (0.5 ml each) were also dialysed in PBS at 4 °C for 3 days, then sterile-filtered, 
the volume adjusted to 0.7 ml (dilution factor: 1.4). These samples were stored at -20 
°C before assaying.
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Figure 6.7a shows the activities of the SLE serum factor(s) in samples before and 
after Protein A separation. In this assay, the untreated serum did not show any 
stimulatory activity presumably due to freezing and thawing of the sample, but it still 
had a high level of inhibitory activity. The inhibitory activity was also detected in the 
dialysed serum with only a slight reduction after the extensive dialysis in PBS buffer. 
In the Protein A fractionated samples, the immunoglobulin fraction (peak 2) did not 
have any significant effect on the growth of CTLL cells. However, the activity existed 
in the first peak, although it was much lower when compared to the untreated or 
dialysed serum. In the normal control serum, inhibitory activity was evident in the 
untreated sample, but it was not detected in the Protein A fractionated samples from 
both peaks. On the contrary, low stimulatory activity was observed in the second peak 
(Fig.6.7b).
To determine the possible role of anti-T-cell antibodies in the inhibition of the T- 
cell growth, normal rat serum was used as a source of complement. CTLL cells were 
cultured with samples from the second peaks (IgG) supplemented with 10% rat serum. 
However, there was no inhibitory but a strong stimulatory effect for both SLE and 
control samples. Since the same effect was also observed in cells cultured with rat 
serum alone (Fig.6.7a,b), the stimulation was considered to be due entirely to 
component(s) from the rat serum itself. In Figure 6.7, all data presented referred to 
adjusted dilutions taking into account the differences between original serum volume 
and the final adjusted volume after the various pre-treatments described.
6 .3  Serum nitric oxide levels in NZB/W, MRL/Ipr, BALB/c and 
CBA mice
To study serological abnormalities in SLE, plasma levels of nitric oxide in lupus 
and normal mice were measured. Eighty-one sera from mice of two lupus strains, 
MRLIlpr (24) and NZB/W (24), and two normal strains, BALB/c (27) and CBA (6), at
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different ages were tested. The sera had been collected periodically and stored at -20 
°C before assaying.
The serum NO level was significantly increased in MRUlpr mice compared to 
both BALB/c and CBA control mice, in every age group (Fig.6.8). In the control 
BALB/c and CBA mice, the serum NO levels seem to correlate with the age of the 
mice, peaking at between 4 to 6 months. However, the increased serum NO levels in 
M RUlpr mice did not seem to have a clear correlation with age although the average 
activity was slightly higher in the 1-2, and 4-6 months age groups. In contrast, 
NZB/W mice showed overall reduced serum NO levels. The reduction was consistent 
in most of the age groups except the 1-2 month old and the 10-12 month old age 
groups. In addition, CBA mice of the 2-4 month old group also had low serum NO 
activity.
6 .4  D iscussion
A major finding from these experiments is a serological abnormality in SLE, viz. 
a soluble serum component, or components, which affect IL-2 activity on CTLL cell 
proliferation. It is already known that rodent serum contains soluble factors that inhibit 
IL-2 activity (Hardt et al., 1981; Male et al., 1985). Of interest is the observations that 
sera and plasma from SLE patients with active disease contain significantly higher 
levels of soluble factors that exhibit not only inhibitory but also stimulatory effects on 
the same target cells depending on sample dilutions.
Djeu and her colleagues (1986) have also described previously a 60,000 - 70,000 
molecular weight IL-2 inhibitor in human sera, which is also heat-labile and inhibits IL- 
2-induced CTLL growth. In contrast to the present finding, they found that such IL-2 
inhibitor was reduced in patients with SLE and other autoimmune diseases. This seems 
difficult to be interpreted. However, Djeu's conclusion drawn from the comparison of
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the inhibitory activities between normal and SLE sera were based on a single dilution of 
serum samples at 1:10, and expressed only as percentage of inhibition. The present 
study were based on assays of a wide range of sample dilutions. The results showed 
that, in cultures with either normal or SLE serum at such a high concentration (1:10), 
thymidine uptake by CTLL cells was extremely low (Fig.6.1). More importantly, the 
present study used pure recombinant IL-2 at 100 pg/ml (about 2 U/ml) which is a 
concentration most sensitive to changes of the IL-2 activity in the culture, because it is 
within the most linear part of response curve (see Fig.2.2a). The IL-2 used in Djeu's 
study was either culture supernatants from the EL4 cell line or Con A/PMA-stimulated 
human mononuclear cells, which was used at 100 U/ml. First of all, changes of the 
cell responses to such high dose of IL-2 might be very different In addition, those 
supernatants Djeu used as a source of IL-2 might contain other factors such as mitogens 
complicating the results. It is worth pointing out that IL-2 at wide range up to 500 ng 
(about 1000 U) per ml was also tested in the present study and showed consistent 
results (Fig.6.4).
An immediate consideration of the nature of these factors is the possible influence 
of drugs. The human SLE serum or plasma samples were taken from patients, most of 
whom had been receiving or had received treatment before the samples were taken. 
The routinely used immunosuppressive drugs like cyclosporin A or Corticosteroids 
might have complicated the events. However, the fact that extensive dialysis of the 
serum samples failed to remove the inhibitory activity does not support such a simple 
explanation. In addition, although some plasma samples were collected in the presence 
of EDTA which could have some effect on the CTLL cells, serum samples, especially 
mouse sera free of such contaminant, also displayed these activities.
Secondly, it is necessary to consider whether these activities were due to soluble 
serum IL-2 receptors. It has been widely reported that sera from patients with SLE 
(Wolf and Brelsford, 1988; Tokano et al., 1989) and rheumatoid arthritis (Campen et
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al., 1988; Wood et al., 1988; Keystone et al., 1988) have increased levels of circulating 
soluble IL-2 receptors that correlate with disease activity. These soluble receptors may 
bind to IL-2 preventing its functions. However, the cell absorption experiments 
showed that these serum factors bound directly to CTLL cells. In particular, since 
exogenous IL-2 (up to 500 ng/ml) did not neutralise activity of the serum factors (at 
1:32 and 1:50.), the possibility of the inhibitory effects on CTLL cells being due to 
soluble IL-2 receptors present in the test sera or plasma may be excluded.
The over-dose toxic effect of IL-2 on CTLL cell proliferation has been described 
previously in Chapter 2. Therefore, the inhibitory effect of the serum samples on 
CTLL cells might be explained by a high or increased serum level of IL-2, which 
became stimulatory when being highly diluted. However, this does not appear to be a 
good explanation either, because addition of serum alone at any dilution did not 
stimulate the growth of CTLL cells. Since the stimulatory activity of the SLE serum 
samples at high dilutions can only be observed when IL-2 is present, the effect is 
clearly synergistic. Despite this, it is still possible that the two concentration dependent 
opposite effects are due to one factor which acts as an IL-2 enhancer at optimal doses 
but becomes inhibitory when the concentration exceeds a certain level. Therefore, in in 
vivo  situations, the factor may serve as a T-cell stimulator during the early 
development of the disease and may subsequently become inhibitory as its serum 
concentration rises. However, in some SLE and normal sera which contained 
significant levels of inhibitor, while serially diluting the samples diminished the 
inhibitory activity, there was no observable stimulatory effect. The fact that the 
inhibitory activity did not correlate with the stimulatory activity in each of the individual 
samples suggests that these effects were more likely to be due to different factors.
Another possibility is anti-T-cell antibodies or immune complexes. It has been 
reported that in the sera from as many as 80% of SLE patients and many family 
members, lymphocytotoxic antibodies (LCA) were detectable (De Horatius and
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Messner, 1975; Tanaka et al., 1989; reviewed by Winfield and Mimura, 1992). The 
cell absorption experiments showed binding of the serum factors to CTLL cells, but the 
Protein A isolated SLE IgG fraction contained no inhibitory activity. Since the factor 
did not bind to Protein A and the inhibitory activity presented in the first peak, it is also 
unlikely to be ICs. Supplementing the IgG fraction with rat serum as a source of 
complement did not show any inhibitory effect either, except for a stimulatory effect 
which was due entirely to the rat serum itself. However, as most of the T-cell 
antibodies found in SLE are of the IgM class (Morrow and Isenberg, 1987), it does not 
therefore exclude the possibility that such T-cell antibodies might be IgM which does 
not bind to Protein A. It is not clear why the Protein A fractionated normal serum had 
lost its inhibitory activity, and rather became stimulatory in the first peak in which IgG 
was removed. The mechanism for these different effects appears to be rather complex.
The pathological significance of these serum factors is still to be investigated. 
The fact that these serum factors were found not only in SLE patients but also in the 
lupus mouse model MRLllpr mice might suggest some relevance to lupus disease. 
However, the activity was low and not detectable in some of the mice. It will be 
necessary to characterise the mouse serum factor before any conclusion can be drawn. 
The significance of the fact that serum NO levels are increased in M RU lpr  but 
decreased in NZB/W mice is also not clear. Since the changes are not related to age of 
mice and disease activities, the pathological importance is unknown. NZB serum factor 
(NZB-SF) is a 60-kDa glycoprotein initially isolated from sera of young NZB mice 
treated with Corynebacterium parvum. It was demonstrated that the factor enhanced 
maturation and proliferation of s lg ' pre-B cells in bone marrow, but was 
distinguishable from many known cytokines. Since a similar factor could also be 
found at very low levels in the sera from mice of several normal strains treated in the 
same way, its physiological and pathological importance has been suggested 
(Jyonouchi et al., 1991). In another study by Tomura et al. (1989), a factor derived 
from the cell culture supernatants of B cells from SLE and RA patients has been shown
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to enhance CTLL cell proliferation, and has therefore been named "B cell derived- 
growth enhancing factor-2 (BGEF-2)". It is not clear whether the serum factor found 
in the present study which also stimulated CTLL cell growth could be the same factor 
found by Tomura in the B-cell culture supernatants. However, after excluding many 
possibilities mentioned above, these biologically potent, heat-unstable, T-cell binding 
serum factors are likely to be protein effectors or cytokines (possibly still unknown), 
which act as antagonists or agonists regulating IL-2 action on T-cells. Further 
characterisation of these factors is therefore recommended.
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Chapter 7
Delivery of murine TGF-pi by Salmonella typhimurium 
aro- mutant in MKL/lpr and BALB/c mice
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7.1 Introduction
7.1.1 TGF-p: its multiple, diverse immune regulatory functions
Transforming growth factor-p (TGF-P) is a group of structurally related polypeptides 
belonging to the TGF superfamily', which are believed to participate in the regulation of 
cell proliferation and differentiation during development and tissue repair (Spom and 
Roberts, 1989). TGF-P was initially found to be able to induce phenotypic transformation 
of mammalian cells in culture (Roberts et al., 1983). It has since been shown to have 
diverse effects on a variety of cells. Its activity, either stimulatory or inhibitory, depends 
on the cell type, the state of differentiation and the culture conditions. The expression of 
this 25-kD homodimeric peptide can be detected in many types of cells and tissues 
including activated T and B lymphocytes (Kehrl et al., 1986a, b) with relatively high levels 
found in platelets; and it is particularly prominent in embryonic tissues. Three TGF-p 
isoforms, TGF-pl, TGF-p2 and TGF-p3, have now been identified in mammals (Derynck 
etal., 1988).
Many studies have demonstrated that TGF-p is an important immunoregulator 
critically involved in the regulation of the immune and inflammatory systems. 
Functioning generally as an immunosuppressive agent, TGF-p has been shown to 
suppress B-cell proliferation, and immuglobulin (IgG and IgM) formation and secretion 
(Kehrl et al., 1986, 1991; Straub and Zubler, 1989; Shalaby and Ammann, 1988; 
Quere and Thorbecke, 1990). It also inhibits T-cell function and cytokine production 
(Kehrl et al., 1986b; Ristow, 1986; Espevik et al., 1987; Chantry et al., 1989). 
However, the multi potential, diverse features of TGF-p activities are also evident for its 
roles in immune regulation. Results from in vitro studies suggest that the inhibition of 
T-cell function is not absolute but selective. For example, it has been shown that TGF- 
p suppresses the development of cells with a Th2-like phenotype but, on the other 
hand, promotes the development of IL-2 and IFN-y secreting cells (Swain, 1991a, b).
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The author suggested, therefore, that TGF-p may act on resting CD4 cells, and direct 
them to commit or to differentiate to a particular subset or pattern of lymphokine 
expression. In another study, Karpus and Swanborg (1991) identified a 'recovery 
associated’ CD4+ T suppressor cell that inhibits experimental allergic encephalomyelitis 
(EAE) in vivo and can abrogate IFN-y but not IL-2 production in target effector cells in 
vitro. The mechanism of action of this CD4+ suppressor was also found to involve 
TGF-p. The importance of TGF-pl as an immunoregulatory cytokine has been further 
confirmed by a study of TGF-pi gene disruption in murine embryonic stem cells (Shull 
et al., 1992). Mouse chimaeras carrying the disrupted TGF-pl gene were shown to 
develop a fast, severe and multifocal inflammatory disease leading to organ failure and 
death.
The role of TGF-p in autoimmunity is however controversial. By using an 
animal model of acute mesangial proliferative glomerulonephritis, Border et al. (1990) 
showed that the induction of glomerulonephritis in the rat by antithymocyte serum is 
associated with increased production and activity of TGF-pi. Administration of anti- 
TGF-pi at the time of induction attenuated the renal pathological changes. In contrast, 
both studies by Kuruvilla et al. (1991) and by Thorbecke et al. (1992) showed 
protective effects of TGF-pl on collagen type II-induced arthritis (CIA) in DBA/1 mice 
which is another well established experimental autoimmune animal model. A recent 
study of gene therapy in MRL/lpr mice has suggested that direct intramuscular injection 
of expression virus vectors encoding TGF-P 1 results in decreased proteinuria and 
deceased levels of serum anti-chromatin antibodies (Raz et al., 1993). The mechanisms 
for the development of these diseases may be different, but all these studies suggest the 
possible involvement of TGF-pl in the pathology of the diseases.
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7.1.2 S. typhimurium aro~ mutant as a vector for antigen and therapeutic 
protein delivery
Aromatic amino acid dependent S. typhimurium mutants are non-virulent live 
vaccines against salmonellosis. They were first developed by Hoiseth and Stocker 
(1981) by introducing defined mutations into genes of virulent Salmonella strains. 
These genes are known to be involved in aromatic biosynthesis essential for the 
organism to establish a clinically significant infection. As a result of the gene insertion, 
the mutants become auxotrophic for two compounds, p-aminobenzoic acid (pAB) and 
2,3-dihydroxybenzoate (DHB), which are not available in vertebrate tissues. For this 
reason, their ability to grow in such tissue is limited.
For many years now, S. typhimurium mutants have also been widely used as 
carriers for delivery of many heterologous protein antigens. It has been proven 
clinically and experimentally that they are a good transport model system for antigens 
like p-galactosidase (Brown et al., 1987), heat labile enterotoxin of Escherichia coli 
(Maskell et al., 1987), M protein of streptococcus pyogenes (Poirier et al., 1988), the 
circumsporozoite antigen of plasmodium (Sadoff et al., 1988; Aggarwal et al., 1990), 
influenza A virus nucleoprotein (Tite et al., 1990), tetanus toxin C fragment 
(Fairweather et al., 1990), gp63 of Leishmania major (Yang et al., 1990), and the P69 
antigen of Bordetella pertussis (Strugnell et al., 1992).
More recently, for the first time, the possibility of using this system for transfer 
of therapeutic recombinant proteins in vivo has been explored with success (Carrier et 
al., 1992). It was shown that recombinant human IL-ip delivered by the Salmonella 
vector in BALB/c mice was adequately expressed in vivo, functionally active and well 
recognised by the immune system. The transfected bacterial vaccine may be 
administered by both injection and oral routes of inoculation. Although it is at present 
unclear how cytokine is delivered to the appropriate tissues, it was suggested that the
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cytoplasmically expressed cytokine might be liberated as a result of cell lysis. The 
release of the effector proteins by the vector is a relatively gradual process. Since most 
cytokines have very short half-lives and low physiological doses, this approach might 
have advantages over the direct injection of cytokines for reducing side effects and dose 
control.
7.1.3 Purposes of the study
In view of the immune suppressive effects of TGF-p, as well as its selective 
regulatory activities on the T-helper cell functions, the main intention of the study 
described in this chapter was to investigate the role of TGF-pi in the development of 
lupus disease. This was a pilot study of cytokine intervention in vivo in a lupus mouse 
model by the new approach of using Salmonella mutant as the cytokine carrier. 
Groups of small number of MRL/lpr mice were employed. Groups of BALB/c mice 
were also included as controls in the treatment scheme.
7 .2  Materials, mouse groups and treatment scheme
7.2.1 TGF-pi gene expression in the transfected S. typhimurium
The expression plasmid pKK-TGF-pi gene transfected S.typhimurium BRD509
was constructed and kindly provided by Dr D-M Xu in the department (see Materials 
and Methods). Before being used for treating mice, the TGF-pl gene transfected 
Salmonella was assessed to determine the cytoplasmic expression of the cytokine. 
Figure 7.1 shows the TGF-p activity detected in the cytoplasmic extracts of the TGF- 
p l gene transfected Salmonella by the TGF-p bio-assay. The average TGF-p activity 
generated from one million recombinant bacteria was about 100 - 180 pg.
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Figure 7 .1  C y to p la sm ic  ex p re ss io n  of T G F -p  in tra n s fe c te d  
S .typh im urium . TG F-p activity in the cytoplasmic extract from the T G F-pl gene 
transfected S.typhimurium (TGF-pl/BRD509, duplicate samples A and B) and the wild 
type control bacteria (BRD509) was measured by the TGF-p bio-assay (MvILu, Section 
2.4.1). Data show the suppression of 3H-thymidine incorporation by mink lung cells 
(open bars) by TGF-p in the test samples compared to the cells cultured in medium alone, 
as well as the equivalent TGF-p activity (hatched bars) estimated from the standard curve 
using r-TGF-pl.
The level of in vivo TGF-pi expression by the bacterial carriers in mice depends 
on both growth and killing of the bacteria in the host and not simply the initial dose 
given. No attempt was made to determine the optimum dose of the vaccine in this pilot 
study. With reference to the dose used in a previous study (Carrier et al., 1992), 
however, a single dose was used at about 1010 bacteria per mouse. The concentration 
of bacteria was determined by optical density using a spectrophotometer at 600 nm.
7.2.2 Animals and treatment scheme
The experiment employed MRLIlpr mice as the lupus mouse model, and BALB/c 
mice as the control strain. The mice were bred in the Animal House, Gartnavel 
Hospital, Glasgow. All mice used were female and the treatment started at the age of 9 
weeks. This was a small scale pilot experiment. Fifteen mice of each strain were 
divided equally into three treatment groups (Groups I, II and III). Group III was 
treated with TGF-p 1 gene transfected Salmonella. The two control groups were mice 
treated with the bacterial vector alone (Group II), or untreated (Group I) (Fig.7.2).
The mice were treated by oral administration of the live bacteria. The first 
treatment was given to the mice at 9 weeks old. After the first boost at 12 weeks, the 
mice in each treatment group were sub-divided into 2 groups: one sacrificed at 15 
weeks of age after the two doses, and the other sacrificed at 20 weeks of age, 4 weeks 
after the second boost. A summary of the treatment scheme is shown in Figure 7.2.
7 .3  Effects of TGF-pl treatment on normal and lupus mice
During the treatment period, one MRUlpr mouse in group II (vector alone treated) 
died one day after the primary immunisation, and one MRUlpr mouse in Group III (IL- 
2/vector treated) died overnight after the first boost. The accidental mouse death was
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Figure 7.2 Schematic diagram representing the plan 
for treatment of 3ALB/c and MRL/lpr mice
with TGF-pl gene transfected S. typhimurium.
caused by the feeding procedure possibly due to respiratory infection. In addition, in 
the untreated MRLIlpr mouse group (Group I), one mouse died at 19 weeks old but 
because it was found dead over a weekend, no examination was given. There was no 
accidental death in the BALB/c mouse groups.
7.3.1 Changes in the cytokine profile
i) Serum TGF-p activity
The serum samples were taken from the mice at the time when the they were 
sacrificed, and kept at -20 °C before being tested by the TGF-p bio-assay. These 
included mice of 15 weeks old (Test 1) 3 weeks after the second dose, and mice of 20 
weeks old (Test 2) 4 weeks after the third dose.
There was no significant change of serum TGF-p activity between the treated and 
untreated mice of either MRUlpr or BALB/c strain at the age of 15 weeks (Fig.7.3). In 
the 20 week old BALB/c groups, although the average level of TGF-p was higher in 
sera from mice of the TGF-p/vector treated group, the differences were not statistically 
significant, due to sample variation and the small number of cases (three in each 
group). However, the untreated old M RUlpr mice showed spontaneously increased 
levels of serum TGF-p at 20 weeks of age. Compared with the untreated controls, 
MRLIlpr mice treated with either TGF-p/vector or vector alone had reduced serum 
TGF-p activities rather then being increased (Fig.7.3b).
ii) Production of IL-2
Con A-induced IL-2 production by spleen cells was significantly suppressed in 
mice after treatment with TGF-p (Fig.7.4). The suppression was effective on mice 
tested at the age of 15 weeks (Fig.7.4a, b) and became less obvious at 20 weeks
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Figure 7 .4  In  vivo effects of TGF-pl treatment on Con A-induced IL-2 
production in BALB/c and M RL/lpr mice. Data show IL-2 activities in cultures
of Con A-stimulated spleen cells from mice which had been treated with TGF-p 1 
transfected S.typhimurium for 2 or 3 doses (closed circles) at age of 15 and 20-weeks 
respectively. Control groups included mice treated with the bacterial vector alone (open 
circles) or untreated (+). The cells from 2 or 3 mice in each group were pooled and, the 
culture supernatants were collected at daily intervals and tested by the CTLL bio-assay. 
(Note scale differences in the graphs).
(Fig.7.4c, d). In the untreated control groups, IL-2 activity in cultures of Con-A 
stimulated spleen cells from MRUlpr mice was twenty times lower compared with the 
BALB/c mice. However, the already deficient IL-2 secretion appeared to have been 
depressed even further after the treatment (Fig.7.4b). In addition, the vector showed 
some stimulatory effect on IL-2 production by spleen cells from BALB/c mice, but was 
rather slightly suppressive for the MRL/lpr mice (Fig.7.4d). Since IL-2 activity was so 
low in all M RL/lpr groups, it is not clear whether the effect was due to TGF-p 
treatment, or to the vector, or that there was no effect at all, only individual variations. 
There was no detectable spontaneous secretion of IL-2 by the cells from any of the 
mouse groups studied.
iii) Production of IFN-y
TG F-p treatment had different effects on Con A-induced IFN-y secretion 
depending on the stages of the treatment and mouse strains (Fig.7.5). Reduced IFN-y 
levels were detected in the culture supernatants of Con A-stimulated spleen cells from 
the TGF-p treated mice at 15 weeks of age (Test 1), compared to the untreated groups 
and the vector treated groups which even showed increased levels (Fig.7.5a, b). The 
suppression was more effective in BALB/c, and just marginal in MRL//pr mice 
possibly because of the already suppressed IFN-y secretion as shown in the untreated 
M RL//pr controls. Results from the ELISPOT assay also indicated a decreased 
frequency of IFN-y secretors in the TGF-p treated BALB/c mice (15-week old groups 
only) confirming the data from ELISA assays. In contrast, the vector-treated BALB/c 
mice had increased frequency of IFN-y secretors. However, in MRL//prmice, the 
frequency of IFN-y secretors was low in the untreated group and there was no 
observable change after the treatments both with vector alone or with TGF-p/vector 
(Fig.7.6).
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Figure 7 .5  In vivo effects of TGF-pi treatment on Con A-induced IFN-
Y production in BALB/c and MRL/lpr mice. Data show IFN-y activities detected 
in cultures of unstimulated (open triangles) and stimulated (closed circles) spleen cells
from mice which had been treated with TGF-pl transfected S.typhimurium for 2 or 3 
doses at age of 15 and 20-weeks respectively. Control groups included mice treated with 
the bacterial vector alone (open circles) or untreated (x). Age of mice is indicated at the 
upper right hand comers. The cells from 2 or 3 mice in each group were pooled and, the
culture supernatants were collected at daily intervals and tested by IFN-y specific ELISA. 
In graph (d), the additional dotted line (untreated*) represents data established in separate 
experiments, of which data shown at day 3 are mean value (±SD) from 11 individual 
MRUlpr mice between 18 to 21 weeks old. (Note scale differences in the graphs).
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Figure 7 .6  ELISPO T assay showing effects of T G F -p l trea tm en t on
Con A -induced IFN-y production (cell frequency) by spleen cells from  
BALB/c and M R L/lpr  mice at 15 weeks of age.
However, a largely increased IFN-y secretion was detected in the culture 
supernatants of Con A-stimulated spleen cells from the TGF-p treated BALB/c mice at 
20 weeks (Test 2, Fig.7.5c). There was no such increase found in MRUlpr mice, but 
the level of IFN-y detected in the samples from the untreated MRL//pr group (2 mice) 
was much higher than that normally detected in other untreated MRUlpr mice at this age 
(Fig.7.5d). In Figure 7.5d, the curve shown as a dotted line is a time course of IFN-y 
secretion established in a separate experiment using untreated MRL//pr mice of the same 
age (20 wks). In addition, the data at day 3 (arrow) is the mean (±SD) of IFN-y 
activities detected by same method in a total of eleven individual MRUlpr mice between 
18 to 21 weeks old.
There was no detectable IFN-y activity in the unstimulated cell cultures in any of 
the groups.
7.3.2 Effects of TGF-pi on Con A-induced T-cell proliferative responses
The effects of TGF-p treatment on T-cell proliferative responses are shown in 
Figure 7.7. In the 15-week (Test 1) mouse groups, the treatment did not show an 
obvious effect on the Con A-induced cell proliferative response, except for a kinetic 
delay in the TGF-p treated BALB/c group (Fig.7.7a) and a modest stimulation in both 
TGF-p/vector and vector alone treated MRLIlpr groups (Fig.7.7b). At the later stage 
(Test 2, 20 weeks), however, the treatment showed adverse effects on the two different 
strains of mice. While T-cells from the TGF-p treated BALB/c mice displayed a 
significantly increased responsiveness to Con A compared to both untreated and vector 
alone treated mouse groups (Fig.7.7c), the response of the T-cells from MRLIlpr mice 
was completely suppressed by the TGF-P treatment (Fig.7.7d). In addition, it was 
noted that the vector alone treatment also had such effects, but to a less degree, on the 
mice of two different strains (Fig.7.7c, d). No significant difference in the thymidine
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Figure 7 .7  In vivo effects of TGF-01 treatment on T-cell proliferative  
responses in BALB/c and M RLIlpr mice. Two or three mice in each group
treated with TGF-pl transfected S.typhimurium (circles), the bacterial vector alone 
(squares) or untreated controls (triangles) at age of 15 (a, b) and 20-weeks (c, d) were 
included. Mouse spleen cells were cultured (106 cells per well) in the presence or 
absence of Con A (2.5 /<g/ml) in a 4-day time course, and the cell proliferation was 
measured by 3H-thymidine incorporation at daily intervals. Data expressed are means 
(±SD) of triplicates. Note scale differences.
uptake by unstimulated cells was observed between groups of each strain (Fig.7.7a, b; 
Test 1 only).
7.3.3 Effects of TGF-pl on lymphoproliferation and splenic cell phenotypes
inMRLZ/prmice
Macroscopically, the size of spleens and the total number of spleen cells obtained 
from the 15-week old mice was similar between groups in each strain. However, 
spleens from the 20-week old MRL//pr mice in both TGF-p/vector and vector alone 
treated groups were smaller compared with the untreated control group. In the 20-week 
mouse groups, the average total numbers of mononuclear cells (XlO8 per spleen; cells 
from 2 spleens in each group were pooled) obtained were: 8.73, 4.55 and 4.81 for 
MRL//pr; 1.59, 1.33 and 1.0 for BALB/c in the untreated, the vector-treated and the 
TGF-p/vector-treated groups respectively.
FACS analysis of splenocytes from the treated and untreated BALB/c and 
MRUlpr mice showed that the treatments did not significantly alter the total percentage 
of CD4+, CD8+ and CD4+CD8+ subsets in the spleens. In M RU lpr mice, the 
percentage of splenic CD4+ cells was slightly higher in mice of the TGF-p/vector 
treated group (26.2%) compared to the untreated group (19.75%), but a similar 
increase was also found in the mice treated with vector alone (26.5%). Figure 7.8 
shows the absolute number (average per spleen) of CD4+, CD8+, CD4+CD8+ and 
other (cells do not express either CD4 or CD8) spleen cells. Regrettably, due to 
shortage of a pan-T cell marker at the time of assaying, the results do not include data 
on the percentage or total number of T-cell and the DN T-cell populations.
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Figure 7 .8  Changes of splenic mononuclear cell num ber and phenotypes
in BALB/c and M RL//pr mice treated with TGF-{51 or the vector alone, or 
the untreated  controls. Total number of spleen mononuclear cells was counted 
microscopically and cell phenotypes were analysed by FACS using antibodies specific to 
mouse CD4 and CD8. Cells from 2 or 3 mice in each of the groups were pooled and the 
data presented are average cell number per spleen.
7.3.4 Effects of TGF-(31 on autoantibody production and renal pathology in 
MRUlpr mice
To monitor effects of TGF-(3 treatment on MRUlpr mice, serum autoantibody 
levels, kidney immune complex deposition and renal histological changes in the mouse 
kidneys were assessed as indications for the disease progression. The results are 
summarised in Table 7.1.
As shown in Table 7.1, the serum levels of autoantibodies (IgG) to ss- and ds- 
DNA are variable among individual mice. However, in general, old (20 wks) MRUlpr 
mice showed higher titres of anti-dsDNA serum antibodies compared with the 15-week 
old groups. Since there were only 2 mice in each of the experimental groups, the 
results have no statistical significance, but 2 sera from the TGF-f3 treated MRUlpr mice
seem to have higher anti-ssDNA antibodies at 20 weeks compared with the controls. In 
the control BALB/c mice, serum titres of both anti-ss and -dsDNA were lower than 60 
and 10 TU respectively in all groups.
For renal histological assessment, mouse kidney sections, prepared from the 
paraffin embedded tissues after Bouin's/formalin fixation and periodic acid-Schiff 
(PAS) staining procedure, were examined by routine light microscopy. The sections 
(4-5 \im) from the mice of different groups were randomly labelled, and examined by 
an experienced renal pathologist, Dr G.B.M. Lindop, in the University Department of 
Pathology. The assessment was a blind but subjective test. Severity of the kidney 
damage was assessed by taking into account the extent of enlargement and structural 
changes of glomeruli, interstitial and glomerular cellular proliferation, membrane 
adhesion, vasculitis, protein casts etc. By combining different degrees of these 
abnormalities, 0 to 5 pluses were given to score each section for statistical comparison. 
It must be pointed out that pyelonephritis with mononuclear cell infiltration in the
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Auto-Ab Tltre Kidney pathology
Age Mouse (IgG, TU)
g ro u p s anti-ssDNA anti-dsDNA KPI C3
1 5 -w k s I 11000 140 + + + + ++++
(Test 1) (Untreated) 9000 50 ■ ++++
II 2700 28 + + + + ++++
(Vector) 8100 73 + + + + ++++
III 2000 5
(TGF-P1) 9800 45 - -
2 0 -w k s 1 4800 1000 +  + ND
(Test 2) (Untreated) 4800 400 + + + + + ND
II 3300 190 + + + + ND
(Vector) 5300 170 + + + + + ND
III 6500 1800 +  + ND
(TGF-pi) 8000 150 + + + + + ND
Table 7.1 Effects of rTGF-pl treatment on autoantibody production  
and renal pathological changes in M KL/lpr mice. Mouse serum antibodies to 
ss and dsDNA were measured by ELISA and expressed as titration units (TU). Kidney 
sections were prepared from individual mice for light and immunofluorescence 
microscopic examinations (see Methods). Degrees of renal pathological changes were 
scored, zero to 5 pluses on a blind basis, according to the severity of kidney damage 
(KPI, Kidney Pathological Index, see Materials and Methods); intensity of 
immunofluorescent staining for kidney deposition of complement component 3 (C3). 
ND: not done.
medulla was common in all MRUlpr groups examined and this was discounted for the 
assessment. Some of the kidney sections were also studied by immunostaining using 
antibodies specific to mouse C3 (see Materials and Methods).
Table 7.1 also summarises results from the histopathological and 
immunopathological studies. Among the 12 MRUlpr mice of different groups, some 
variable degrees of kidney damage, indicated by the 'kidney pathology indices (KPI)1, 
were evident in 5 out of the 6 groups of mice. However, glomerulonephritis and the 
other renal changes mentioned above were absent in the two mice in the TGF-p treated
group at 15-weeks. This was in agreement with results from the complement C3 
immunostaining of the kidney sections, although there was no positive staining for IgG 
on these formalin-fixed, paraffin embedded tissue sections. It is not certain whether the 
apparent delay of renal pathological change was due to the effect of the treatment or 
individual variations since one out of two untreated MRUlpr mice also showed absence 
of glomerulonephritis at this age. In addition, there was no correlation between the 
serum autoantibody levels (IgG) and the degrees of kidney damage.
7 .4  D iscussion
First of all, it must be pointed out that this was a pilot study within a small scale 
of experimentation. The preliminary results described in this chapter are to be further 
confirmed.
Cytoplasmic expression of TGF-p in the recombinant Salmonella bacteria was an
important precondition for the study. It ensured that the transfected bacteria used for 
treatment did carry the gene of interest and expressed murine TGF-P in its cytoplasm. 
However, its ability to deliver TGF-p in vivo depends on whether these antigenically 
modified bacteria were able to penetrate the immunological barriers of the host, to 
multiply and to release TGF-p. A recent similar study using the same model system to
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deliver IL -ip  in BALB/c mice has shown evidence demonstrating the presence of 
viable S. typhimurium expressing IL-ip in vivo in the lymphoid organs after oral 
immunisation (Carrier et al., 1992).
The present study included BALB/c mice which were used not only as a control 
strain for the lupus disease model, but also as a test model to demonstrate or to confirm 
the in vivo effects of TGF-p on the normal immune system, which are still not fully 
understood. As a positive control, it was also important to be able to verify that the 
bacteria expressed and released biologically active TGF-p in vivo. The TGF-p 
treatment has shown clear immunosuppressive effects on the BALB/c mice at the early 
stage of treatment. It reduced the ability of spleen cells to produce IL-2 in response to 
Con A stimulation. Suppression was also indicated by decreased IFN-y production and 
the delayed proliferative response to Con A at 15 weeks (Test 1). However, at the later 
stage (20 wks, Test 2), the inhibitory effects were not only diminished, but also 
followed by a greatly enhanced responsiveness of the cells to Con A to secrete IFN-y 
and to proliferate. The 'rebound' might suggest the presence of some feedback 
mechanism as a result of the early inhibitory effects of TGF-p. This observation is in 
agreement with the in vitro finding that, in long term cell cultures, TGF-p increases 
activities of IFN-y secreting cells (Swain, 1991a, b), but induces no such increase in 
the IL-2 activity.
In MRLUpr mice, the effects of TGF-p treatment were weak and variable, 
possibly due to two factors. One is the already suppressed T-cell responsiveness in the 
untreated mice. The fact that serum TGF-p activity was increased in the untreated old 
MRL Upr mice (20 wks) might suggest an on-going mechanism of spontaneous 
suppression in vivo. The effects of further treatment with TGF-p exogenously could 
therefore be masked. Unlike the effects of TGF-p on BALB/c mice, the lack of the 
post-treatment 'rebound' in MRLUpr mice indicates the complex mechanism of the
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spontaneous suppression in lupus disease. It might suggest an inability of self­
regulation in the mice. Another factor involved could be the influence of the bacterial 
vector stimulation. In MKL/lpr mice treated with TGF-p/vector or vector alone, the 
equally reduced, rather than increased, serum TGF-p activities suggest an adverse, but 
nonspecific effect of the bacterial vector. In addition, the reduced size of the spleens, 
decreased number of total spleen cells and increased percentage of CD4+ cells in both 
of the treated groups also support the notion of this 'vector effect'. Presumably, these 
were due some antigenic or mitogenic substances released by the lysis of the bacterial 
vector, such as LPS or superantigens.
The levels of serum autoantibodies to ss and dsDNA, which were variable among 
all MRL Upr groups, did not correlate with the kidney pathological changes. This 
suggests the importance of other factors which may be involved in the formation and 
deposition of ICs resulting in kidney damage, conditions necessary for complement 
activation for example, as supported by the agreement of results from the kidney 
histological assessments and C3 staining. Both of the observations showed a possible 
delay of the renal pathological changes in the MRLIlpr mice after treatment with TGF- 
p. This might be explained by the early immune suppressive function of the cytokine. 
However, due to the limited number of cases and the fact that one untreated mouse was 
also free of such changes, the results are to be confirmed.
Through this pilot study, much useful information has been gained, although the 
scale of the experiment was too small to draw any definite conclusion. The new 
approach for cytokine intervention may be an applicable tool for future in vivo studies 
of cytokine regulation in autoimmune and other diseases. For undertaking further 
investigations, larger numbers and different strains of mice would have to be used and 
factors such as the optimum dose, the kinetics and the vector effect would need to be 
carefully considered.
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Chapter 8
Delivery of murine IL-2 by 
Salmonella typhimurium arom mutant in MRL Upr mice
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8.1 Introduction
The in vitro observations about the possible intrinsic nature of the IL-2 defect in 
lupus mice have provided a basis for undertaking further an in vivo investigation. In 
the previous chapters, it has been demonstrated that there exists an early, progressive 
defect in responsiveness to T-cell activation in SLE. It was then shown that exogenous 
IL-2 was able to by-pass the defect in vitro. Thus, what impact IL-2 intervention might 
have on the development of the disease in vivo becomes the next most important 
question to answer.
As reviewed by Kroemer et al. (1989, 1991) and Tsokos (1992), the role of IL-2 
in autoimmune diseases is still controversial. In SLE, the focus of arguments has been 
the interpretation of the in vitro findings over their clinical relevance. Seemingly, the 
B-cell hyperactivation and the T-cell functional hypoactivity are mutually exclusive. IL- 
2 treatment of lupus disease, in which the immune system is thought to be already in an 
overactivated state, would therefore appear to be theoretically unfavourable. For this 
reason, presumably, as well as the early failed attempts in the in vitro study using 
exogenous IL-2 (Altman et al., 1981), there have been few studies of such an in vivo 
cytokine intervention being carried out. IL-2 interventions by injection of cytokine 
w'hich has a very short half-life may have a major drawback for being difficult to 
maintain its lasting effects in vivo (Owen et al., 1989), or otherwise running into 
problems of high-dose side effects. The possibility of using vector system to deliver 
IL-2 might be able to solve this problem. A previous approach using recombinant 
vaccinia virus expressing human IL-2 to treat MRUlpr mice has shown positive effects 
om the recovery of lupus mice from autoimmunity (Gutierrez-Ramos et al., 1990).
The present study has explored a new vector system for delivering cytokines by 
S.ityphimurium aro- mutant in lupus mice. As part of the pilot study using the same
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model system as that for delivering TGF-p 1 (Chapter 7), a reconstructed live S. 
typhimurium expressing mouse IL-2 was used to study the in vivo effect of IL-2 in 
MRUlpr mice.
8 .2  Materials, mouse groups and treatment scheme
8.2.1 IL-2 gene transfected S.typhimurium
The expression plasmid pKK-IL-2 gene transfected S.typhimurium BRD509 was 
also constructed and kindly provided by Dr D-M Xu in the department (see Chapter 2). 
Before being used for treating mice, the transfected Salmonella were assessed to 
determine expression of IL-2 in the cytoplasm. After the extraction procedure which is 
described in Chapter 2 (Section 2.9.2), IL-2 activity in the cytoplasmic extract was 
measured by the CTLL IL-2 bioassay.
High levels of IL-2 activity (equivalent to 440 ng/ml of r-human IL-2 in the 
extract, or about 44 ng/ml of the original bacterial culture) were detected in the 
cytoplasmic extract of IL-2 gene transfected Salmonella, but not in that of untransfected 
control bacteria (Figure 8.1). The average IL-2 activity generated from a million of the 
recombinant bacteria was about 440 pg. The expression of IL-2 was confirmed using 
different samples taken from repeated treatments.
8.2.2 Animals and treatment scheme
Thirty MRL-Mp-llprllpr (MRUlpr) female mice of three week old were purchased 
from Harlan Olac Ltd, UK. The treatment was carried out in the Animal House, 
Gartnavel Hospital, Glasgow. The mice were divided into three treatment groups 
(Groups I, II and III). Group I (8 mice) received no treatment; Group II (11 mice) was
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Figure 8 .1  Cytoplasmic expression of IL-2 in the gene tr a n s fe c te d  
S .ty p h im u riu m , IL-2 activity in the cytoplasmic extract from the IL-2 gene 
transfected S.typhimurium  (IL-2/Vector) is shown by its ability to promote the 
proliferation of the IL-2 dependent CTLL cells. The wild type bacteria were used as 
control (Vector alone).
treated with the bacterial vector alone, and Group III (11 mice) with IL-2 gene 
transfected Salmonella.
Figure 8.2 shows a diagram of the treatment scheme in summary. The early 
onset of IL-2 deficiency is one of the features of the immunological abnormalities in 
lupus mice. The fact that an IL-2 defect exists in young mice, at an age when thymic 
influence is important for establishing a normal immune system was the reason for 
starting the IL-2 treatment at an early age. The first treatment was given to the mice at 3 
weeks old, and subsequent boosts at 3-week intervals. The mice in each group were 
then divided into 2 sub-groups, one sacrificed after 4 doses of the treatment at 14 
weeks of age, and the other sacrificed after 5 doses at 19 weeks of age. For the same 
reasons mentioned in Chapter 7, there was no attempt to determine the optimum dose of 
the treatment. Each single dose of 1010 bacteria in 0.2 ml PBS was given per mouse 
orally using a gavage tube. The 5th dose was doubled because of the increased body 
weight of the mice.
Since accidental mouse death could be caused by the feeding procedure mainly 
due to respiratory infection and 2 mice (one in Group II and another in Group III) 
which developed severe lupus disease at ages between 17 to 18 weeks, the numbers of 
mice in each test group were not even. In addition, it was noted that mice of the 
untreated group used in this experiment developed lupus disease earlier compared to 
that in the study of TGF-p treatment. This was the reason for the earlier sacrifice of the 
mice at 14 and 19 week old, rather than at 15 and 20 week as the TGF-p experiment 
(Chapter 7).
8 .3  Effects of IL-2 treatment on MRL Upr mice
8.3.1 Cellular aspects: effects of IL-2 on lymphoproliferation in vivo
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Figure 8.2 Schematic diagram representing the plan 
for treatment of MRL/lpr mice with IL-2 
gene transfected S . typhimurium.
Lymphadenopathy develops in the MRL/lpr mice. As described previously, 
cellular hyperplasia in peripheral lymphoid organs with accumulation of the immature 
DN T-cells is a feature of the MRL/lpr disease resulting in enlarged spleen and lymph 
nodes, and development of sub-dermal lymphoid tumours (lymphocytoma). To assess 
the effect of IL-2 treatment on the abnormal lymphoproliferation in the MRUlpr mice, 
degrees of the development of these lymphoid abnormalities were compared between 
the mouse groups
i) Effects on the development of lymphoid tumours in the mice
The assessment was kindly done by Mr Derek Milroy and Mr Kevin Jones, 2 
experienced workers in the animal house, combining measurements of number and size 
of the sub-dermal lymphoid tumours. The results are expressed as Tumour Index 
(TI)'. Table 8.1 shows the rating criteria and scale.
Table 8.1 Scoring criteria for the assessment of sub-dermal 
lymphoid tumour development in MRL//pr mice
Score number/size of tumours
- no tumour
+ 1 to 2 small (< 0.5 cm3) tumours
++ 3 small or 2 including 1 large (>0.5 cm) tumours
+++ 4 small or 2 to 3 large tumours
++++ 5 to 6 tumours
+++++ more than 6 tumours
Sub-dermal lymphoid tumours were observable at 14-weeks of age in all of the 
experimental groups. However, differences in the number and size of the lymphoid 
tumours between the IL-2 treated group and the 2 control groups were observed. In 
spite of considerable variations in all three mouse groups, the IL-2 treated mice showed
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an overall reduction in the number and size of lymphoid tumours compared to the 
control group treated with vector only (Fig.8.3). The difference between the tumour 
indexes for the 2 mouse groups is statistically significant (1.4 vs 2.2, P < 0.05). 
Although the difference between IL-2-treated and untreated mouse groups was not 
statistically significant (P>0.05), the mean T I1 was also lower in the IL-2-treated 
group (1.4 vs 1.875).
ii) T-cell number and phenotype changes in the mouse spleens
The size of the spleens of the 14-week old mice were similar in all 3 groups 
measuring about 2.5 X 0.7 X 0.3 cm. In the 19-week old mouse groups, all mice 
showed enlarged spleen, but the spleens of the IL-2 treated mice were relatively smaller 
compared to the ones in the 2 control groups. The average total numbers of 
mononuclear cells obtained from the spleens of the 19-week old mice were 5.85, 6.25 
and 5.53 (x 108) per spleen in the untreated, vector alone treated and IL-2/vector treated 
mice respectively.
To monitor effects of IL-2 treatment on lymphoproliferation and the peripheral 
accumulation of DN cells, spleen cells from the IL-2-treated and control mice were 
analysed by T-cell phenotyping. The mice at 14-weeks had shown the beginning of 
spontaneous T-cell proliferation and appearance of the double negative cells, but with 
no significant difference between groups (Fig.8.4a). The average total numbers of 
splenic T-cells (CD3+) were 2.39, 2.869 and 2.023 (x 108) per spleen in the untreated, 
vector alone treated and IL-2/vector treated mice respectively. However, when the T - 
cell abnormalities became more apparent in 19-week old mice, a much lower percentage 
and number of the DN cells, as well as a reduction in total number of CD3+ cells, was 
observed in the IL-2 treated group (Fig.8.4b). Due to reduction of the DN subset, the 
percentage of single positive (CD4+CD8\ CD4'CD8+) T-cell populations was relatively 
increased, though the absolute cell number of these 2 subsets remained unchanged.
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Figure 8 .3  Effects of IL-2 treatment on lymphoid tumour development 
in M RL/lpr  mice. Degree of lymphadenopathy developed in the MRL Upr mice treated 
with IL-2/vector (n=10) or vector alone (n=10) for 4 doses, and the untreated control 
mice (n=8), at an age of 14 weeks was kindly assessed by Mr. D. Milroy and Mr. K. 
Jones in the Departmental Animal House. The severity of tumour development in 
individual mice is indicated by Tumour Index (TUI)' according to the scoring criteria 
described in Table 8.1 .
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F ig u re  8 . 4  E ffec ts  of IL -2  t r e a tm e n t  on to ta l  n u m b e r  o f  sp le n ic  T -ce l ls  
( C D 3 +) a n d  p h e n o ty p e  changes  in M R L //p r  m ice by flow cy to m e try .  T -cell 
phenotypes were analysed using antibodies specific to mouse CD3, CD4 and CDS. Cells 
from 2 or 3 mice in each of the groups were pooled and the data presented are average 
number of cells (CD3+) per spleen. The percentage indicated in the 19-wk mouse groups 
refers to the double negative cells in the entire CD3+ populations. Age of the mice is 
indicated at the upper left hand comer of the graphs. (The double positive cell population 
in all groups was below 1.5%).
The average total numbers of splenic T-cells (CD3+) in the 19-week old mice were 
4.06, 4.94 and 3.27 (x 108) per spleen in the untreated, vector alone treated and IL- 
2/vector treated mice respectively.
8.3.2 Effects of IL-2 on T-cell functional activities
i) Production of IL-2 and IFN-y
After IL-2 treatment, the ability of the mouse T-cells to produce IL-2 and IFN-y in 
response to Con A was assessed. At the age of 14 and 19-weeks, spleen cells from 3 
to 5 mice of each group were prepared, pooled and stimulated with Con A as 
previously described. Culture supernatants were taken at daily intervals for the 
cytokine assays. The samples from all of the 6 mouse groups showed low levels of IL- 
2 activities (< 300 pg/ml). There was no kinetic difference in Con A-induced IL-2 
secretion between groups of the same age. IL-2 activity in culture supernatants of 
spleen cells from the IL-2 treated mice of 14-week old was similar to that of the 
untreated control group, although it was slightly higher if compared with the vector 
alone treated group (Fig.8.5a). The IL-2 treatment did not increase the ability of lupus 
T-cells to produce IL-2. On the contrary, IL-2 activity was further depressed in the 19- 
week old mice, in both IL-2/vector and vector alone treated groups (Fig.8.5b).
IFN-y production was assayed at 3 days after Con A stimulation, its peak activity 
in cultures according to the time course established previously . The levels of IFN-y in 
culture supernatants of spleen cells from 14-week old mice of the 3 groups were 
comparable. However, a clear suppression of IFN-y secretion was observed in the IL- 
2 treated mice at age of 19-weeks compared to the 2 control groups (Fig.8.6).
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Figure 8 .5  In  vivo effects of IL-2 treatm ent on Con A-induced IL-2 
production in vitro in MRL Upr mice. Data show IL-2 activities in cultures of Con 
A-stimulated spleen cells from mice which had been treated with IL-2 transfected 
S.typhimurium  for 4 or 6 doses (closed circles) at 14 and 19-weeks of age respectively. 
Control groups included mice treated with the bacterial vector alone (open circles) or 
untreated (open triangles). The cells from 3 to 5 mice in each group were pooled and, 
the culture supernatants were collected at daily intervals and tested by the CTLL bio­
assay.
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Figure 8 .6  In vivo effects of IL-2 trea tm en t on Con A -induced IFN-y
production in M RL Upr mice. Data show IFN-y activities detected in cultures of 
Con A-stimulated spleen cells from mice which had been treated with IL-2 transfected 
S.typhimurium  or the bacterial vector alone for 4 or 6 doses (at age of 14 and 19-weeks 
respectively), and from mice of the untreated groups. The cells from 3 to 5 mice in each
group were pooled and, the culture supernatants were assayed at day 3 by IFN-y specific 
ELISA. Data expressed are means (±SD) of triplicate samples.
ii) Cytokine mRNA expression
In the 14-week old mouse groups, low levels of IL-2 mRNA were detectable in 
freshly isolated spleen cells from the IL-2/vector and the vector alone treated mice, but 
not from the untreated mice (Fig.8.7(i)a), which might suggest an in vivo activated state 
of these cells. Spontaneous gene expression for IFN-y was detected in all freshly 
isolated spleen cells. In contrast to the protein assays (Fig.8.5; 8.6), analysis of 
cytokine gene expression showed increased Con A-induced mRNA expression for both 
IL-2 and IFN-y in the IL-2/vector treated mice compared with the untreated group 
(Fig.8.7(i)c). The results do not include the vector control group because of accidental 
loss of the RNA sample during the extraction procedure. Therefore it is not clear 
whether the increase of mRNA expression was due to IL-2 treatment or simply a vector 
effect. In addition, since expression of p-actin mRNA in these samples was not 
included in the assay, the results are not intended for much quantitative comparison.
In the 19-week old mouse groups, IFN-y mRNA was detected in freshly 
isolated spleen cells from the IL-2/vector treated, vector treated and untreated mice with 
slightly increased levels in the two treated groups (Fig.8.7(2)a), but it disappeared after 
6 hours of culture without Con A (Fig.8.7(2)b). Spontaneous mRNA expression for 
IL-2, IL-4 and IL-6 were not detected in cells freshly isolated or cultured without Con 
A, except some weak expression of IL-6 gene (just identifiable on the gels) in both of 
the treated groups (Fig.8.7(2)a,b; II & III). After 6 hrs of Con A stimulation, the spleen 
cells from the 3 groups of mice had readily detectable mRNA for IL-2, IFN-y, IL-4 and 
IL-6 (Fig.8.7(2)c). However, a slightly reduced expression of mRNA for these 4 
cytokines by the Con A-stimulated spleen cells was observable in both IL-2/vector 
treated and vector alone treated mice in comparison with the untreated controls.
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Figure 8 .7  PCR analysis of the effects of IL-2 tre a tm e n t on cytokine 
mRNA expression in M R L/lpr  mice. Total RNA extracted from spleen cells from 
14 (1) and 19 (2) weeks old mice freshly isolated (a), cultured without Con A (b, 19-wks 
only) and with Con A for 6 hours (c) were reversed transcribed into cDNA. Specific
cDNA coding for IFN-y, IL-2, IL-4, IL-6 and (3-actin was amplified by PCR technique 
for 30 cycles using pairs of primers listed in Materials and Methods.
iii) Con A-induced T-cell proliferative response
Figure 8.8 shows a time course of Con A-induced proliferative responses of 
spleen cells from the treated and untreated mice at ages of 14 and 19 weeks. Splenic T- 
cells from both the IL-2/vector treated and vector alone treated mice showed reduced 
proliferative responses to Con A, compared to the untreated mice. The suppression 
was observable in the 14-week old group (Fig.8.8a) and became obvious in the 19- 
week old group (Fig.8.8b). No significant difference was observed between groups in 
the thymidine uptake by unstimulated cells (day 0).
8.3.3 Effects of IL-2 on autoantibody production and kidney pathology
To monitor effects of IL-2 treatment on lupus disease progression, serological 
and renal pathological changes in the IL-2 treated and control MRLIlpr mice were 
studied. Serum levels of autoantibodies (IgG) were measured by specific antibodies to 
ss and dsDNA by ELISA methods. For renal immunohistopathological and 
histophological studies, the procedure including tissue section preparation and scoring 
criteria was the same as that described in Chapter 7. The histopathological assessment 
was kindly done by Dr GBM Lindop, in the University Department of Pathology. 
Since this was entirely a subjective judgement, a repeat examination of all of the 
sections was carried out one week after the first assessment, and results from the 2 
assessments compared for reproducibility. Among 23 kidney sections examined, 14 
(58.3%) of them were scored exactly the same, and the rest had only a one plus 
difference, in 2 separate assessments done on different dates.
There were considerable individual variations of the serum levels of 
autoantibodies to ss and dsDNA in the mice (Fig.8.9). The results showed that the 
mean serum level of anti-ssDNA was higher in both of the treated groups compared to
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Figure 8 .8  Effects of IL-2 treatm ent on T-cell p ro liferative  responses in 
M R L/lpr  mice. Mouse spleen cells from 3 to 5 mice in each group, treated with IL-2 
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3H-thymidine incorporation at daily intervals. Data expressed are means (±SD) of 
triplicate cultures (note scale differences).
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Figure 8 .9  Serum anti-ssDNA and anti-dsDNA antibody levels in 
MRL Upr mice after in vivo IL-2 treatment. Serum samples were taken from 
M RUlpr mice in the IL-2/vector or vector alone treated groups, and the untreated control 
group at 14 (a, c) and 19-wks (b, d) of age. Serum levels of antibodies to ssDNA (a, b) 
and dsDNA (c, d) were measured by ELISA. The data are expressed as titration units 
(TU) obtained from individual mice as well as the mean values (±SD) from 3 to 5 mice of 
the same group. All differences between the IL-2 treated and the two corresponding 
control groups are not statistically significant (p > 0.05).
the untreated group at 14-weeks, although the anti-dsDNA was similar between the 
groups. In the 19-week mouse groups, the mean serum level of anti-ssDNA was 
lower, but anti-dsDNA was higher, in the IL-2 treated mice compared to the vector 
treated and untreated controls. However, due to the individual variations, the 
differences are not statistically significant (p > 0.05). In addition, it was also noted 
that, in the IL-2-treated mice of 19-week old group, there were 1 or 2 out of 5 mice 
showed significantly higher serum levels of anti-ssDNA (Fig.8.9b) and anti-dsDNA 
(Fig.8.9d) than the rest of mice in the same group.
Degrees of kidney damage indicated by the 'kidney pathology index (KPI)' were 
also variable among individual mice of each group except the untreated mice at 19- 
weeks (Table 8.2). In the 14-week old mice, KPI varied between 0 to 4 in the 
untreated group, 0 to 5 in the vector treated group and 0 to 3 in the IL-2/vector treated 
group, with no statistically significant difference between groups. In the 19-week old 
mouse groups, however, KPI was significantly lower in the IL-2 treated mice 
compared to the untreated controls (P = 0.05), but not if compared to the vector alone 
treated mice (P > 0.05). Mice in the vector treated group showed considerable variation 
between individuals in their kidney pathological changes (KPI: 0 to 5 pluses). Some of 
these mice showed severe glomerulonephritis while others in the same group were free 
of the pathological changes. Figure 8.10 shows representative pictures of the mouse 
kidney histology in the 19-week old mice, with contrast between the reduced renal 
pathology in the IL-2 treated group (a, b) and the severe glomerulonephritis in the 
untreated control group (c, d). The pictures shown in Figure 8.10(c) and (d) in the 
vector treated group are selected ones from a mouse which had most severe renal 
damage (+++++) in the group.
Results from the immunohistopathological studies are shown in Table 8.2 with 
no clearly cut difference between groups, except a relative low C3 staining observed in 
the IL-2 treated mice at 19-weeks compared to the vector treated and untreated mice. In
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Age Mouse Auto-Ab Titre Kidney pathology
groups (IgG.TU)
anti-ss anti-ds KPI igG C3
14-w ks I 400 40 + + + + ++++ +++++
(Test 1) (Untreated) 2700 290 - +++ ++++
4800 290 - ++ ++
(NT)* (NT)* (NT)* (NT)* (NT)*
II 4000 290 + + + + + ++++ +++++
(Vector) 4400 600 + + ++ ++++
8200 290 + +++ +++++
12000 200 + ++ +++
12000 370 - ++++ +++++
(NT)* (NT)* (NT)* (NT)’ (NT)*
III 900 90 + + + +++++ +++++
(IL-2) 10500 330 + + ++ ++
10500 160 + +++ +++
10000 400 - ++ ++++
5200 220 - + +++-H-
(NT)* (NT)* (NT)* (NT)* (NT)*
19-w ks I 3400 200 + + + + + + ++++
(Test 2) (Untreated) 8000 1200 + + + + + + + + + + +++++
81000 460 + + + + + ++ +++++
26000 18 00 + + + ++ ++++
II 1000 80 + + + + + +++++ +++++
(Vector) 8500 4600 + + ++ +++++
20000 1300 - +++ +++++
81000 1050 - + +++
13000 600 (NT)*’ (NT)** (NT)**
III 18000 9000 + + ++ +++
(IL-2) 4800 270 + ++++ +++
3600 400 + + ++++
2700 160 (NT)* (NT)* (NT)*
20000 810 (NT)** (NT)** (NT)*’
(NT)*: not tested, died due to feeding prdcedure, no lupus symptom 
(NT)**: not tested, killed due to severe lupus disease
Table 8.2 Comparison of autoantibody production, renal im m une 
complex deposition and pathological changes in the IL-2 treated MKL/lpr  
mice. Mouse serum antibodies , to ss and dsDNA were measured by ELISA and 
expressed as titration units (TU). Kidney sections were prepared from individual mice 
for light and immunofluorescence microscopic examinations (see Methods). Degrees of 
renal pathological changes were scored, zero to 5 pluses on a blind basis, according to 
the severity of kidney damage (KPI, Kidney Pathological Index); intensity of 
immunofluorescent staining for kidney deposition of complement component 3 (C3) and 
immunoglobulin G (IgG). The data shown are intended to illustrate the relationship 
between KPI (shown as bold) and other parameters of changes in individual mice 
corresponded.
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Fieure 8 .1 0  Renal histopathology. Representative photomicrographs of kidney 
sections from MRLIlpr mice (19 week old) showing severe kidney damage (+++++) in 
the two control groups (a-d) in comparison with the relatively normal kidney structure (+)
in the IL-2 treated mice (e-f). (a, c) pictures at low power (X120) showing severe 
glomerulonephritis ( ^ ) and protein casts in the tubules ( |  ); (b, d) pictures at high
power (X 480) showing details of the damaged glomeruli including their enlargement and 
structural change, cellular proliferation and Bowman's capsule thickening, the 'crescent' 
like changes (A*).
addition, as shown in Table 8.2, there is no any correlation between serum 
autoantibody levels, including both anti-ssDNA and anti-dsDNA, and the pathological 
changes in the kidneys of the individual mice.
8 .4  D iscussion
Delivery of exogenous IL-2 in vivo did not restore the ability of lupus T-cells to 
produce IL-2. On the contrary, mice given exogenous IL-2 showed even further 
suppressed IL-2 activity compared with untreated M RL/lpr mice. Since the 
suppression was also observed in the mice treated with vector alone, it was probably 
due to a feedback suppressive mechanism of the host to Salmonella challenge. As a 
secondary effect of IL-2 hypoactivity, this may also explain the proliferative 
hyporesponsiveness of the T-cells after the treatment, as well as the decreased mRNA 
expression for the other T-cell derived cytokines. Although relatively increased IL-2 
mRNA expression was observed in the IL-2 treated mice at 14-weeks compared to 
untreated controls, it is not clear if this was also due to the "vector effect". However, 
levels of IL-2 activity in the culture supernatants of the Con A-stimulated cells were still 
low, suggesting that the lack of endogenous IL-2 is not merely due to a defect in gene 
activation. There might exist some other defects of the T-cells at post-transcriptional 
levels, such as protein synthesis or secretion.
The significance of IL-2 treatment on IFN-y production is not clear. In contrast to 
its in vitro effects, IL-2 treatment effectively depressed the ability of T-cells to produce 
IFN-y. The level of this lymphokine in culture supernatants of Con A-stimulated 
spleen cells from IL-2 treated mice was about 3 to 4 fold lower compared to both vector 
treated and untreated groups. It was not simply due to low IL-2 activity in the cell 
culture because IFN-y was not reduced in the vector treated group in spite of similar 
level of IL-2 in the culture (Fig.8.5b). In addition, the suppression did not occur at 14 
weeks, but at 19 weeks when peak disease activity developed in the control groups
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suggesting the importance of the immune suppression mechanism in relation to 
outcome of the disease.
Similar to the observations in the study of TGF-j3 treatment, individual variation 
has been a problem in judging effects of the cytokine delivery on the mice, particularly 
in the pilot studies of such small scale. The variations may be due to differences in the 
susceptibility of the mice, such as differences in the state of immunisation to Salmonella 
Carrier et al. (1992) or stomach pH of the mice (Schorr et al., 1991). However, in 
spite of these, the IL-2 treatment did appear to have some effect on reducing 
glomerulonephritis and other renal changes in MRUlpr mice. It is encouraging to note 
that the IL-2 treatment brought about a significant reduction of the abnormal DN cells 
which characterise MRUlpr disease. It reduced the size of spleens and total number of 
splenic T-cells indicating the effect on blocking lymphadenopathy. This might also 
explain why these mice had developed lymphoid tumours to a less degree compared to 
the control groups. The results have not only confirmed the in vitro observation that 
the proliferation of DN cells is not IL-2 dependent, but also suggested a possible role of 
IL-2 in suppressing or eliminating these pathogenic and autoreactive cells. Although 
there was no correlation between serum anti-ssDNA or anti-dsDNA of IgG class and 
kidney pathology, complement activation might be another important factor determining 
the deposition of immune complexes. It addition, it is still to be determined whether 
there may be any effect on the IgM class.
In summary, the pilot study has shown encouraging effects of in vivo IL-2 
treatment of lupus disease, confirming the previous study by Gutierrez-Ramos et al. 
(1990; 1991). However, the results were limited for a comprehensive interpretation of 
their clinical significance. For undertaking further investigations, larger numbers and 
different strains of mice would have to be used and other factors such as the optimal 
dose and the kinetics would need to be considered.
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Chapter 9 
GENERAL DISCUSSION
161
Immune regulation is a complex network governing the functions of the immune 
system in a self-modulating manner. Numerous factors are involved in the network, 
interacting with, balancing or limiting each other. Abnormal expression of a particular 
factor during the development of disease can be the cause or outcome of another factor, 
or a reflection of the self-balancing processes in response to physiological feedback or 
pathological changes. Therefore, one must avoid a narrow interpretation of 
experimental data from in vitro or in vivo findings without considering all aspects of 
the system that may be involved.
9 .1  The functional defects of lupus T-cells in vitro
The present study has demonstrated a variety of immunological defects in SLE. 
Many of them, particularly the functional abnormalities of T-helper cells, indicate a 
regulatory disorder confirming previous findings by other investigators. Lupus T-cells 
are hyporesponsive to mitogenic stimulation including an inability of T-cells to 
proliferate and failure to express high affinity functional IL-2 receptors. These together 
with the abnormal production of IL-2, IL-4 and IFN-y in vitro appear to be a 
generalised activation defect. Lymphokine disorders reflect a malfunctioning state of T- 
helper cells. In spite of controversial views about its origin, the inability of T-cells to 
produce IL-2 in vitro has been consistently demonstrated in both lupus patients and the 
mouse models (Kroemer and Martinez-A, 1991). In the present study, the defect in the 
production of IL-2 was found in lupus mice of both NZB/W and MRLIlpr strains and 
the reduction was highly significant in all age groups, except the one-week old mice 
that lack CD4 cells (Chapter 3). Since the presence of IL-2 as a second signal is 
required for a complete activation of T-cells by Con A, a deficient IL-2 activity could be 
directly responsible for the activation failure.
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The inability of T-cells to proliferate parallels with the kinetics of the disease, 
occurring much earlier in the MRLUpr mouse which is a typical early-disease model 
than in the NZB/W mouse (late-life model). However, in both of the lupus mouse 
models, the inability of lupus T-cells to proliferate precedes the onset of clinical 
disease. This suggests the unlikelihood that such a defect results from autoimmune 
lesions, at least in young lupus mice. On the other hand, spleen cells from some young 
NZB/W mice had normal proliferative responses to Con A alone while IL-2 activities in 
the cultures were reduced. This might be explained by a threshold of minimum IL-2 
activity that is required for a full proliferative response. An impaired T -cell 
proliferation is usually observed when IL-2 activity in the culture is below a certain 
level. Indeed, following a further suppressed IL-2 activity in the older mice, 
proliferative hyporesponsiveness of T-cells becomes established in both NZB/W and 
MRUlpr mice. Taken together, it is probably sufficient to conclude that the inability of 
lupus T-cells to proliferate in response to Con A is a secondary event due to IL-2 
deficiency. In confirming this, a demonstration that exogenous IL-2, but not IL-1, IL- 
4 or IFN-y, is able to bypass such a defect in vitro has provided convincing evidence 
(Chapter 5). Addition of IL-2 during Con A activation not only restores fully the ability 
of lupus T-cells to proliferate, but also upregulates the expression of IL-2R and 
increases the frequency of IFN-y secretors resulting in normal levels of IFN-y 
secretion. This suggests that IL-2 deficiency may also play a primary role in the 
abnormal production of IFN-y and the defective IL-2R expression.
However, the defect in IFN-y production is not consistently established in both 
NZB/W and MRUlpr mice until peak disease activity is developed at old age. It is not 
clear whether, in the young lupus mice, the seemingly normal production of IFN-y in 
contrast to the reduced IL-2 activity might reflect an unbalanced functional activity 
within the Thl phenotype, or this could be because of the complication of abnormal 
production of this cytokine by other cell types. An interesting finding described in 
Chapter 4 shows that the WEP999 Thl cell clone expresses IL-2 but not IFN-y, the
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WEP988 Th2 cell clone expresses IL-4 but not IL-6, and the CTLL cell line expresses 
IFN-y but not IL-2, IL-4 or IL-6 (Fig.4.13f). It is therefore also possible that there 
might be some T-cell subsets in vivo which secrete IL-2 or IFN-y but not both. To 
clarify this, development of a 2-colour ELISPOT assay would be very useful.
The effects of exogenous IL-2 on upregulation of IL-2R expression in vitro were 
weaker in old mice than young mice, especially in the MRUlpr strain. Addition of rlL- 
2 in vitro only partially restored the ability of the T-cells to express surface IL-2R with 
increased positive cell frequency but low density and delayed kinetics. This indicates 
that there may also be T-cells which are intrinsically defective in their ability to express 
IL-2 receptors. One of the explanations is that the IL-2 responders might be of T-cell 
subsets other than the abnormally expanded DN cells because the latter do not express 
IL-2R p-chains and are hence incapable of generating the high affinity a p  IL-2 
receptors (Rosenberg, 1989; Tanaka et al., 1993). To examine this further, it may be 
necessary to study the effect of IL-2 on purified DN cells. However, the results from 
cell phenotypic analysis have indicated that IL-2 does not promote but rather suppresses 
the expansion of the abnormal cell population both in the in vitro (Chapter 5) and in 
vivo (Chapter 8) conditions.
9 .2  The nature of IL-2 deficiency in SLE: a primary or secondary 
defect ?
A focus of arguments on the defect in IL-2 production concerns its nature. One 
of the questions is how the in vitro data can be used to explain what may actually 
happen in vivo, especially when elevatedjsaumlevdscfIL-2 were found in patients with 
SLE (Huang et a l, 1988). Huang's other finding (Huang et al., 1986) which shows 
restoration of IL-2 production by resting cells in culture before stimulation has been 
regarded as evidence in favour of the view that the defective IL-2 production may be
164
secondary to autoimmune lesions. These T-cells, which might otherwise be too 
"exhausted" to respond to stimulation due to their post-activated state in vivo, are 
thought to be able to restore their responsiveness during the resting period. This has 
been proposed to be the most easily acceptable interpretation that explains both the 
hyperactive B-cell state and the mutually contradictory in vivo and in vitro data. 
Indeed, results from the present study show that the defect in IL-2 production is 
progressive with age and it is most prominent at the peak of clinical disease expression, 
suggesting some association with the autoimmune activity.
9.2.1 Are T-cells from lupus mice in an activated, post-activated or exhausted 
state ?
The 'exhaustion theory1 is obviously based on the assumption that T-cells are 
polyclonally activated in SLE. This is because T-cell mitogens, such as Con A, 
stimulate T-cells non-specifically. Thus, if the defective mitogen-induced IL-2 
production is due to T-cells being exhausted, it would have to be a generalised state of 
T-cell exhaustion.
However, what the 'theory' does not explain is, firstly, the normal 
responsiveness of the majority of T-cells from lupus mice of different ages to IL-2 
upon Con A stimulation. These T-cells have the ability to respond to the signals 
generated by Con A providing a sufficient level of IL-2 is present. Secondly, the fact 
that there was no significantly increased responsiveness of the T-cells to IL-2 without 
the presence of Con A indicates that they were not in an ongoing activated stage either. 
Thus, even if some T-cells were in an activated or post-activated exhausted state, they 
would have to be a minority of the T-cell population. It is possible that T-cell activation 
in vivo in lupus disease is also clonally restricted, similar to the oligoclonal nature of 
autoantibody secreting B-cells (Stott, 1992). In addition, freshly isolated spleen cells 
from lupus mice do not spontaneously express IL-2, IFN-y, IL-4 and IL-6 which are
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characteristic T-cell derived lymphokines usually considered as cell activation markers. 
It would be difficult to interpret that the IL-2 secretors are in a post-activated state 
because of a non-specific T-cell activation while the majority of other T-cells are 
apparently resting.
The pathogenic DN T-cells which are a characteristic feature of MRUlpr mice are 
in a state of active proliferation. However, these cells lack the ability to express IL-2R 
and can proliferate in the absence of IL-2. Therefore, the expansion of this cell 
population is unlikely to have resulted from IL-2 hyperactivity in vivo. On the other 
hand, it is obvious that the defective IL-2 activity in young lupus mice, including young 
MRL//pr mice with normal T-cell phenotypes, is not due to the expansion of DN cells. 
Lymphoid cells from Ipr gene-bearing mice are known to produce spontaneously 
factors other than IL-2, which induce B-cell differentiation and immunoglobulin 
synthesis (Prud'homme et al., 1983; Dobashi et al., 1987; Ashiba et al., 1987a,b). 
More recent studies have also shown that double negative T-cells isolated from 
M RLIlpr, NZB/W and NZB/SWR mice (Datta, 1989), as well as from patients with 
active SLE (Shivakumar et al., 1989) can secrete soluble factors providing help to B- 
cells necessary for the production of pathogenic autoantibodies. However, the DN cell- 
derived factors responsible for the autoantibody production, and the factors that control 
the proliferation of the DN cells have still not been well characterised. Interestingly, 
exogenous IL-2 inhibits the growth of the DN cells while allowing those phenotypically 
more mature, single positive cell subsets to expand. My results support Prud'homme's 
view that defective IL-2 production might be a necessary prerequisite for the increased 
production of B-cell differentiation factor(s), reflecting an imbalance in cytokine 
regulation.
9.2.2 The role of co-stimulatory factors in lupus T-cell activation
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The present study has also investigated the role of costimulators and accessory 
cells in the defective T-cell activation in lupus mice. Monocytes from both SLE patients 
and the lupus mouse models have reduced activation with abnormally low IL-1 
secretion (Linker-Israel et al., 1983; Dinarello et al., 1989; Doelly et al., 1990; 
Steinberg et al., 1991). The IL-1 defect has been detected in MRL mice at birth (Levine 
et al., 1993). Such IL-1 deficiency may underlie IL-2 secretion abnormalities, because 
of the important role of the APC-derived cytokine as a costimulatory factor in antigen- 
dependent T-cell activation. However, addition of r-human IL-1 did not bypass the T- 
cell activation defect in either NZB/W or MRUlpr mice, which confirms the previous 
study in SLE patients by Linker-Israel et al. (1983). Replacement of adherent cells 
from H-2 compatible normal mice also failed to restore the ability of T-cells from 
MRL/lpr mice to proliferate, to secrete IL-2 and to express IL-2R in response to Con 
A, indicating that the defect responsible for the abnormal T-cell activation exists in the 
non-adherent cells (Chapter 4). Further study is needed to answer the question whether 
there might be a defect in providing co-stimulatory signals necessary for T-cell 
activation through the CD28/B7 (Norton et al., 1992) or CTLA-4/GL1 (Hatchcock et 
al., 1993) interactions. However, although it is possible that the defect could be in the 
B-cell compartment which provides B7 and GL1 molecules, DN T-cells isolated from 
M R U lpr  mice do not lack CD28 expression (Giese et al., 1993; Clements et al., 
1993).
Another point which has been taken into consideration is whether the effects of 
exogenous IL-2 on T-cell activation observed in lupus mice might have been due to a 
re-activation of anergised cells. It is possible that autoreactive cells in the autoimmune 
mice are in an anergised or refractory state (Giese et al., 1993; Clements et al., 1993), 
rendered by the immune system to avoid immune responses to self. Clonal anergy 
which results from the absence of co-stimulatory signals may be reversed by IL-2- 
driven cell division (Jenkins, 1992). However, the present study has shown that the 
lupus spleen cells, especially the DN cells from MRUlpr mice, did not proliferate in
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response to exogenous IL-2, and IL-2-treated MRUlpr mice had significantly reduced 
DN cells both in terms of percentage and total cell number. Moreover, addition of IL-2 
to the cultures of spleen cells from the lupus mice did not increase the spontaneous 
secretion of autoantibodies to ss and dsDNA.
9.2.3 An unbalanced T-helper function or mechanisms of feedback 
suppression?
T-helper cells exhibit reciprocal negative regulation between Thl and Th2 
phenotypes by secreting distinct soluble cytokine mediators. This is probably one of 
the important mechanisms that the normal immune system relies on to maintain self­
balance. However, in situations where cytokines or other functional activities of either 
of the phenotypes are abnormally produced, the balance may be broken leading to 
pathology (Romagnani, 1990). Alternatively, where an intact immune system has the 
capacity to regulate itself efficiently, a new balance may be reached instead to avoid 
pathology. In SLE, the suppressed IL-2 activity suggests a deficient function of Thl 
phenotype. This is accompanied by a concomitant hyperactivity of B-cells that 
indicates an increased B-cell help. Th2 cells produce IL-4, IL-5 and IL-6 which are 
known as B-cell growth or differentiation factors, and IL-10 which has been given the 
name of ’cytokine synthesis inhibitory factor' (Moore et al., 1990). Since both IL-4 
(Brooks et al., 1992) and IL-10 (Malefyt etal., 1991) may down-regulate IL-2 activity 
via their action on monocytes, an increased Th2 activity could well explain the 
immunological features in the disease. Results from the present study did not suggest 
an increased IL-4 activity in lupus mice but this does not rule out the role of IL-10 or 
other cytokines such as the DN cell-derived factors that enhance autoantibody 
production (Datta et al., 1989), and the SLE serum factor that affects the IL-2 
dependent CTLL cells. The balance between Thl and Th2 functional activities is 
relative. An increased Th2 activity may also be due to a deficiency of the Thl 
phenotype. In other words, enhanced B-cell help could be due not only to an increased
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production of a given cytokine but also to a lack of negative control of its functional 
activity on target cells.
It is noteworthy that exogenous IL-2 was able to restore the ability of splenic T- 
cells from lupus mice to respond to mitogen in cultures at physiological doses, but 
increasing concentrations of IL-2 failed to neutralise the inhibitory activity of the serum 
factor, or factors, even at high doses. However, as the serum factor binds to T-cells, 
the inhibition is more likely to be through a direct effect on the cells rather than binding 
to IL-2. Thus, routine washing of cells before culturing could remove serum that 
contains such inhibitor. This might explain why pre-culture of the spleen cells 
increased responsiveness of T-helper cells to mitogen stimulation (Huang et al., 1986), 
because the lasting effects of the inhibitor might be further limited during the pre-culture 
period. The factor which inhibits IL-2 activity on the proliferation of CTLL cells is 
elevated in patients with active SLE and some old lupus mice. It is possible that the 
serum factor might also bind to T-helper cells inhibiting their function. Therefore, the 
fact that IL-2 activity is suppressed progressively with disease activity may partially be 
explained by the factor. Thus, although the defect in IL-2 production that exists in 
young lupus mice prior to clinical disease could be intrinsic, some secondary 
suppressive mechanism that contributes to the abnormality at later stages is not 
excluded. In addition, the serum factor can also be detected at low levels in normal 
individuals suggesting its possible physiological role. It is likely that the rise in the 
factor(s) acting as an antagonist of IL-2 could be due to a mechanism of feedback 
suppression in response to some pathological changes such as autoimmune lesions. Its 
presence may reflect an active process, or a passive 'frustrated' attempt, at down- 
regulating the self-destructive process as suggested previously (Kroemer and Martinez- 
A, 1991). Consequently, it further suppresses IL-2 activity non-specifically.
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9.2.4 The early onset and origin of IL-2 deficiency in lupus mice
The most strong evidence that counters the 'exhaustion hypothesis' is the early 
inability of T-helper cells from lupus mice to produce IL-2. This T-cell defect is 
detectable in mice of both lupus strains as early as 4 weeks of age or younger, which is 
at a stage long before the rise in serum autoantibodies, clinical symptoms and lymphoid 
hyperplasia. The CD4/CD8 T-cell ratio and total numbers of spleen cells in these 
young mice were similar to the normal control mice. Therefore IL-2 deficiency in lupus 
disease cannot simply be attributed to a "cell dilution effect" by the DN cells either. 
However, the results do not rule out the possibility that the absolute number of T hl 
cells or IL-2 producers might be abnormal in these mice, and the "cell dilution effect" 
may have some role at later stages of the disease.
Taken together, many aspects of the study discussed so far have exclusively 
pointed out that the T-cell functional abnormalities are possibly due to a defect in the T- 
helper cell itself. To address the question concerning at which level the defect may 
exist, the study has been extended to an analysis of cytokine expression at the 
transcriptional level. Different degrees of reduction in cytokine gene expression for IL- 
2, IL-4, IL-6 and IFN-y were observed, especially in the MRUlpr mice. Although the 
quantitative information provided by the PCR technique is limited, the reduction of Con 
A-induced IL-2 and IL-4 mRNA expression in the 25-week old MRUlpr mice was 
unambiguous. However, the question still remains as to whether such a reduction 
might be due to some immunosuppressive mechanism that regulates the transcriptional 
factors at the cell activation stage, or to a defect in the gene. In these 25 weeks old 
MRUlpr mice, the lack of gene expression for IL-2 and other lymphokines could have 
been a cell dilution effect due to proliferation of the DN cells which were significantly 
increased in the old mice. In addition, it is not clear whether the abnormal cytokine
170
production was due to the lack of cytokine gene expression only, or if there is also a 
defect in the process of protein synthesis or secretion. To explore further, other studies 
including cytoplasmic expression of the cytokines, cellular signalling transduction and 
gene analysis, especially in young MRUlpr mice before the lymphoproliferation 
occurs, will be needed.
In conclusion, the defective IL-2 production does not appear to be simply due to a 
'passive T-cell exhaustion' or lack of co-stimulatory signals from adherent cells. The 
early onset of the IL-2 defect rather suggests the possibility of an intrinsic and 
phenotypically restricted T-helper functional defect.
9 .3  The possible pathological significance of the T-helper cell 
functional defect in the development of lupus disease
To discuss the mechanism of the development of autoimmunity, one of the 
fundamental issues to be considered is why and how those self-reactive clones are 
allowed to be selected, activated and expanded in the first place. The presence of these 
cells, which should be otherwise eliminated or inactivated in an intact immune system, 
is the evidence that indicates the failure of self-tolerant mechanisms during the 
establishment and development of the immune system.
9.3.1 A role in the early establishment of lymphocyte repertoire ?
The early onset of IL-2 deficiency in lupus mice gives rise to the possibility that 
the T-helper functional abnormality might prevent the normal development of the 
lymphoid system. This refers particularly to immune regulatory events during the early 
establishment of the lymphocyte repertoire.
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Differentiation and maturation of T-cell precursors occur in the thymus, and T- 
cells recognising self-components are deleted before maturity while T-cells responding 
to foreign antigens are exported to the peripheral T-cell pool (Marrack and Kappler, 
1990). To establish a normal T-cell repertoire, T-cells are believed to undergo a 
vigorous process of selection in the thymus where the majority of cell clones are deleted 
due to their self-reactivity. The early T-cell development and process of T-cell 
maturation therefore depend critically on the functions of the thymus. However, a 
rapidly declining thymic function, known as the early thymic atrophy found in all lupus 
mice, is a prominent feature of murine lupus disease. In MRL/lpr mice, it is 
accompanied by the accumulation of the DN cells. It has been suggested that the DN 
cells are immature T-cells which are arrested at a stage of development similar to foetal 
thymocytes (Katagiri et al., 1987). Since the Ipr gene is associated with the Fas 
antigen which mediates apoptosis, the escape of these autoreactive cells to the 
peripheral circulation may be a result of a defect in negative selection (Matsumoto et al., 
1991; Watanabe-Fukunaga et a l, 1992; Watson et a l, 1992).
The role of IL-2 in the process of immunocyte selection is not fully understood, 
but recent evidence indicates that IL-2 is involved in the induction of thymocyte 
apoptosis (Migliorati et al., 1993). IL-2 has been shown to induce an active process of 
cell death on immature mouse thymocytes in vitro. Therefore, a deficient IL-2 activity 
may interfere with the normal thymic functions impairing the mechanism of self­
tolerance. In addition, a targetted disruption of the IL-2 gene in mice has been shown 
to lead to severe inflammatory lesions associated with the presence of immature B-cells 
in peripheral lymphoid organs (Sadlack et al., 1993). Thus, it is conceivable that the 
potentially autoreactive T or B-cells that escape from normal selection process and are 
released into the peripheral circulation may seed a pre-determined immune repertoire 
with an autoimmune tendency.
9.3.2 Failure in maintaining other mechanisms of self-tolerance ?
Apparently, a failed mechanism of thymic selection does not itself explain the 
autoimmune responses in the periphery. The existence of potentially autoreactive cells 
which remain unresponsive in normal individuals indicates that some other mechanisms 
are also operational in dealing with those immunocytes which may be at the edge of self 
tolerance (Mitchison, 1993). Thus, conditions that allow the activation and expansion 
of autoreactive clones initiating autoimmune responses can be envisaged as a result of 
impaired mechanisms of post-thymic tolerance.
Suppression of immune responses as a phenomenon in immunology has been 
long observed and established in adoptive transfer experiments. It is believed to play 
an important role in the mechanisms of tolerance in the peripheral immune system. 
Although many cloned suppressor cells have been found to have no specific gene 
rearrangement or deletion in their TcR (Hedrick et al., 1985), as an alternative 
explanation, the phenomenon of suppression is now believed to be explained by the 
interaction of different soluble mediators or cytokines (Bloom et al., 1992), such as IL- 
4, IL-10, IFN-y and TGF-p, that deliver negative signals. Since IL-2 deficiency is
primarily responsible for many abnormal T-cell functional activities in lupus mice, links 
between the deficient T-helper function, the lack of T-suppressor activity (Bresnihan 
and Jasin, 1977), and the commonly observed impaired cell-mediated immunity cannot 
be excluded. The effects of exogenous IL-2 on expansion of CD8+ cells (Chapter 5), a 
phenotype traditionally associated with suppressor activities, suggests its role in 
maintaining immune suppression. It provides some explanation for the effect of IL-2 
treatment that down-regulates the pathogenic immature DN cells in MRLIlpr mice. 
However, the mechanism of such an IL-2-mediated suppression, particularly the role of
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IFN-y that suppresses the Th2 phenotype, is not clear. It seems contradictory that IL-2 
upregulated IFN-y production in vitro while spleen cells from the IL-2-treated MRUlpr 
mice had reduced IFN-y production. Perhaps, the stimulatory effect of exogenous IL- 
2 on IFN-y secretion may induce some mechanism of negative feedback in vivo or, in 
this case, the "exhaustion" mechanism may apply.
There is evidence that apoptosis is not limited to immature thymocytes. Normal 
mature splenic T-lymphocytes have been observed to undergo such programmed cell 
death too (Lenardo, 1991; Perandones et al., 1993; Kabelitz et al., 1993), although the 
regulatory mechanism might differ from that of the intrathymic process (Perandones et 
al., 1993). It appears therefore that the activation-induced cell death can also occur in 
T-cells that have escaped intrathymic selection. Since mice bearing the Ipr mutation are 
defective in Fas which mediates apoptosis, it has been recently suggested that the age- 
related accumulation of DN in the mice might be because cells die less rapidly than do 
their normal counterparts (Cohen, 1993). Therefore, Cohen used the term 
'lymphoaccumulation' instead to describe what has been called 'lymphoproliferation' in 
these mice.
The role of IL-2 in peripheral apoptosis is controversial. It has been suggested 
that IL-2 programmes mature mouse T-cells for apoptosis and provides an essential 
second signal for anti-CD3-stimulated apoptosis of murine T-cell clones (Ucker et al., 
1992; Lenardo, 1991). However, Kabelitz and Wesselborg (1992) showed that such a 
T-cell death may occur following anti-CD3 signalling in the absence of exogenous IL- 
2. In addition, T-cell clonal anergy which does not involve clonal deletion can render 
cells unresponsive to self antigens or superantigens, but the mechanism of self- 
tolerance by the functional inactivation of autoreactive T-cells can also be overridden by 
the presence of IL-2 (Jenkins, 1992). On one hand, IL-2 may favour the tolerance 
process by mediating apoptosis, but on the other it might also prevent the induction of 
tolerance by different mechanisms, such as reversal of anergised lymphocytes. Thus, it
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is probably inappropriate to conclude unilaterally that IL-2 would either favour or block 
the induction of tolerance without the consideration of particular circumstances. Like 
many other cytokines, IL-2 is an immune modulator with pleiotropic functions, and its 
inhibitory or stimulatory activity is often related to certain conditions as well as cell 
types. IL-2 induces apoptosis of immature thymocytes but withdrawal of IL-2 results, 
for example, in apoptotic changes of CTLL cells (Fadok et al., 1992). In addition, the 
serum IL-2 inhibitor which is increased in SLE patients has completely opposite effects 
on CTLL cells at different concentrations.
It is possible that, as a non-specific immune regulator, IL-2 could prevent or even 
reverse anergy by providing costimulation which is otherwise missing during the 
anergy induction. In the meantime, however, IL-2 may induce an active suppressive 
function by promoting CDS*- T suppressor cells or other tolerant mechanisms which are 
otherwise lacking in a deficient immune system. Circumstances under which 
autoreactive clones are allowed to be activated will then depend on the nature of the 
original defect that determines the disease and balance of the regulatory mechanisms 
that influences it. It is also likely that the escape of these cells from the process of 
thymic negative selection is due to a deficient immune recognition, or the presence of 
some apoptosis-inhibitors (Perandones et al., 1993). The active process of IL-2- 
mediated apoptosis in the thymus is known to require protein synthesis (Perandones et 
al., 1993). An induction of the refractory DN cells (Giese et al., 1993; Clements et al., 
1993) could be necessary for eliminating more effectively the hidden clones which are 
otherwise difficult for the immune control mechanisms to recognise. Although the 
functional inactivation of self-reactive cells may be an important complementary 
mechanism of tolerance in normal individuals, the nature of this type of tolerance is 
relatively passive. These anergised cells will remain potential risks, particularly in 
autoimmune situations where mechanisms of suppression are often absent. In other 
words, self-tolerance will not be properly maintained unless an intact immune 
regulatory network is established. Nevertheless, the regulatory mechanisms for
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tolerance induction might differ from one another, but what is most important is the
outcome of the regulation that may eventually limit, or escalate, autoaggression.
9 .4  Approaches to treatment of SLE with new insights into 
the underlying mechanisms of autoimmunity
The ultimate aim of studying and understanding mechanism of a disease is to 
develop effective therapeutic approaches that may eventually cure the disease. In 
return, the outcome effects of a treatment of the disease can also help to gain a better 
understanding of the mechanism of the disease development. On the basis of the in 
vitro findings, the in vivo pilot studies of treatment of lupus mice by delivering TGF- 
p i  and IL-2 using Salmonella vectors have provided some preliminary but useful 
information. The issue is now how we can use this information to explain the disease 
and what we may learn from it.
As described in Chapter 7, TG F-pl treatment in vivo inhibited functional 
activities of T-cells in both normal and lupus mice. In MRUlpr mice, it seems to result 
in a delay in the disease kinetics. This might be attributed to the immunosuppressive 
function of TGF-(31 that has been suggested to have a cyclosporin A-like activity. 
Interestingly, a 'rebound' effect was observed later in which BALB/c mice had an 
enhanced immune responsiveness, and the MRUlpr mice developed glomerulonephritis 
similar to controls and even increased levels of serum autoantibodies. It is possible that 
the repeated doses might have triggered the production of antibodies against the 
bacterial vector thus decreasing the effectiveness of the treatment. However, such a 
'rebound' was not observed in the IL-2 treated mice who received two or three more 
doses in each of the corresponding groups. An alternative explanation may be that, in 
the BALB/c mice, the enhanced T-cell responsiveness including production of IFN-y 
and cell proliferation at the later stage of treatment could reflect a negative feedback 
mechanism in response to the suppressive action of exogenous TGF-pi. Therefore,
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the lack of such responses in the MRUlpr mice might also indicate an incapacity for 
self-regulation.
The in vivo effects of IL-2 treatment of lupus mice were much in agreement with 
the previous study using recombinant IL-2 /vaccinia viruses (Gutierrez-Ramos et al. 
1990; 1991). This includes the phenotypic, serological and histological normalisation 
of autoimmune MKLIlpr mice. It is interesting that amelioration of autoimmune 
disease, as judged by the renal histopathology, was observed in MRUlpr mice of both 
groups treated with either IL-2 or TGF-pl, however, the mice treated with IL-2 
showed suppressed disease activity at a later stage than the TGF-pi-treated mice. 
Unlike the latter which had only a transient delay in disease onset, the reduced kidney 
damage in the mice after IL-2 therapy appeared to be more sustainable even at the peak 
of disease kinetics expressed by the control mice. Most notably, in agreement with the 
in vitro results, the IL-2 treatment of mice starting at 3 weeks of age resulted in a 
reversal of T-cell phenotypic abnormalities. It can be predicted that the mechanism of 
this IL-2-mediated suppression of the autoreactive DN cells could also be important 
during thymic selection in the early life of mice when the normal process of clonal 
deletion is taking place.
It must be pointed out again that the preliminary results are still to be confirmed in 
a future study. The main limitation of these results is probably the size of the 
experimental groups and the individual variations, which affect the statistical analysis of 
the data. The variations may be partially due to differences in the susceptibility of the 
mice. Individuals who are already immune to Salmonella would be expected to 
eliminate the organisms more quickly than the others. Using a similar model system, 
Carrier et al. (1992) have shown differences of IL-ip-mediated radioprotection effect 
between three routes of administration. They found that the effects of oral or i.p. 
treatment tended to be more variable than by the i.v. route of administration. It was
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suggested that the i.v. route may lead to more effective colonisation of the Salmonella 
construct in the liver and spleen, generating a higher concentration of the cytokine. The 
present study used the oral route because it has the advantage of being simple, but it 
will be necessary to compare these other routes in future experiments. It is also 
possible that one of the factors which might account for the variations between 
individual mice could be the low pH in the stomach possibly preventing the penetration 
of the live bacteria in the gut. Therefore, neutralisation of the stomach pH in the mice 
before feeding them with the bacteria may be essential (Schorr et al., 1991).
The "vector effect" observed in both the TGF-|51 and IL-2 treatments is however 
interesting. It is surprising to note that some of the vector alone treated MRUlpr mice 
showed little or no sign of renal pathology while others suffered from severe 
glomerulonephritis. The reason for the 'vector effect' is not clear. Presumably, this is 
due to an effect of non-specific stimulation of the immune system by the vector, as 
might be induced by superantigen and bacteria-derived LPS. Production of 
endogenous cytokines by an activated endothelial reticular system could then be 
responsible. In fact, IL-2 itself is a non-specific immune regulator. The clue from this 
notion is that a general immune stimulation might trigger active immune suppressive 
functions which would require production of IL-2 and possibly other cytokines. IL-2 
treatment of these IL-2 deficient mice might be able to restore or enhance such a 
process. Therefore, a good vector system which can deliver controllable physiological 
doses of the cytokine over a certain period is needed. However, before this approach 
of using Salmonella vector to deliver cytokines can be applied to human disease, a 
detailed analysis of this vector stimulation with particular attention to possible 
consequences of bacterial lysis which may release large amount of antigenic or 
mitogenic substances, is absolutely necessary.
Nevertheless, the hint from the finding that IL-2 therapy might have disease 
limiting rather than escalating effects is important because it calls our attention to the
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need for fresh insights into the underlying mechanisms of autoimmune phenomena. 
Essential features of an intact immune system require both the ability to generate 
immune responses to foreign antigens and to maintain tolerance to self. The "Ying- 
Yang theory" (relatively 'Ying' refers to inhibition and 'Yang1 refers to activation) on 
which traditional Chinese medicine has been long based emphasises the importance of 
an internal balance of the body system. In particular, the theory stresses the necessity 
of discriminating the nature of an imbalance between 'Ying' and 'Yang', where a 
disease could be due to either a hyperactivity or deficiency of Ying1 or 'Yang1, or the 
two. This is considered to be crucial for therapeutic strategies in deciding whether to 
suppress or to compensate one or the other, or both, so that a re-balance may be 
reached at an appropriate level. Autoaggression, which could be due to a deficient 
immune function that controls self-tolerance usually gives an impression of an overt 
immunity. Clinically, attention is often focused on developing strategies to suppress, 
though non-specifically and passively, the autoimmune responses using 
immunosuppressive agents rather than treatments that help patients to restore their own 
immune regulatory function. While immunosuppressive therapy temporarily 
suppresses the autoimmune responses in the recipients, it might further undermine their 
self-regulatory capability. The importance of this concept lies in the necessity that 
therapeutic efforts should be made to restore the active mechanisms of self-tolerance 
rather than a passive and non-specific immunosuppression, or to combine the two 
approaches. A strengthened immune system may also be beneficial if slow infections 
are the causes of some autoimmune diseases as proposed by Rook and Stanford 
(1992). The hypothesis is that, in other words, some autoimmune disorders could be 
just another form of expression of immunodeficiency.
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APPENDICES
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I. REAGENTS AND CHEMICALS
i) Antibodies and antibody conjugates
Donkey anti-goat/sheep IgG
FITC-conjugated (Sapu)
Goat (Fab’)2 anti-m ouse C3
FITC-conjugated (Cappet)
Goat anti-mouse immunoglobulin
alkaline phosphatase conjugated (y-chain specific, Sigma)
Goat anti-rabbit IgG
alkaline phosphatase conjugated (Sigma)
Ham ster monoclonal antibody (Clone 145-2C11, IgG2)
anti-mouse CD3, FITC-conjugated (Boehringer Mannheim, Germany)
M ouse monoclonal antibody (Clone IE2, ascites) 
anti-human IL-2 (Biogen)
Rabbit anti-human IL-2 (R005865, R004896)
antisera, IgG fractions or biotinylated (The Laboratory)
Rabbit anti-m ouse IFN-y (Wellcome Lab, UK)
Rabbit anti-mouse IgG (K-chain specific, MR11 and MR13)
IgG fractions, HRP-conjugated or FITC-conjugated (The Laboratory)
Rabbit anti-mouse IgM (RC406/8/9)
IgG fraction, AP-conjugated, or FITC-conjugated (The Laboratory)
Rat monoclonal antibody
anti-mouse CD4, PE or FITC-conjugated (Becton & Dickinson)
Rat monoclonal antibody
anti-mouse CD8 , FITC or PE-conjugated (Becton & Dickinson)
Rat monoclonal antibody (Clone AMT13, IgG2a)
anti-mouse CD25 (IL-2R a-chain specific), PE-conjugated 
(Boehringer Mannheim, Germany)
Rat monoclonal antibody (Clone R46AT)
anti-m ouse IFN-y (Wellcome Lab, UK)
Rat monoclonal antibody (Clone B VD6-24GA, IgG l) 
anti-mouse IL-4 (Pharmingen)
Rat monoclonal antibody (Clone X T22.11)
anti-m ouse T N F -a  (Wellcome Lab, UK)
Sheep anti-mouse IgG
FITC-conjugated (Sapu)
2 1 2
ii) Buffers and solutions
Borate-buffered saline:
0.1 M Boric acid, 0.025 M di-sodium tetraborate (Borax),
0.075 M  sodium chloride in distilled water, pH 8.3-8.5.
Carbonate coating buffer
0.1 M  sodium carbonate in distilled water, pH 8.2.
Carbonate-bicarbonate coating buffer
14.15 raM  sodium carbonate 34.88 mM sodium hydrogen carbonate, 3.08 
m M  sodium azide in distilled water, pH 9.6.
Blocking buffers:
2%, 1% and 0.5% (w/v) BSA, o r 20% , 10% and 5% FCS, 
in PBS or BBS as indicated in different assay protocols.
Greiss solution:
obtained by mixing equal volume of 0 .1% alpha-napthyl-amine in distilled 
water (Solution A) and 1% sulphanilamide in 5% phosphoric acid (Solution B). 
K ept dark.
M cllwaine's buffer:
17.9 mM  citric acid, 64.2 mM disodium hydrogen orthophosphate 
dihydrate, pH 6.0.
Nitrate-nitrite conversion reaction buffer
5 mg/ml NADPH, 41.5 mg/ml FAD, 0.5 M potassium dihydrogen 
orthophosphate and 35 mg/ml nitrate reductase ( S i g m a )
Phosphate-buffered saline:
0.15 M  sodium chloride, 1.98 mM potassium dihydrogen orthophosphate,
7 .96 m M  disodium hydrogen orthophosphate, pH 7.3.
Tris-buffered saline:
0.05 M tris, 0.15 M sodium chloride in distilled water, adjusted to 
pH 8.0 with HC1.
Tris-Tween washing buffer
0.2 M tris-HCl, 0.19 M sodium chloride, 0.05% (v/v) Tween 20, 
adjusted to pH 7.4  with HC1.
Urea buffer:
10% (w/v) SDS, 8 M urea, 10 mM Tris in ditilled water, 
adjusted to pH 7.0 with HC1 and sterilised by autoclaving.
20x SSC (Sodium chloride, sodium citrate)
3 M sodium chloride, 0.3 M trisodium citrate in distilled water, 
adjusted to pH 6.5 with HC1.
Acetic buffer:
0.05 M sodium acetate in ditilled water, adjusted to pH 5.0 with acetic acid.
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iii) Cytokines
Recom binant human IL -lp  (Wellcome Lab., UK)
Recombinant human IL-2 {Glaxo)
Recom binant murine IL-4 {Immunex, USA)
Recombinant murine IFN-y {Bender Wien, Austria)
Recombinant murine T N F -a  {Bender Wien, Austria)
Recom binant murine TGF-j32 (from Dr Joe Carlino, Palo Alto, USA)
iv) Enzymes
S I nuclease {BoehringerMannheim, Germany)
Trypsin-EDTA (For resuspending adherent cells)
0.025% EDTA {Sigma) in calcium and magnesium-free tris buffered saline 
containg 0.5 mM Na2EDTA.
v) Enzyme substrates
For ELISA assays:
Orthophenylene diamine (OPD) HRP substrate {Sigma)
2.21 mM  OPD dissolved in Mcllwaine's buffer, and 0.032% (v/v) 
hydrogen peroxide (added immediately before use, kept in dark).
TM B Microwell Peroxidase Substrate solution {Dynatech)
p-NPP alkaline phosphatase substrate tablets {Sigma)
1 mg/ml dissolved in the p-NPP substrate buffer.
For ELISPQT assays:
BCIP/NBT alkaline phosphatase substrate
3 mg of 5-bromo-4-chloro-3-indoyl phosphate (BCIP, Sigma), and 6 mg of 
p-nitroblue tetrazolium chloride (NBT, Sigma) (dissolved separately in 0.2 ml 
dimethylformamide), in 20 ml 0.1 M NaHCQ3 containing 1 mM M gCl2 
(pH 9.8).
A EC HRP substrate
5 mg of 3-amino-9-ethyl carbazole (AEC, Sigma) (dissolved in 0.4 ml 
dimethylformamide), in 19 ml 0.05 M NaOAc (pH 5.0).
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vi) Media
RPMI 1640 medium (G i b c o )
For cell culture, the complete culture medium was RPMI 1640 containing 2 m M  
L-Glutamine, 100 units/ml penicillin, 100 ug/ml streptomycin, and foetal calf 
serum at 5%, 10% or 20%. (stored at 4  °C)
H BSS (Hanks' balanced salt solution, with pyruvate, G i b c o )
D M EM  (Dulbecco's Modified Eagle's Medium)
Containing 1 mg per ml glucose, 100 units/ml penicillin, 100 ug /m l' 
streptomycin, and 10% foetal calf serum, stored at 4  °C { G i b c o ) .
M edium for freezing cells
contained 15% (v/v) DMSO (Koch-Light Ltd.) in heat-inactivated foetal calf
serum .
vii) Molecular biological reagents
A garose (Electrophoresis grade, B e t h e s d a  R e s e a r c h  L a b o r a t o r y ,  U S A )
dissolved in 0.5 x TBE buffer containing 0.5 pg/ml ethidium bromide.
Anhydrous isopropanol ( S i g m a )
dA TP, dCTP, dGTP and dTTP ( G i b c o  B R L )
lk b  DNA ladder ( G i b c o  B R L ,  U K )
m.w. markers giving bands at 12216, 11198, 10180, 9162, 8144, 7126,
6108, 5090, 4072, 3054, 2036, 1636, 1018, 517, 506, 396, 344, 298,
220, 201, 154, 134 and 75bp
DTT ( G i b c o  B R L )
M oloney murine leukemia virus (M-MLV) reverse transcriptase ( G i b c o  B R L )
Oligo-dT 15 ( P r o m e g a )
lOx PCR buffer ( P r o m e g a ) - .
15 mM MgCl2, 500 mM KC1, 100 mM Tris-HCl, and 1% Triton X-100.
Prim er pairs for mouse IL-2, IFN-y, IL-4, IL-6 and p-actin:
synthesised by G e n o s i s  ( U S A ) .  For the oligonucleotide 
sequences see Tables 2.1, 2.2 (Materials and Methods).
Random  hexanucleotides ( G i b c o  B R L )
5x Reverse transcrition buffer ( G i b c o  B R L ) :
250 mM Tris HCL (pH 8.3), 375 mM KC1, 15 mM  M gCl2.
RNasinR RNase inhibitor (P r o m e g a )
R N A zol™  B ( B i o g e n e s i s )
0.5x Tris-borate-EDTA electrophoresis (TBE) buffer.
0.045 M Tris-borate, 0.001 M EDTA in distilled water, pH 8.0.
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T E  (Tris-EDTA) buffer
10 mM  Tris, Im M  EDTA in double distilled water, pH 7.0.
Therm  us aquaticus thermostable (Taq) DNA polymerase { P r o m e g a )
vii i)  Other serum products
Foetal calf serum { G ib c o )
inactivated for cell culture by heating at 56 °C for 45 minutes.
Bovine serum albumin
Fraction V, 96-99% albumin { S ig m a )
Norm al goat serum { S a p u )
Norm al sheep serum { S a p u )
vii) Other reagents
Avidin AP-conj ugated ( V e c t o r  L a b o r a r o r y )
Avidin HRP-conjugated { V e c t o r  L a b o r a r o r y )
Avidin PE-conjugated { V e c t o r  L a b o r a r o r y )
Biotin (long arm, S i g m a )
Concanavalin A, Type I Vs{ S ig m a )
Calf thymus DNA { S ig m a )
Complete Freund's Adjuvant { D I F C O  L a b o r a t o r i e s )
Fluorochrome isothiocyanate { S i g m a )
Incomplete Freund's Adjuvant { D I F C O  L a b o r a t o r i e s )
2-Mercaptoethanol, cell culture grade { S i g m a )
Penicillin/Streptomycin { G i b c o )
Phytohaem agglutinin { W e l l c o m  L a b .  U K )
Poly-L-lysine { S i g m a )
Protein A column Sepharose 4B fast flow { S ig m a )
Propidium  iodide { S i g m a )
Tritiated thymidine { A m e r s h a m  I n t e r n a t i o n a l ,  U K )
G-25M  Sephadex column { P h a r m a c i a )
Sheep liver powder { S i g m a )
Donkey liver powder { S ig m a )
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